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Abstract 
Type 2 diabetes is a chronic metabolic disorder primarily caused by a systemic insulin 
resistant state to which obesity is a major contributor.  Increasing visceral adipose tissue 
augments adipokine secretion provoking an enduring low-grade inflammatory response 
that negatively impacts on the insulin signalling cascade.  In an intervention study of a 
murine diet-induced model of type 2 diabetes, a novel compound, RTC-1, designed to 
reduce serum levels of one such adipokine, RBP, improved glucose handling and 
prevented weight gain.  This compound also had a direct positive effect on glucose 
uptake in vitro, independent of its predicted mode of action.  Through cellular analysis 
this study has established the mechanism by which this is achieved.  RTC-1 was found 
to inhibit complex I of the mitochondrial respiratory chain (NADH:ubiquinone 
oxidoreductase), leading to a likely increase in the AMP to ATP ratio and the 
consequential activation of the cellular energy regulator, AMPK.  This in turn 
stimulated the signalling pathway which enhanced the incorporation of the glucose 
transporter, GLUT4, into the plasma membrane.  RTC-1 was also found to prevent 
adipogenesis and induced osteogenesis in an AMPK dependent manner.  Additionally, 
RTC-1 was observed to provoke an increase in insulin sensitivity.   
In a separate project, the signalling capabilities of an orphan GPCR, GPR21, were 
investigated.  Knockout studies have suggested a role for this receptor in macrophage 
infiltration into adipose tissue to augment insulin resistance through an unknown 
mechanism.  Overexpression studies revealed GPR21 to be a constitutively active 
receptor, which couples Gαq type G proteins leading to the activation of the MAP 
kinases.  Overexpression of GPR21 markedly attenuated insulin signalling and
Abstract 
 iv 
promoted macrophage migration. Interestingly, the effect of GPR21 on insulin 
signalling lessened in the presence of increasing concentrations of serum, inferring the 
possibility of a native regulatory ligand.  Homology modelling and ligand docking 
studies led to the identification of a novel compound that interacted with GPR21.  Its 
effects offered the potential as an anti-diabetic therapy as it was found to regulate 
GPR21-induced macrophage migration and to counteract the influence of GPR21 on the 
insulin signalling pathway. 
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1.1 Diabetes 	
Type 2 diabetes accounts for more than 90 % of diabetic cases and has steadily become 
one of the greatest modern public health threats in terms of human, social and economic 
costs.  According to the World Health Organization (2014), 371 million people are 
currently estimated to suffer with the disease, while a staggering 552 million people are 
predicted to be affected by 2030.  The chronic complications of diabetes; diabetic 
retinopathy, nephropathy, neuropathy and macrovascular disease, contribute to the 
enhanced risk of morbidity and mortality in individuals with this condition.  In 2012, 
diabetes accounted for approximately 1.5 million deaths worldwide.   
Type 1 and type 2 diabetes develop as a consequence of defective production and action 
of insulin.  Type 1 diabetes is an autoimmune disease caused by a combination of 
genetic and non-genetic factors, which lead to the destruction of insulin secreting 
pancreatic β-cells.  Type 2 diabetes, however, is a progressive disease, primarily caused 
by insulin resistance.  The global prevalence of type 2 diabetes has been attributed to a 
rise in obesity associated with genetic, epigenetic and societal factors (Chen, Magliano  
and Zimmet, 2012).  In 2014, 39 % of adults worldwide were classed as overweight, 
approximately 13 % were obese, while the dangerous rise in childhood and adolescent 
obesity is further contributing to this epidemic (Singh et al., 2008, Reinehr, 2013, 
World Health Organization, 2014). 
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1.2 Insulin 	
Under normal physiological conditions, insulin, along with its primary counter-
regulatory hormone glucagon, regulate blood glucose homeostasis through sophisticated 
signalling cascades (Aronoff et al., 2004).  Insulin is a peptide hormone synthesised in 
the β-cells of the islets of Langerhans in the pancreas, the biosynthesis and secretion of 
which is controlled by gene transcription, translation, post-translational modifications 
and regulatory factors that impact on its release from mature secretory granules.  While 
glucose is the primary regulator of insulin secretion, other factors including 
acetylcholine, amino acids, fatty acids, glucose-dependent insulinotropic polypeptide 
(GIP) and glucagon-like peptide-1 (GLP-1) can influence its release (Wilcox, 2005).  
As blood glucose levels rise above 3.3 mmol/l postprandially, insulin secreted by 
pancreatic β-cells binds to its plasma membrane receptor, present in all cells, to 
stimulate glucose uptake and inhibit glucagon secretion from pancreatic α-cells, thus 
preventing hepatic glucose production (Gerich, 1993).  
1.2.1 The Insulin Signalling Pathway 
Insulin initiates its action by binding to its receptor, a heterotetrameric membrane-
bound glycoprotein consisting of two extracellular α-subunits and two 
intramembraneous β-subunits linked by disulphide bonds (Fig. 1.1).  Upon binding the 
α-subunit, insulin induces a conformational change that allows ATP to interact with the 
intracellular face of the β-subunit, triggering the rapid autophosphorylation of the 
receptor at a number of tyrosine residues, including Tyr1150/1151 in the regulatory loop of 
the receptor (Tornqvist et al., 1987, Wilcox, 2005, Hubbard, 2013).  The 
phosphotyrosine-binding domain of insulin receptor substrates, such as insulin receptor 
substrate 1 (IRS1) then interact with the receptor, which in turn phosphorylates the 
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substrate at numerous tyrosine residues (White, 1997).  The phosphorylated tyrosine 
residues are recognised by the Src homology 2 (SH2) domain of the p85 regulatory 
subunit of the lipid kinase phosphatidylinositol 3 kinase (PI3K).  This interaction 
translocates PI3K to the plasma membrane where the activated catalytic subunit, p110, 
phosphorylates its substrate phosphatidylinositol 3,4,5-bisphosphate (PIP2) on the 3′ 
position of the inositol ring, producing the lipid second messenger phosphatidylinositol 
3,4,5-triphosphate (PIP3) (Shepherd et al., 1998, Pirola et al., 2004).  PIP3 recruits 
pleckstrin homology (PH) domain containing proteins such as phosphoinositide-
dependent protein kinase 1 (PDK1) and Akt, also known as protein kinase B (PKB), to 
the plasma membrane.  PDK1 then relays its signal potential by phosphorylating Akt at 
Thr308 in the catalytic domain, while mammalian target of rapamycin complex 2 
(mTORC2), which is activated by ribosomes in response to PI3K signalling, is believed 
to phosphorylate Akt at Ser473 in the carboxyl terminal hydrophobic domain (Zinzalla et 
al., 2011, Vadlakonda et al., 2013, Mackenzie and Elliott, 2014). 
Once activated, Akt can regulate glucose homeostasis through a multitude of signalling 
cascades.  Akt phosphorylates and deactivates glycogen synthase kinase 3 (GSK3) 
resulting in the activation of glycogen synthase, which leads to the conversion of 
glucose to glycogen (Rayasam et al., 2009).  Akt also suppresses forkhead transcription 
factor of O group 1 (FoxO1) transactivation, promoting its relocation outside of the 
nucleus, thereby inhibiting the expression of gluconeogenic genes and stimulating that 
of glycolytic genes (Zhang et al., 2006).  Furthermore, Akt directly influences glucose 
uptake through the Akt substrate of 160 kDa (AS160), also known as TBC1D4, 
phosphorylation of which facilitates the translocation of glucose transporter 4 (GLUT4) 
to the plasma membrane.  AS160 is a Rab GTPase-accelerating protein (Rab GAP).  
Rab proteins bind transport vesicles and influence their localisation based on its 
Chapter 1: Introduction 
 5 
nucleotide-bound state.  GLUT4 storage vesicles (GSV) are associated with a number of 
Rab proteins, which in their inactive GDP-bound state hold the vesicle in the cytosol.  
AS160, catalyses the hydrolysis of any bound GTP to GDP sustaining the Rab in its 
inactive state.  Akt phosphorylates AS160 at a number of key residues including Thr642 
and Ser588, leading to its dissociation from GSVs.  This allows GTP to associate with 
one or more Rab proteins to facilitate the trafficking of GSVs to the plasma membrane 
(Sano, 2003, Larance et al., 2005, Hutagalung and Novick, 2011).  Defects in this 
tightly regulated signalling cascade have been attributed to the development of type 2 
diabetes (Fröjdö et al., 2009). 
 
 
Figure 1.1 The insulin signalling pathway. 
 
Upon autophosphorylation triggered by the binding of insulin, the insulin receptor 
recruits and phosphorylates IRS1, which interacts with the p85 regulatory subunit of 
PI3K, targeting this enzyme to the plasma membrane where the p110 catalytic subunit 
generates PIP3.   PIP3 recruits PH domain containing proteins such as Akt and PDK1 to 
the plasma membrane.  Akt is then phosphorylated by the now activated PDK1, in 
conjunction with mTORC2.  Once activated, Akt can regulate glucose homeostasis by 
promoting glycogen synthesis, preventing gluconeogenesis and stimulating glucose 
uptake.  
Chapter 1: Introduction 
 6 
1.3 Obesity-Induced Inflammation 
 
Adipose tissue functions as a multicellular endocrine organ composed of adipocytes, 
stromal-vascular cells and immune cell populations.  The expansion of white adipose 
tissue associated with overnutrition leads to hypoxia, cell death, changes in fatty acid 
metabolism, altered adipose tissue specific cytokine (adipokine) secretion and pro-
inflammatory immune cell infiltration, which can lead to development of insulin 
resistance (McArdle et al., 2013).  Since visceral adipose tissue accumulates more pro-
inflammatory cells in obesity, it is more metabolically damaging than subcutaneous 
adipose tissue (O’Rourke and Metcalf, 2009).  As obesity progresses, adipocytes secrete 
chemotactic cytokines such as monocyte chemotactic protein-1 (MCP-1) and 
leukotriene B4 (LTB4) recruiting monocytes into the adipose tissue where they 
differentiate into macrophages (Osborn and Olefsky, 2012).    
1.3.1 Macrophage Infiltration into Adipose Tissue 
 
Macrophages infiltrating adipose tissue undergo polarisation, switching from the anti-
inflammatory M2 type subset to the pro-inflammatory M1 type subset under the 
influence of interferon-gamma (IFN-γ) as well as interleukin 17 (IL-17), secreted by 
resident pro-inflammatory T cells (Fig. 1.2) (Lumeng et al., 2007, Winer et al., 2009).  
M1 macrophages secrete a repertoire of pro-inflammatory cytokines including IL-1β, 
IL-6, and tumour necrosis factor-alpha (TNF-α) to further stimulate obesity-associated 
inflammation (Chawla et al., 2012).  Increased levels of circulating free fatty acids, 
produced as a consequence of augmented lipolysis, have also been reported to trigger 
macrophage secretion of the pro-inflammatory cytokines MCP-1, IL-6, IL-1β and TNF-
α in vitro (Nguyen et al., 2007).  Several studies have demonstrated the central role M1 
macrophages play in the promotion of insulin resistance, since deletion of this subset of 
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macrophages reduces adipose tissue inflammation and normalises insulin sensitivity 
(Patsouris et al., 2008). 
 
 
Figure 1.2 Adipose tissue in lean and obese states. 
 
In the lean state, M2 macrophages (M2 Mϕ) and regulatory T cells (Treg) reside in the 
adipose tissue and stem inflammation.  In the case of obesity, where adipocytes increase 
in number and in mass, the inflammasome is triggered by saturated free fatty acids and 
pro-inflammatory cytokines resulting in the secretion of MCP-1 to promote the 
infiltration of pro-inflammatory M1 macrophages (M1 Mϕ) into adipose tissue.  M1 
macrophages recruit effector (CD8+) and memory (CD4+) T cells, which release pro-
inflammatory cytokines further contributing to the development of insulin resistance 
(Kanneganti and Dixit, 2012). 
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1.4 Insulin Resistance 	
Insulin resistance is characterised by a diminished capacity for insulin to act on its 
receptor in peripheral tissues, leading to hyperglycaemia and hyperinsulinaemia as 
pancreatic β-cells produce excessive amounts of insulin to control blood glucose 
homeostasis.  As the condition progresses, β-cell function deteriorates exacerbating 
hyperglycaemia, leading to the development of type 2 diabetes and its associated 
complications (Wilcox, 2005).  Augmented adipokine secretion associated with obesity 
is now recognised as a major cause of this pathophysiological defect. 
1.4.1 Pro-inflammatory Cytokines and Insulin Resistance 	
Chronic low-grade inflammation induced by obesity negatively impacts on the insulin 
signalling pathway largely through the increased production of the pro-inflammatory 
cytokines IL-1β, IL-6 and TNF-α.   
1.4.1.1 IL-1β 	
Pro-IL-1β is cleaved by caspase-1 to form mature IL-1β (Lopez-Castejon and Brough, 
2011) chronic exposure to which reduces IRS1 expression, leading to a decrease in 
AS160 phosphorylation and GLUT4 translocation in a manner dependent on the 
mitogen activated protein kinase (MAPK), extracellular signal related kinase (Erk) 
(Jager et al., 2007).  Receptor-mediated effects of IL-1β have been observed to trigger 
the activation of I-kappa-B kinase beta (IKKβ) (Section 1.4.1.4.1) and the MAPKs 
(Section 1.4.1.4.2), which negatively impact on the insulin signalling pathway.  
Furthermore, the NOD like Receptor 3 (NLRP3)-caspase-1 inflammasome, which 
induces caspase-1 activity to produce IL-1β (Martinon et al., 2002), also has been 
implicated in the development of insulin resistance.  A decrease in NLRP3 expression is 
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associated with improved insulin sensitivity, while NLRP3 deficient mice display 
decreased obesity-induced inflammation and an increase in insulin-stimulated 
phosphorylation of Akt (Vandanmagsar et al., 2011). 
1.4.1.2 IL-6 
A two to three-fold increase in circulating IL-6 is observed in obese and type 2 diabetic 
patients (Kern et al., 2001).  Exposure of HepG2 cells and primary murine hepatocytes 
to this pro-inflammatory cytokine has been found to inhibit insulin receptor signal 
transduction (Senn et al., 2002), through a mechanism now believed to involve the 
JAK-STAT signalling pathway (Section 1.4.1.4.3).  However, the effect of IL-6 on 
insulin signalling occurs with elevated levels of the cytokine only, as Wallenius and 
colleagues (2002), observed an obesogenic phenotype in IL-6 deficient mice, to which 
low doses of centrally administered IL-6 increased energy expenditure, demonstrating 
anti-obesity effects.  Carey and colleagues (2006), attributed this to the influence of IL-
6 on the cellular energy regulator AMP activated protein kinase (AMPK) (Section 1.5), 
as glucose disposal was enhanced in an AMPK-dependent manner in healthy humans 
exposed to recombinant IL-6.  
1.4.1.3 TNF-α 
TNF-α is by far the most well-established pro-inflammatory cytokine contributing to 
insulin resistance, with triple the amount of this protein secreted from the adipose tissue 
of obese subjects (Kern et al., 2001).  Neutralisation and deletion of TNF-α, which is 
also markedly upregulated in the adipose tissue of experimental models of obesity, has 
been found to significantly improve insulin sensitivity (Hotamisligil and Spiegelman, 
1994, Uysal et al., 1997).  Receptor-mediated effects of TNF-α have been observed to 
trigger the activation of IKKβ, the MAPKs and the JAK-STAT pathway to promote 
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insulin resistance making it the most prominent of the pro-inflammatory cytokines to 
impede the insulin signalling pathway.  
1.4.1.4 Cytokine Signalling and Insulin Resistance 
 
TNF-α and IL-1β transiently activate both IKKβ and the MAPK c-Jun N-terminal 
kinase (JNK), which have been directly implicated in the development of insulin 
resistance through multiple mechanisms (Fig. 1.3) (Solinas and Karin, 2010).  Ablation 
of IKKβ (Yuan et al., 2001) and JNK (Hirosumi et al., 2002) has been shown to protect 
mice from the development of insulin resistance.  Additionally, TNF-α and IL-6 can 
trigger the activation of suppressors of cytokine signalling 3 (SOCS3) through the JAK-
STAT pathway, deletion of which prevents obesity-induced insulin resistance in skeletal 
muscle (Jorgensen et al., 2013). 
1.4.1.4.1  IKKβ 
 
Phosphorylation of IKK at the β-subunit can be induced by the RIP1-TRADD-TRAF2 
complex formed at the death domain of the activated TNF-α receptor and through IL-1β 
signal transduction involving MyD88, IRAK and TRAF6 (Karik et al., 2004).  IKKβ 
has been proposed to phosphorylate IRS1 at multiple serine residues, which prevents 
insulin-induced tyrosine phosphorylation of its substrate, rendering the insulin 
signalling pathway inactive (Gao et al., 2002).  However, the primary role of IKKβ in 
the development of insulin resistance is believed to be through its influence on nuclear 
factor kappa B (NF-κB) to promote pro-inflammatory gene expression (Cai et al., 
2005).  
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1.4.1.4.2  MAPKs 
 
Downstream of TNF-α and IL-1β receptor activation, TRAF2 and TRAF6 also activate 
the MAPK cascade (Fig. 1.4) to trigger the phosphorylation of JNK.  Activation of 
MAP/Erk kinase kinase 1 (MEKK1) and apoptosis signal regulating kinase 1 (ASK1), 
leads to the stimulation of MAPK kinases 4 and 7 (MKK4/7), highly specific activators 
of JNK (Liu et al., 1996, Tournier et al., 2001).  Since JNK deficient mice display 
reduced expression of pro-inflammatory cytokines, this protein is believed to exacerbate 
metabolic inflammation through the phosphorylation of the downstream transcription 
factor c-Jun (Tuncman et al., 2006).  However, the most notable mechanism by which 
JNK induces insulin resistance is through the phosphorylation of IRS1 at Ser307, which 
prevents insulin from acting upon its substrate, impeding the insulin signalling cascade 
(Aguirre et al., 2000).   
 
The other MAPKs, which can be activated by TNF-α receptor signalling, p38 and Erk 
(Sabio and Davis, 2014), have also been observed to influence the insulin signalling 
cascade.  Mice lacking the δ isoform of p38 are protected from obesity-induced insulin 
resistance and oxidative stress-stimulated β-cell failure as a result of the increased 
activation of protein kinase D, a positive regulator of insulin secretion (Sumara et al., 
2009).  Furthermore, mice overexpressing p38α exhibit reduced insulin-stimulated IRS1 
tyrosine phosphorylation as a result of increased serine phosphorylation, while liver 
specific expression of dominant negative p38α in ob/ob mice has been found to improve 
glucose tolerance (Hemi et al., 2011). 
Pharmacological inhibition of Erk attenuates the effect of IL-1β on IRS1 (Jager et al., 
2007) and enhances the transcriptional activity of the redox sensitive transcription factor 
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Nuclear Factor-Erythroid 2 p45–related factor 2 (Nrf2), preventing oxidative stress-
induced insulin resistance (Tan et al., 2011).  However, an opposing role has been 
suggested for this MAPK, as inhibition of Erk has been found to promote insulin 
resistance in Drosophila as a result of decreased insulin receptor expression (Zhang et 
al., 2011). 
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Figure 1.3 The effects of TNF-α and IL-1β-mediated activation of IKKβ and JNK 
on the insulin signalling pathway. 
 
The TNF-α receptor undergoes trimerisation following ligand binding, allowing the 
scaffolding protein, receptor interacting protein 1 (RIP1), to initiate complex formation 
with the intracellular death domain (DD) of the receptor, the adaptor protein, TNF 
receptor associated death domain (TRADD), and TNF receptor associated factor 2 
(TRAF2).  In response to activation by IL-1β, the Toll/IL-1 receptor (TIR) domain of 
the IL-1 receptor interacts with the TIR domain of myeloid differentiation factor 88 
(MyD88), which transduces the signal to a family of IL-1 receptor-associated kinases 
(IRAKs).  IRAKs undergo phosphorylation by other IRAKs inducing the activation of 
TNF receptor-associated factor 6 (TRAF6).  Both TRAF2 and TRAF6 phosphorylate 
IKKβ and lead to the activation of the JNK MAPK cascade.  IKKβ and JNK provoke 
further expression of pro-inflammatory genes such as TNF-α, pro-IL-1β and IL-6 
through NF-κB and c-Jun respectively.  IKKβ and JNK also directly attenuate insulin 
signalling by phosphorylating IRS1 at serine residues, which prevents insulin-induced 
tyrosine phosphorylation of this protein. Adapted from (Karik et al., 2004). 
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Figure 1.4 MAPK signalling cascades. 
 
The three-tiered MAPK cascades can be activated by a multitude of factors including 
mitogens, cytokines, growth factors, cellular stresses and guanine nucleotide binding 
protein coupled receptor (GPCR) signal transduction.  An activate MAPK kinase kinase 
(MAPKKK) triggers a MAPK kinase (MAPKK) to specifically phosphorylate one of 
the MAPKs Erk, p38 and JNK.  Once activated MAPKs can target intracellular proteins 
or enter the nucleus to trigger transcription factor activation (Jeffrey et al., 2007). 
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1.4.1.4.3  SOCS3 
Cytokine binding to its receptor can also lead to the activation of the JAK-STAT-SOCS 
pathway, which negatively influences insulin signalling (Fig. 1.5).  TNF-α receptor 
stimulation leads to the recruitment of one or more Janus kinases (JAK), which 
phosphorylate the receptor, creating docking sites for signal transducers and activators 
of transcription (STAT) (Ehlting et al., 2007).  Upon phosphorylation STATs form 
homo- or heterodimeric complexes that translocate to the nucleus and activate the 
transcription of target genes.  Upon interaction with its ligand, the IL-6 receptor 
associates with the signalling receptor glycoprotein 130 (GP-130), which dimerises 
leading to the activation of the JAK-STAT pathway (Heinrich et al., 1998, Sommer et 
al., 2005).  TNF-α and IL-6-induced activation of this pathway can lead to the 
transcription of SOCS3 (O’Sullivan et al., 2007).  SOCS3 has been observed to bind 
Tyr960 of the insulin receptor, partially impairing receptor autophosphorylation.  As 
Tyr960 is a critical recognition site for IRS1, cytokine-induced activation of SOCS3 also 
suppresses IRS1 signalling, attenuating insulin-induced glycogen synthesis (Ueki et al., 
2004).  However, more recently Sachithanandan and colleagues (2010), demonstrated 
liver specific deletion of SOCS3 to improve insulin sensitivity yet promote lipogenesis 
leading to obesity, increased inflammation and the development of nonalcoholic fatty 
liver disease.  Furthermore, Pedroso and colleagues (2014), found that inactivation of 
SOCS3 improved insulin sensitivity, while having no effect on diet-induced obesity.  
These studies and countless others highlight obesity-induced type 2 diabetes as a 
multifactorial disease, to which the contributory factors may be differentially regulated 
in any given case, and therefore unlikely to be curtailed by targeting any one element 
alone.  
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Figure 1.5 Cross talk between the JAK-STAT pathway and the insulin signalling 
pathway. 
 
TNF-α and IL-6-induced receptor activation triggers JAK to phosphorylate the 
cytoplasmic domain of the receptor creating a docking site for STAT.  Once 
phosphorylated, STATs dimerise and enter the nucleus to activate the transcription of 
SOCS3.  SOCS3 inhibits tyrosine phosphorylation of IRS1 decreasing glucose uptake 
and glycogen synthesis and increasing gluconeogenesis.  
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1.4.2 Retinol Binding Protein and Insulin Resistance 	
Retinol binding protein (RBP) facilitates the transport of hydrophobic retinol (vitamin 
A) from its primary storage site, the liver, to target tissues (Kanai et al., 1968).  Retinol-
bound RBP circulates in the bloodstream bound to transthyretin (TTR), which prevents 
the glomerular filtration and excretion of RBP due to the increased mass of the RBP-
TTR complex (Goodman, 1984, van Bennekum et al., 2001).  At the target tissue, 
retinol is transported across the cell membrane via the RBP receptor, stimulated by 
retinoic acid 6 (STRA6), which competes with TTR to bind RBP (Heller, 1975, 
Sivaprasadarao and Findlay, 1988a, 1988b, Kawaguchi et al., 2007).  STRA6 then 
mediates the transfer of retinol to the cellular retinol binding protein (Sundaram et al., 
1998).  As retinol-free RBP does not bind TTR, it is then easily excreted by the kidney. 
While liver is the primary site of RBP secretion, adipose tissue, amongst others, has 
also been found to contribute to circulating RBP levels (Tsutsumi et al., 1992).   
 
This adipokine has been implicated in the genesis of obesity-related insulin resistance as 
serum RBP levels are elevated in obese subjects.  Furthermore, the characteristic insulin 
resistant state of the adipose tissue specific GLUT4 knockout mouse is associated with 
a significant increase in adipose tissue secretion of RBP (Yang et al., 2005).  
Continuing on from this, Yang and colleagues (2005), found mice injected with 
recombinant human RBP to be insulin resistant and glucose intolerant, while RBP 
knockout mice displayed increased insulin sensitivity.  Additionally, treatment with 
fenretinide, a synthetic retinoid that inhibits RBP binding to TTR, promoting RBP 
excretion, was found to improve glucose tolerance in obese insulin resistant mice.  
However, fenretinide treatment also demonstrated beneficial effects in obese, insulin 
resistant RBP knockout mice, suggesting an RBP-independent response.  Nonetheless, 
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the improvement in glucose disposal associated with weight loss also correlates with a 
decrease in RBP levels, demonstrating the significant role this adipokine may play in 
obesity-related insulin resistance (Graham et al., 2006). 
 
Conflicting reports have emerged as to how RBP contributes to the development of 
insulin resistance.  Berry and Noy (2012), suggest retinol-bound RBP induces the 
phosphorylation of STRA6, which activates a JAK-STAT pathway, involving JAK2 
and STAT5, to upregulate SOCS3 expression, thereby inhibiting insulin signalling. 
However, when Muenzner and colleagues (2013), exposed control and STRA6 
overexpressing cells to RBP, in the presence or absence of retinol, no change in STAT5 
phosphorylation was observed.  Furthermore in mice overexpressing RBP in the liver, 
the increased serum levels of retinol-bound RBP were not associated with a change in 
SOCS3 mRNA expression in the adipose tissue.  Norseen and colleagues (2012), 
suggest RBP acts independently of STRA6 to incite an immune response that 
contributes to the development of insulin resistance.  Direct stimulation of adipose 
tissue macrophages with RBP led to an increase in IL-6, IL-1β, TNF-α and MCP-1 
expression and a reduction in the negative regulator of inflammation, peroxisome 
proliferator-activated receptor gamma (PPARγ).  This effect was triggered with retinol-
free RBP just as proficiently as with retinol-bound RBP.  RBP was also found to 
activate the NFκB, p38, Erk and JNK signalling pathways in macrophages.  RBP 
demonstrated a reduced effect on MCP-1 and IL-6 expression in JNK deficient 
macrophages and in Toll like receptor 4 (TLR4) deficient macrophages.  However, the 
effect of RBP was not completely inhibited, suggesting other signalling pathways may 
be involved in RBP-induced insulin resistance.  More recently Young and colleagues 
(2015), in this laboratory, found retinol-bound RBP to decrease levels of protein 
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phosphatase 1β, a regulator of the rate limiting enzymes involved in glycogen 
metabolism, in C2C12 muscle cells.  As a consequence of the observed decrease in 
glycogen synthase activity a detrimental effect on insulin stimulated glycogen 
production was observed.  The reduced ability to store glucose as glycogen and the 
attenuated capacity to utilise glycogen stores can contribute to the development of 
insulin resistance and may account for the influence of elevated RBP levels on this 
condition.   
1.4.3 Adipose Tissue Hormones and Insulin Resistance 	
The perturbed release of hormones from adipose tissue has also been found to 
contribute to the pathogenesis of insulin resistance.  The secretion of resistin is 
markedly upregulated in murine models of genetic and diet-induced obesity and has 
been found to play a central role in the production of inflammatory molecules such as 
TNF-α and IL-6 through the activation of NF-κB (Codoñer-Franch and Alonso-Iglesias, 
2015).  Leptin release is also upregulated in obese subjects (Silha et al., 2003).  Under 
normal physiological conditions, leptin regulates energy balance by suppressing food 
intake and increasing fatty acid oxidation through the action of AMPK (Minokoshi et 
al., 2002, Klok et al., 2007).  However, with obesity, subjects are essentially resistant to 
the positive effects of leptin, as the increased levels of SOCS3 associated with obesity 
impair leptin-induced activation of AMPK (Yang et al., 2012).  Conversely, the 
expression of adiponectin is significantly decreased with obesity, this adipokine also 
enhances fatty acid oxidation through AMPK, suppresses TNF-α and IFN-γ production 
and improves insulin sensitivity (Carbone et al., 2012).  These hormones play a pivotal 
role in the regulation of energy homeostasis, the impact of both leptin and adiponectin 
on AMPK to maintain this balance, stresses the importance of this kinase in the 
regulation of a fundamental aspect of the type 2 diabetic phenotype.  
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1.5 AMP Activated Protein Kinase (AMPK) 	
AMPK is a highly conserved metabolic master switch present in all eukaryotes, which 
responds to fluctuations in ADP:ATP and AMP:ATP ratios to restore energy 
homeostasis by regulating pathways involved in glucose metabolism, lipid metabolism, 
protein synthesis and mitochondrial biogenesis (Sanders et al., 2007, Xiao et al., 2011, 
O’Neill, Holloway and Steinberg, 2013).  Although cellular processes are driven by the 
hydrolysis of ATP to ADP and a free phosphate, adenylate kinases rapidly catalyse two 
ADP molecules to generate one ATP and one AMP molecule (Zeleznikar et al., 1990), 
giving great emphasis to this ratio as an indicator of energy status in times of enhanced 
cellular stress.   
1.5.1 AMPK Structure 	
AMPK is a heterotrimeric kinase consisting of a catalytic α-subunit and regulatory β 
and γ subunits.  In mammals AMPK is encoded by seven genes for the specific isoforms 
of each subunit (α1, α2, β1, β2, γ1, γ2, γ3; α1, γ2 and γ3 isoforms also have splice 
variants) (Table 1.1) (Steinberg and Kemp, 2009, Viollet et al., 2010, Hardie, 2011).  
Combinations of the diverse isoforms lead to the formation of at least 12 different 
complexes which confer defined properties to the kinase in terms of localisation and 
signalling functions (Viollet et al., 2010).  The subunits of AMPK are generally 
unstable when expressed individually, with co-expression of all three necessary for 
kinase activity (Hardie, 2011). 
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Table 1.1 Tissue distribution of AMPK subunits. 
Subunit Tissue Distribution 
α1 Adipose tissue, lung, brain, liver, kidney, spleen, pancreas, heart, skeletal muscle 
α2 Heart, skeletal muscle, kidney, liver, brain, lung, adipose tissue, spleen, pancreas 
β1 Widespread 
β2 Skeletal muscle, heart 
γ1 Widespread 
γ2 Widespread; brain, placenta, heart, skeletal muscle  
γ3 Skeletal muscle 
 
Key:         High expression, low expression 
The catalytic α-subunit of AMPK is a 63 kDa protein containing a serine/threonine 
kinase domain.  The phosphorylation of Thr172 confers activation (Hawley et al., 1996, 
Stein et al., 2000), whereas that of Ser485 triggered by Akt and potentially through 
autophosphorylation, renders the kinase inactive (Horman et al., 2006, Hurley et al., 
2006).  The α-subunit also comprises an auto-inhibitory domain (AID) at the N-
terminus, while the C-terminus contains binding domains for the β and γ subunits.  The 
β-subunit has a central carbohydrate binding molecule (CBM) and a C-terminal region 
that binds the α and γ subunits.  The N-terminal region of the γ-subunit is followed by 
Bateman domains; regulatory adenine nucleotide-binding sites composed of four highly 
conserved cystathionine-beta-synthase (CBS) sequence repeats (Kemp, 2004).  The 
CBS motifs gather such that there are four sites where adenine nucleotides can 
potentially bind (Fig. 1.6).  
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Figure 1.6 Domain map of AMPK. 
The α and γ subunits come together at the β-subunit carboxy-terminal domain (β-CTD) 
to form the AMPK complex.  Image from (Hardie, Ross and Hawley, 2012). 
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1.5.2 AMPK Activation 	
In its inactive state, AMPK is bound to ATP, until a change in cellular energy balance 
allows AMP to compete with ATP to occupy the kinase at the CBS1 and CBS3 sites, 
while ADP appears to bind to CBS3 only.  Nucleotide exchange at these two CBS 
motifs triggers a conformational change that provokes AMPK activation through three 
main mechanisms (Fig. 1.7) (Corton et al., 1994, Davies et al., 1995, Hawley et al., 
1996).  
1. Under moderate stress, AMP or ADP bind to CBS3 to promote the 
phosphorylation of Thr172 by upstream kinases, conferring more than 200-fold 
increased activity.   
2. The replacement of ATP at CBS3 also stimulates an association between the N-
terminal lobe of the kinase domain and the CBM of the β-subunit to protect 
against Thr172 dephosphorylation.  
3. Under more severe stress, AMP displaces ATP at CBS1 to allosterically activate 
previously phosphorylated AMPK, adding a further 10-fold activation status to 
the kinase.  
The CBS4 site contains a permanently bound AMP molecule, whereas CBS2 appears to 
be always vacant, potentially due to the lack of an aspartate residue which interacts with 
the ribose ring of a bound nucleotide in the other three CBS sites (Viollet et al., 2010, 
Hardie, 2011, Xiao et al., 2011, Carling and Viollet, 2015). 
In addition to IL-6, adiponectin and leptin as previously mentioned, pharmacological 
agents, hormones and cellular stresses such as glucose starvation, ischemia, hypoxia and 
exercise can all initiate specific signalling cascades that lead to the activation of AMPK. 
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Figure 1.7 Model of AMPK activation. 
(A) A mechanistic model for the activation states of AMPK governed by nucleotide 
binding, regulatory kinases and phosphatases.  As ADP can readily bind to the CBS3 
site, it can promote and maintain the phosphorylation of AMPK at Thr172.  However, 
ADP cannot bind to CBS1 and therefore cannot allosterically activate phosphorylated 
AMPK to trigger the greater than 2000-fold increase in kinase activity, emphasising the 
critical role AMP plays in the regulation of this protein.  (B) Predicted nucleotide 
concentrations under various levels of cellular stress.  Image adapted from (Hardie, 
Ross and Hawley, 2012). 
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1.5.2.1 Pharmacological Activation of AMPK 	
A number of pharmacological agents have been reported to activate AMPK through 
direct and indirect mechanisms.  5-Aminoimidazole-4-carboxamide riboside (AICAR), 
which is phosphorylated into the AMP analog ZMP by adenosine kinase, was the first 
compound identified to directly activate AMPK.  ZMP mimics AMP as it binds the γ-
subunit of AMPK inducing allosteric activation, which facilitates the phosphorylation 
of Thr172 by upstream kinases (Sullivan et al., 1994, Corton et al., 1995).  PT1 
allosterically activates AMPK in vitro and is believed to interact with the α-subunit near 
the autoinhibitory domain to directly relieve autoinhibition (Pang et al., 2008).  
Salicylate (Hawley et al,. 2012) and the small-molecules A769662 (Scott et al., 2008) 
and 991 (Xiao et al., 2013), have also been observed to directly activate AMPK as they 
stabilise the AMP-induced interaction between the CBM of the β-subunit and the kinase 
domain of the α-subunit to protect against the dephosphorylation of Thr172.  Several 
activators of AMPK such as biguanides, of which metformin is the first line of 
treatment for type 2 diabetes (Bridges et al., 2014, Matsuzaki and Humphries, 2015), 
berberine (Turner et al., 2008) and the novel compound R419 (Jenkins et al., 2013) 
have been observed to indirectly activate AMPK by inhibiting complex I of the 
mitochondrial respiratory chain.  
1.5.2.1.1  Inhibition of NADH:ubiquione oxidoreductase 	
The mitochondrial respiratory chain comprises five complexes, complex I 
(NADH:ubiquinone oxidoreductase), complex II (succinate:ubiquinone 
oxidoreductase), complex III (ubiquinol:cytochrome c oxidoreductase), complex IV 
(cytochrome c oxidoreductase) and complex V (ATP synthase) (Fig. 1.8).  Oxidative 
phosphorylation begins as electrons are donated from NADH to NADH:ubiquinone 
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oxidoreductase or from FADH2 to succinate:ubiquinone oxidoreductase.  
NADH:ubiquinone oxidoreductase establishes the proton gradient as it releases two 
hydrogen ions for every one electron across the matrix into the intermembrane space, 
while the other complexes release one hydrogen for every electron processed 
(Wikström, 1984).  Furthermore, ubiquinol:cytochrome c oxidoreductase and 
cytochrome c oxidoreductase form a supramolecular association with 
NADH:ubiquinone oxidoreductase, creating respirasomes which confer a kinetic 
advantage to NAD-linked respiration (Genova and Lenaz, 2014).   
Electrons are sequentially transferred to cytochrome c oxidoreductase where they 
interact with molecular oxygen and hydrogen ions to generate a water molecule.  The 
energy associated with the proton gradient is then exploited by ATP synthase to 
generate ATP from ADP and inorganic phosphate (Fernández-Vizarra et al., 2009).  
Inhibition of NADH:ubiquinone oxidoreductase perturbs this energy generation leading 
to a significant decrease in ATP synthesis, as NADH:ubiquinone oxidoreductase is 
believed to provide 40 % of the protons required for ATP production  (Efremov et al., 
2010).  The resultant build-up of ADP may then directly interact with AMPK, or is 
subject to the action of adenylate kinase to increase cellular AMP levels, all of which 
enhance AMPK activation. 
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Figure 1.8 The mitochondrial respiratory chain. 
Electrons generated from NADH and FADH2 are passed through the complexes of the 
mitochondrial respiratory chain with the aid of the carrier molecules, ubiquinone (Q) 
and cytochrome c (Cyt) leading to the reduction of molecular oxygen to water.  The 
energy liberated during respiration through the creation of the H+ gradient is used by 
ATP synthase to catalyse the condensation of ADP and inorganic phosphate (Pi) into 
ATP.  Inhibition of NADH:ubiquinone oxidoreductase leads to a significant decrease in 
energy production which is sensed by AMPK.  
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The naturally occurring phytochemicals quercetin and resveratrol also activate AMPK 
as they inhibit ATP synthase to alter cellular energy balance (Zheng and Ramirez, 
2000).  Numerous other natural and synthetic compounds with anti-diabetic and anti-
obesogenic properties have also been observed to influence AMPK activity including, 
DHPO (Kandadi et al., 2010), curcumin (Kim et al., 2010) and tangeretin (Kim et al., 
2012) however, the mechanism by which this occurs remains elusive.  
1.5.2.2 Exercise-Induced Activation of AMPK 	
As well as through a decrease in ATP production, AMPK can be activated by an 
increase in ATP consumption through the more physiological condition of metabolic 
stress that is exercise.  The rise in cellular ADP and AMP as a consequence of intense 
muscle contraction and prolonged low impact exercise leads to the activation of one of 
the three AMPK complexes expressed in human skeletal muscle; α1β2γ1, α2β2γ1 and 
α2β2γ3 (Richter and Ruderman, 2009).  As the potent AMPK activator AICAR 
regulates glucose and lipid metabolism in a similar manner to contraction in skeletal 
muscle, AMPK is believed to mediate many of the beneficial effects of exercise (Merrill 
et al., 1997).  Furthermore, exercise induces the release of IL-6 which has been found to 
activate the kinase (Kelly et al., 2004).   
The leptin-receptor-deficient Zucker Diabetic Fatty (ZDF) rat displays the importance 
of AMPK and exercise in the management of the type 2 diabetic phenotype as treadmill 
training of the ZDF rat, which displays decreased AMPK activity, markedly improves 
glucose tolerance and insulin sensitivity (Becker-Zimmermann et al., 1982, Yu et al., 
2004).  Furthermore, AMPKβ1β2 (O’Neill et al., 2011) and AMPKα1α2 (Lantier et al., 
2014) skeletal muscle specific knockout mice have reduced exercise capacity while 
β1β2 knockout mice display significantly reduced contraction-stimulated glucose 
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uptake.  These studies also proposed a role for AMPK in exercise-induced stimulation 
of mitochondrial biogenesis to expand the mitochondrial network within muscle cells, 
increasing the capacity for aerobic ATP provision (Hood, 2009). 
1.5.2.3 Regulation of AMPK Phosphorylation 	
Once bound by AMP or ADP the phosphorylation of AMPK at Thr172 can be regulated 
(Fig. 1.9). AMPK is primarily phosphorylated by a complex formed between liver 
kinase B1 (LKB1) and two accessory subunits, the pseudokinase sterile-20-related 
adaptor (STRAD) and the scaffolding protein, mouse protein-25 (MO25) (Hawley et 
al., 2003, Woods et al., 2003).  STRAD induces LKB1 relocalisation from the nucleus 
to the cytoplasm with the aid of the histone/protein deacetylase, sirtuin 1 (Lan et al., 
2008).  STRAD then stimulates the catalytic activity of LKB1 and promotes interaction 
with MO25, which stabilises the activation loop of LKB1 in a conformation necessary 
for it to catalyse the phosphorylation of AMPK (Zeqiraj et al., 2009).  Although tissue-
specific deletion of LKB1 has demonstrated the central role this protein plays in the 
phosphorylation of AMPK, kinase activation can also be modulated by Ca2+/calmodulin 
dependent protein kinase kinase β (CaMKKβ) in a Ca2+ dependent manner.  This action 
is particularly important in neurons, endothelial cells and T lymphocytes (Hawley et al., 
2005, Shackelford and Shaw, 2009).  Furthermore, the effects of leptin (Park et al., 
2013) and adiponectin (Lee and Shao, 2012) on AMPK activity are proposed to be 
mediated through the action of CaMKKβ.  
Other proteins that play a role in AMPK activity include the protein phosphatases 2 A 
(PP2A) and C (PP2C) (Davies et al., 1995), and the MAPKKK TGF-beta-activated 
kinase 1 (TAK1) (Momcilovic et al., 2006).  Both PP2A and PP2C suppress AMPK 
activity in the absence of ADP and AMP through dephosphorylation, while TAK1 has 
Chapter 1: Introduction 
 30 
been found to increase AMPK phosphorylation at Thr172 in vitro.  
 
 
Figure 1.9 The regulation of AMPK phosphorylation.  
Alterations in cellular energy balance lead to an increase in intracellular ADP that is 
promptly converted into ATP and AMP through the action of adenylate kinase.  The 
increasing levels of AMP and ADP displace ATP bound to the CBS domain of the γ-
subunit of AMPK.  The resultant conformational change allows AMPK to be 
phosphorylated at Thr172 within the activation loop of the α-subunit by the LKB1 
complex, CaMKKβ and TAK1.  ADP as well as AMP binding stabilises AMPK in an 
active conformation preventing its dephosphorylation by PP2A and PP2C.  Activated 
Akt stimulates AMPK phosphorylation at Ser485 to impede phosphorylation at Thr172. 
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1.5.3 Downstream Effects of AMPK Activation 	
Once activated, AMPK restores cellular energy balance by switching on ATP 
generating pathways and switching off ATP consuming pathways, a response that has 
been found to counteract many of the cellular abnormalities of type 2 diabetes (Fig. 
1.10) (Kahn et al., 2005). 
1.5.3.1 Lipid Metabolism 	
The primary role attributed to AMPK, which aided its discovery, was as a regulator of 
key enzymes involved in lipid metabolism (Munday et al., 1988, Hardie et al., 1989).  
Activated AMPK phosphorylates 3-hydroxy-3-methylglutaryl-CoA reductase 
(HMGCR) to suppress cholesterol synthesis, while AMPK-induced phosphorylation of 
acetyl-CoA carboxylase (ACC) influences fatty acid synthesis and oxidation.  
Phosphorylation of ACC at Ser79 halts its enzymatic activity leading to a decrease in 
malonyl CoA, a key substrate for fatty acid synthesis.  The fall in malonyl-CoA content 
leads to a subsequent increase in fatty acid oxidation by heightening carnitine 
palmitoyltransferase 1 in skeletal muscle (Winder and Hardie, 1996, Ruderman et al., 
1999).  AMPK also prevents the cleavage and activation of sterol regulatory element-
binding protein 1C (SREBP1C)-induced triglyceride synthesis (Li et al., 2011).  
1.5.3.2 Glucose Metabolism 	
Consistent with a role in maintaining energy homeostasis AMPK exploits glucose 
metabolism, promoting catabolism and suppressing anabolism to restore cellular ATP 
levels.  AMPK converges with the insulin signalling pathway to promote glucose 
uptake through GLUT4 translocation in an AS160 dependent manner (Treebak et al., 
2006).  The CBM domain of the AMPK β-subunit has been postulated to facilitate its 
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interaction with glycogen-associated proteins such as glycogen synthase (Hardie et al., 
2012).  In fact, AMPK has been observed to phosphorylate glycogen synthase, 
inhibiting the process of glycogen synthesis in favour of glycolysis, yet whether this is 
dependent on a CBM-mediated interaction remains unclear (Bultot et al., 2012).  
AMPK also acts on 6-phosphofructo-2-kinase and 6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase 3 (PFKFB3), a key regulator of the glycolytic enzyme 
phosphofructokinase-1 to inhibit the process of glycolysis (Marsin et al., 2000, 2002, 
Bando, 2005, Doménech et al., 2015).  Furthermore, AMPK reduces gluconeogenesis 
as it phosphorylates CREB-regulated transcription co-activator 2 (CRTC2) (Koo et al., 
2005), and Class IIa histone deacetylases (HDACs) (Mihaylova et al., 2011). 
1.5.3.3 Mitochondrial Biogenesis 
The expression of peroxisome proliferator-activated receptor-gamma co-activator 1 
alpha (PGC1α), which enhances the activity of mitochondrial gene transcription factors, 
can be augmented by AMPK-induced phosphorylation to stimulate mitochondrial 
biogenesis, promoting ATP production (Jäger et al., 2007). 
1.5.3.4 Protein Synthesis 
To maintain intracellular ATP levels, activated AMPK phosphorylates the RNA 
polymerase I-associated transcription factor (TIFIA), preventing the assembly of 
transcription complexes necessary for the synthesis of ribosomal RNA (Hoppe et al., 
2009).  In addition to this, AMPK phosphorylates key components of mTORC1; 
tuberous sclerosis 1 (Inoki et al., 2003) and the regulatory associated protein of mTOR 
(Gwinn et al., 2008) to suppress protein synthesis. 
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1.5.3.5 Autophagy 	
As a consequence of reduced mTORC1 signalling, AMPK alleviates the inhibitory 
effect of the complex on unc-51-like kinase 1 (Ulk1) and Ulk2 to promote autophagy 
and mitophagy, the specific engulfment of damaged mitochondria by autophagosomes.  
AMPK has also been postulated to directly phosphorylate Ulk1/2, however, the results 
remain inconsistent (Alers et al., 2012).  
 
The impact of AMPK on autophagy demonstrates a cytoprotective response, 
modulating some of the damaging effects of type 2 diabetes (Gonzalez et al., 2011). 
Hyperglycaemia associated with type 2 diabetes, causes an imbalance in the antioxidant 
capacity of the cell leading to organelle damage.  The insulin secreting β-cells rely on 
autophagosomes to sequester and recycle misfolded pro-insulin, defective secretory 
granules and dysfunctional mitochondria to maintain normal cell function (Lee, 2014).  
Impairments in this system have been observed to attenuate these protective effects as 
hepatic suppression of the murine autophagy related gene 7 results in increased 
endoplasmic reticulum stress and insulin resistance (Yang et al., 2010).  
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Figure 1.10 Downstream targets of activated AMPK. 
AMPK regulates cellular energy balance by switching on ATP generating catabolic 
processes; glucose metabolism, fatty acid oxidation, mitochondrial biogenesis and 
autophagy and by switching off ATP consuming anabolic processes; fatty acid 
synthesis, triglyceride synthesis, cholesterol synthesis, protein synthesis, 
gluconeogenesis, glycogen synthesis and ribosomal RNA synthesis.  Image adapted 
from (Hardie, Ross and Hawley, 2012). 
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1.6  Therapeutic Interventions for Type 2 Diabetes 	
Given the beneficial effects of AMPK on many of the hallmarks of type 2 diabetes, it is 
unsurprising that some anti-diabetic drugs target this kinase to regulate glycaemic 
control.  Although the beneficial effects of exercise and weight loss on insulin 
sensitivity are undisputed (Henriksen, 2002, Kopp et al., 2005), perseverance often 
proves difficult (Gage, 2012).  Failing dietary intervention, the AMPK activator 
metformin is the primary drug of choice to control type 2 diabetes, which may be used 
in conjunction with a range of other therapies if treatment goals are not met (Inzucchi et 
al., 2015). 
1.6.1 Metformin 	
Anti-hyperglycaemic effects have been observed in response to many guanidine-
containing compounds. However, metformin is the only drug of its class, the 
biguanides, available as a therapeutic intervention, as the more potent effects of 
phenformin and buformin carry a higher risk for lactic acidosis (Rena et al., 2013).  
Metformin has been in use for over 50 years, however, some understanding of its 
mechanism of action has only been gained in recent years and remains an area of 
dynamic research.  The anti-diabetic effects of metformin originate with the suppression 
of hepatic gluconeogenesis and glucagon signalling and the promotion of glucose 
uptake.  Metformin is believed to enter the cell through the organic cation transporter 1, 
which demonstrates high levels of expression in the liver and kidney (Pernicova and 
Korbonits, 2014).  Metformin then inhibits NADH:ubiquinone oxidoreductase 
increasing cellular ADP and AMP, leading to the activation of AMPK and the 
consequential downstream effects (Rena et al., 2013).  However the glucose-lowering 
influence of m
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mechanism.  Miller and colleagues (2013), proposed that metformin-induced increases 
in AMP inhibit adenylate cyclase to reduce the accumulation of cyclic AMP (cAMP), 
thus attenuating the signalling capabilities of glucagon.  Binding of glucagon to its 
receptor activates adenylate cyclase, consequently stimulating the cAMP dependent 
kinase, protein kinase A (PKA), to phosphorylate downstream targets that increase 
hepatic glucose production.  
In circumstances where metformin is contraindicated, gastrointestinal complications 
prove problematic (Bailey et al., 1996), or treatment goals are not met, one of the 
second line anti-diabetics may be prescribed, yet these often have more undesirable side 
effects. 
1.6.2 Thiozolidinediones 	
Initially the thiazolidinediones were thought to activate PPARγ to modulate the 
transcription of essential genes involved in lipid metabolism, reducing pro-
inflammatory cytokines to attenuate insulin resistance.  However, like metformin the 
thiazolidendiones have been found to exert a cohort of their effects through the action of 
AMPK (LeBrasseur et al., 2006).  More recently, these compounds been found to bind 
to the mitochondria pyruvate carrier 1 (mpc1) and mpc2, to modulate the entry of 
pyruvate into the tricarboxylic acid cycle (Colca et al., 2013).  The thiazolidendiones 
may therefore regulate mitochondrial fatty acid synthesis and branched-chain amino 
acid levels to modulate insulin sensitivity, as a change in the supply of branched-chain 
amino acids has been proposed to activate mTOR, a negative regulator of insulin action 
and β-cell function. Side effects of this class of anti-diabetics include weight gain, 
osteoporosis, heart failure and increased low-density lipoprotein cholesterol (LDL-C) 
(Colca et al., 2014). 
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1.6.3 Sulfonylureas 	
The sulfonylureas comprise the oldest anti-diabetic therapy.  However, these drugs have 
been phased out due to a high incidence of adverse reactions.  The second generation of 
sulfonylureas represent the next most commonly prescribed drugs after metformin for 
the treatment of type 2 diabetes.  These compounds bind to the sulfonylurea receptor 
(SUR), a major component of KATP channels in pancreatic β-cells, mimicking the effect 
of ATP binding to close the channels.  This depolarises the β-cell membrane, opening 
Ca2+ channels, which stimulates the fusion of insulin secretory vesicles with the cell 
membrane.  Sulfonylureas have also been observed to promote insulin secretion as they 
bind the exchange protein directly activated by cAMP, which interacts with the Rap1 
protein to increase vesicle fusion.  However, as a consequence of augmented insulin 
secretion, the sulfonylureas often cause hypoglycaemia, which is associated with an 
increased risk of cardiovascular events.  Furthermore, SUR isoforms are also found on 
cardiomyocytes and help mediate adaptations to cardiac ischemia by increasing K+ 
efflux, although this predisposes malignant ventricular arrhythmias.  Sulfonylureas may 
therefore confer antiarrhythmic properties but may enlarge infarct size (Thulé and 
Umpierrez, 2014). 
1.6.4 Metaglitinides 
The meglitinides function in a similar way, yet with a different molecular binding site to 
the sulfonylureas, as they close β-cell membrane KATP channels to promote insulin 
secretion.  These compounds have a shorter duration of action and thus a reduced but 
not eliminated risk of hypoglycaemia (Stein, Lamos and Davis, 2013). 
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1.6.5 α-Glucosidase Inhibitors 	
The α-glucosidase inhibitors attenuate intestinal α-glucosidase to delay the absorption 
of consumed carbohydrates resulting in a reduction in blood glucose levels.  Side effects 
are minimal, however, gastrointestinal complications and frequent dosing regimes 
significantly reduce compliance (Stein, Lamos and Davis, 2013).   
1.6.6 Dopamine-2 Agonists 	
The dopamine-2 agonist bromocriptine is believed to alter the hypothalamic circadian 
rhythm to offset an insulin resistant state. Taken within two hours of waking, 
bromocriptine reduces the increased prolactin levels typically associated with type 2 
diabetics in a state of fasting hyperglycaemia.  As a consequence, the dopamine-2 
agonist is believed to restore dopaminergic activity, decreasing plasma levels of 
glucose, triglycerides and free fatty acids.  Furthermore, bromocriptine reduces 
uncoupled inducible nitric oxide synthase (iNOS)- and endothelial NOS (eNOS)-
stimulated generation of reactive oxygen species to protect against atherogenesis in the 
high fat–fed spontaneously hypertensive rat.  It has been observed to also decrease 
major cardiac events in human subjects (Defronzo, 2011).  However, these anti-diabetic 
agents seem to exert a modest influence on glycaemic control with associated reports of 
nausea, dizziness, fatigue and rhinitis (Inzucchi et al., 2015).  
1.6.7 Sodium-Glucose Co-Transporter 2 Inhibitors 	
The sodium-glucose co-transporter 2 (SGLT2) is solely expressed in the apical domain 
of the epithelial cells in the early proximal convoluted tubule of the kidney, where this 
protein couples the transport of glucose with sodium against a concentration gradient. 
SGLT2 inhibitors block the action of the transporters, enhancing the excretion of 
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glucose to improve glycaemic control.  Mild side effects include genitourinary 
infections, polyuria, hypotension and increased LDL-C and creatinine levels (Idris and 
Donnelly, 2009, Inzucchi et al., 2015). 
1.6.8 Amylin Agonists 	
Amylin is a pancreatic β-cell glucoregulatory hormone, co-released with insulin.  Upon 
binding to its receptor, a GPCR in the brain, amylin reduces glucagon release from the 
pancreas, suppresses appetite and modulates gastric emptying.  The amylin agonist, 
pramlintide exhibits a similar biological effect to amylin. However, frequent 
administration is required and side effects including hypoglycaemia and gastrointestinal 
problems have been observed (Hay et al., 2015). 
1.6.9 Bile Acids Sequesterants 	
The bile acids sequesterant, colesevelam binds bile acids in the intestine forming a 
complex that cannot be reabsorbed through the enterohepatic circulation. As a 
consequence bile acid synthesis increases, facilitated by the nuclear farnesoid X 
receptor, while incretin hormones are also augmented through the action of the GPCR, 
TGR5.  As a result, gastric emptying is delayed, hepatic glucose metabolism improves, 
insulin secretion is enhanced and glucose absorption is reduced.  Complications of these 
drugs include gastrointestinal complaints, an increase in triglycerides and compromised 
absorption of other medications (Hansen et al., 2014). 
1.6.10 Incretin Based Therapies 
As observed with bile acid sequesterants, targeting the incretin system is a promising 
approach to attenuate the effects of type 2 diabetes.  The incretin hormones GIP and 
GLP-1 are secreted in response to nutrients entering the gut.  Upon binding to their 
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receptors, GPCRs in β-cells, GLP-1 and GIP induce a signalling cascade to increase 
insulin secretion before being rapidly inactivated by dipeptidyl peptidase 4 (DPP-4). 
This effect is responsible for 50 – 70 % of insulin secretion, yet is markedly reduced 
and sometimes absent in subjects with type 2 diabetes.  The GLP-1 receptor agonists 
exhibit increased resistance to DPP-4 degradation to markedly improve insulin 
secretion, decrease glucagon release, delay gastric emptying and increase satiety 
(Garber, 2011).  However, as this is an injectable therapy, training is required and may 
be disconcerting. Apprehension also surrounds this therapy as cases of acute 
pancreatitis have been reported with implications for pancreatic cancer, while medullary 
thyroid tumors have been observed in animals (Nauck and Friedrich, 2013).  
The DPP-4 inhibitors reduce the degradation of both GIP and GLP-1.  However, the 
hypoglycaemic efficacy is less than that of GLP-1 agonists as concentrations cannot rise 
above physiological levels.  The DPP-4 inhibitors also demonstrate no effect on satiety 
or gastric emptying.  Concerns have been raised regarding the safety of these 
compounds as cases of acute pancreatitis and seronegative polyarthropathy have been 
reported (Tomkin, 2014). 
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1.7  Guanine Nucleotide Binding Protein Coupled Receptors 	
The actions of dopamine-2, amylin, GIP, GLIP-1 and bile acids to modulate glycaemic 
control through the action of GPCRs emphasises the importance of these receptors in 
the regulation of a multitude of cellular functions that may contribute to the 
development of type 2 diabetes.  GPCRs comprise the largest protein superfamily in 
mammalian genomes, with more than 800 genes encoding for these versatile receptors 
in humans (Fredriksson et al., 2003).  GPCRs are characterised by the presence of seven 
membrane spanning α-helical segments separated by alternating intracellular and 
extracellular loop regions.  These membrane-bound receptors recognise a variety of 
extracellular stimuli, such as photons, ions, small molecules, peptides and proteins and 
propagate this signal potential across the membrane over a distance of 50 Å to elicit 
intracellular responses (Stevens et al., 2013).  With each GPCR highly specific to a 
particular signal, these receptors mediate most cellular responses to hormones and 
neurotransmitters, as well as being responsible for vision, olfaction and taste 
(Rosenbaum et al., 2009).  Based on their sequence and structural similarity, GPCRs are 
commonly divided into five families named Glutamate, Rhodopsin, Adhesion, 
Frizzled/taste receptor 2 and Secretin (GRAFS) (Fig. 1.11) (Fredriksson et al., 2003).   
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Figure 1.11 The GRAFS Classification of GPCRs. 
The GRAFS classification system places more than 800 human GPCRs into five major 
families: Rhodopsin (class A); Secretin and Adhesion (class B); Glutamate (class C); 
and Frizzled/taste receptor 2 (TAS2), based on their sequence and structural similarity.  
Image from (Stevens et al., 2013).  
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1.7.1 Guanine Nucleotide Binding Proteins 	
Despite these resounding similarities, GPCRs employ diverse and complex regulatory 
processes to convey extracellular signals to the internal environment of the cell.  
Classically, GPCRs were solely believed to achieve this by coupling the binding of an 
agonist to the activation of multiple heterotrimeric guanine nucleotide binding protein 
(G protein) subtypes (Rosenbaum et al., 2009).  G proteins are composed of an αβγ 
trimer from the various combinations of the 21 α, 6 β and 12 γ subunits (Downes and 
Gautam, 1999).  The α-subunit is GDP-bound and complexed to a Gβγ heterodimer, 
which acts as a guanine nucleotide dissociation inhibitor, stabilising the protein in the 
inactive GDP-bound state (Higashijima et al., 1987).   Based on sequence similarity of 
the α-subunit, which confers similar downstream signalling mechanisms, G proteins are 
divided into four families (Table 1.2) (Strathmann and Simon, 1991, Kimple et al., 
2014).  
Table 1.2 G protein families. 
G protein family Family members Effector protein 
Gs Gs, Golf Adenylate Cyclase 
Gi Gi1, Gi2, Gi3, Go1, Go2, Gz. Gt, Ggust    Adenylate Cyclase 
Gq Gq, G11, G14, G15/16 Phospholipase C 
G12/13 G12, G13  RhoGEF 
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1.7.2 Canonical GPCR Signalling 	
The binding of an agonist to a GPCR promotes a change in the relative positioning of 
transmembrane α-helices III and VI which leads to reorientation of the third 
intracellular loop of the receptor to uncover previously cryptic G protein binding sites 
(Wess, 1997, Kobilka, 2002).  The Gβγ heterodimer serves to target Gα to the 
membrane (Rehm, 1997) and present it to the receptor in the appropriate conformation 
(Oldham and Hamm, 2006, Smrcka, 2008).  Upon interaction, the receptor acts as a 
guanine nucleotide exchange factor (GEF), inducing the release of GDP from the α-
subunit of the G protein in favour of GTP.  The active GTP-bound α-subunit dissociates 
from the receptor and the Gβγ dimer to interact with effector proteins with 20 – 100 fold 
higher affinity than in their GDP-bound state (Hamm, 1998, Knall and Johnson, 1998). 
The now independent Gβγ dimer relays signals from the GPCR to a number of target 
proteins including; adenylate cyclase isoforms, phospholipase isoforms, ion channels, 
PI3K, and MAPKs (Khan et al., 2013).  The α-subunits of the Gs and Gi subfamily 
members regulate adenylate cyclase to stimulate (Gs) or inhibit (Gi) the production of 
cAMP, which influences PKA (Krebs, 1989).  Gαq activates phospholipase C (PLC) to 
modulate intracellular levels of 1,2-diacylglycerol (DAG) and inositol 1,4,5 
triphosphate (IP3) (Birnbaumer et al., 1990, Rhee, 2001).  DAG signals directly to 
protein kinase C (PKC) (Kishimoto et al., 1980), whereas IP3 binds to its receptor in the 
endoplasmic reticulum to trigger the release of Ca2+ (Berridge and Irvine, 1984).  
Gα12/13 stimulates the activation of Rho guanine nucleotide exchange factors 
(RhoGEFs) which initiate Rho-dependent signalling cascades through Rho-associated 
coiled-coil containing protein kinases (Hart et al., 1998, Siehler, 2009) (Fig. 1.12).  The 
activation of these secondary messengers imparts the signal potential of the GPCRs to 
regulate a multitude of specific cellular cascades throughout the cell (Offermanns, 
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2003).   
 
Figure 1.12 GPCR signal transduction through G proteins.  
Upon ligand binding a GPCR undergoes a conformational change to recruit and activate 
a specific G protein by exchanging GDP for GTP at the α-subunit.  The now 
independent Gβγ dimer targets specific effector proteins while the four classes of GTP-
bound Gα proteins transmit signal potential to family dependent target proteins.  
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1.7.3 GPCR Signal Termination 
The duration of one cycle of receptor activation of an effector can be dictated by the 
intrinsic guanosine triphosphatase (GTPase) activity of Gα as the hydrolysis of GTP to 
GDP promotes reconstitution and membrane localisation of the Gαβγ heterotrimer 
(Neer, 1995).  This step is often influenced by regulators of G protein signalling (RGS) 
that bind Gα and accelerate GTP hydrolysis (Fig. 1.13) (Siderovski and Willard, 2005, 
Oldham and Hamm, 2008). 
 
Figure 1.13 Regulation of G protein activity. 
Focusing on the G protein α-subunit, ligand occupied GPCRs act as GEFs, facilitating 
GDP release and the subsequent binding of GTP to activate the G protein.  RGS 
proteins act as GTPase-accelerating proteins (GAPs) for Gα, dramatically enhancing 
their core rate of GTP hydrolysis to terminate GPCR signal transduction.  
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However, GPCRs have been found to have more complex signalling behaviour beyond 
the control of G proteins alone.  To rapidly terminate activation, negative feedback 
loops uncouple GPCRs from heterotrimeric G proteins through covalent modifications 
of the receptor as a consequence of phosphorylation by intracellular kinases  
(Thompson and Findlay, 1984, Premont et al., 1995).  G protein coupled receptor kinase 
(GRK) association is promoted by Gβγ dimers (Daaka et al., 1997), whereas second 
messenger dependent kinases; PKA and PKC are stimulated by cAMP and IP3 as a 
consequence of Gαi/s and Gαq respective activation (Tobin, 2008).  The phosphorylated 
receptor has increased affinity for cytosolic cofactor proteins called β-arrestins, which 
more effectively uncouple the receptor from the G protein by sterically inhibiting 
interactions (Lohse et al., 1990).  The β-arrestin-receptor complex becomes associated 
with clathrin-coated pits which shape rounded vesicles in the cytoplasm for intracellular 
handling (Goodman et al., 1996).  The receptor can then be trafficked to lysosomes for 
degradation or to recycling endosomes which dephosphorylate and reprocess the GPCR 
back to the plasma membrane (Fig. 1.14) (Pierce et al., 2002). 
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Figure 1.14 GPCR desensitisation.  
(1) Ligand binding recruits a G protein to the GPCR, which becomes activated through 
receptor-induced exchange of GDP for GTP.  The free Gβγ dimer and Gα subunits 
signal to downstream effector proteins eventually initiating a negative feedback loop to 
desensitise the receptor to the bound ligand.  (2) Activation of PKA, PKC and GRK 
leads to GPCR phosphorylation and the recruitment of β-arrestin.  (3) The GPCR-β-
arrestin complex binds with high affinity to clathrin.  (4) Clathrin-coated pits lead to 
receptor internalisation. (5) The receptor is then processed by endosomes (Pierce et al., 
2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction 
 49 
1.7.4 Non-Canonical GPCR Signalling 	
Activation of GPCR signalling may also go beyond the classical function of coupling an 
agonist to a G protein to modulate a downstream effector.  Functional studies of the β-
adrenergic receptor (β2AR), the most well characterised GPCR, demonstrate 
constitutive activity of the receptor which can be blocked by an inverse agonist (Chidiac 
et al., 1994).  Furthermore, a β2AR mutant incapable of G protein activation was found 
to activate MAPK pathways in a β-arrestin dependent manner (Shenoy et al., 2006).  As 
this multifaceted behaviour has been observed for many different GPCRs (Pierce and 
Lefkowitz, 2001, Tao, 2008), a complex picture of GPCR activation has emerged, while 
the structural changes associated with activation may be similar, the mechanism by 
which these changes are evoked is quite different. 
1.7.5 Kinetics of GPCR Activation 	
Natural and synthetic ligands acting on GPCRs are classified into full agonists, partial 
agonists, inverse agonists and antagonists.  A number of kinetic models have been 
developed to describe the response of a GPCR to ligand binding to transition between 
active and inactive states (Bouvier, 2013).   
 
In the classical two-state model (Leff ,1995) (Fig. 1.15A), GPCRs are thought to exist 
in equilibrium between two states; resting (R) and activated (R*).  In the absence of a 
ligand the equilibrium of most receptors favours the R state while few, like rhodopsin, 
demonstrating constitutive activity, lie in the R* state.  The efficacy of a ligand reflects 
its ability to alter the equilibrium between these two states (Kobilka, 2007).  Inverse 
agonists stabilise the R state favouring the transition toward inactive conformations to 
reduce the level of basal or constitutive activity below that of the resting receptor, while 
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agonists preferentially bind the active conformations to amplify receptor activity.  
 
In the three state model (Fig. 1.15B), in the absence of a ligand, the receptor is in an 
intermediate state (R*), showing some level of activity.  Inverse agonists favour 
inactive conformations (R), transitioning receptor equilibrium towards this state, 
whereas agonists favour active conformations (R**).  Full agonists maximally stimulate 
the biological responses of the receptor while partial agonists are unable to elicit full 
activity even at saturating concentrations.  Fully active conformations are promoted by 
GPCR coupling to multiple G proteins based on the specificity of the ligand (Leff et al., 
1997).  
 
A revised model (Fig 1.15C), proposes that the unliganded receptor is largely in an 
inactive conformation promoted by inverse agonists.  Agonists favour intermediate 
states (R*), while unique fully activated conformational states (R**, R## and R’’) are 
promoted by specific signalling effectors such as G proteins, kinases and β-arrestins 
(Kenakin, 2003).  Antagonists have equal affinity for inactive, intermediate and active 
states and therefore have no effect on the signalling potential of the receptor but can 
prevent other ligands from binding (Rosenbaum et al., 2009).  
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Figure 1.15 Active and inactive states of GPCRs. 
(A) The two state model of GPCR kinetics. (B) The three state model of GPCR kinetics. 
(C) The adapted three state model which considers agonist stabilisation of unique fully 
activated conformational states promoted by specific signalling effectors such as G 
proteins (R**G), kinases (R##K) and β-arrestins (R’’βarr).  Image adapted from 
(Bouvier, 2013). 
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1.7.6 GPCRs and Type 2 Diabetes 	
The diverse GPCR superfamily plays a key role in the overall homeostasis of complex 
organisms making them important physiological regulators of many disease states.  The 
ability of GPCRs to transduce extracellular signals into intracellular effector pathways 
makes them appealing drug targets with 30 – 40 % of marketed drugs affecting these 
versatile receptors (Ma and Zemmel, 2002, Lappano and Maggiolini, 2011, 
Tautermann, 2014).  Moreover, the specific impact of GPCRs on immune responses, 
appetite, insulin secretion and energy homeostasis makes them attractive for the 
treatment of type 2 diabetes (Table 1.3).  In addition to targeting GPCRs with known 
ligands and downstream effects, several of the more than 140 orphan receptors (Tang et 
al., 2012), have been found to regulate key aspects of the diabetic phenotype, as 
evidenced by knockout and knockin studies (Matsuda and Aiba, 2004).  
 
Table 1.3 GPCRs and type 2 diabetes. 
GPCR Effects mediated by receptor References 
Adrenergic Receptors 
β2AR Regulates energy metabolism and glycogenolysis 
during exercise 
 
(Chruscinski et al., 1999) 
α-(2A)AR Contributes to defective insulin secretion in diabetic 
patients 
(Robertson et al., 1976) 
(Rosengren et al., 2010) 
Arginine Vasopressin Receptor 
AVPR2 Maintains water homeostasis; loss of function causes 
nephrogenic diabetes insipidus 
 
(van der Ouweland et al., 
1992) 
Bombesin Receptors 
NMBR Female specific role in the regulation of energetic 
homeostasis, with female KO mice partially resistance 
to diet-induced obesity  
 
(Paula et al., 2010) 
GRPR Regulates satiety and participates in the termination of 
meals 
 
(Ladenheim et al., 2002) 
BRS3 Regulates body weight, satiety and glucose/insulin 
homeostasis 
 
(Ohki-Hamazaki et al., 
1997) 
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Table 1.3 GPCRs and type 2 diabetes. 
 
GPCR Effects mediated by receptor References 
Cannabinoid Receptors 
GPR55 Increases calcium transients and insulin secretion 
stimulated by glucose 
 
(Romero-Zerbo et al., 
2011) 
CB1 Modulates the endocrine hypothalamic-peripheral 
endocrine axes to regulate appetite and energy balance 
 
(Ravinet Trillou et al., 
2004) 
CB2 Modulates Tnf and Ccl2 expression to promote insulin 
resistance and liver inflammation 
 
(Deveaux et al., 2009) 
Cholecystokinin Receptors 
CCK-AR Inhibits short-term food intake 
 
(Kopin et al., 1999) 
CCK-BR Regulates digestion and absorption 
 
(Nagata et al., 1996) 
Estrogen Receptors 
GPR30 Induces insulin secretion  (Sharma and Prossnitz, 
2011) 
Fatty Acid Receptors 
GPR41 Regulator of host energy balance through effects that 
are dependent upon the gut microbiota  
(Samuel et al., 2008) 
 
 
GPR43 Inhibits lipolysis, regulates plasma lipid profiles and is 
involved neutrophil chemotaxis 
 
(Ge et al., 2008) 
GPR40 Enhances glucose-stimulated  insulin secretion. 
Conflicting KO studies have showed this receptor to 
protect mice from obesity-induced hyperinsulinemia 
and exacerbate insulin resistance 
 
(Steneberg et al., 2005) 
(Shapiro et al., 2005) 
(Kebede et al., 2008) 
 
GPR84 Regulates IL-4 production by activated T lymphocytes (Venkataraman and Kuo, 
2005) 
 
GPR120 Induces secretion of GLP1 and GIP. Inhibits 
inflammatory signalling in macrophages 
 
(Oh et al., 2010) 
GPR119 Important for incretin and insulin secretion (Lan et al., 2009) 
Ghrelin Receptors 
GHS-R Stimulates growth hormone secretion, modulates 
glucose sensing and insulin sensitivity 
 
(Sun et al., 2008) 
GPR39 Regulates body weight and endocrine function  (Tremblay et al., 2007)  
(Holst et al., 2009) 
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Table 1.3 GPCRs and type 2 diabetes. 
 
GPCR Effects mediated by receptor References 
Glucagon Receptor 
GCGR Regulates insulin sensitivity and β cell function 
 
(Sørensen et al., 2006) 
Hydroxycarboxylic Acid Receptors 
GPR109a Mediates anti-lipolytic effects of ketone bodies, activates 
immune cells 
 
(Taggart et al., 2005) 
GPR109b Anti-lipolytic effects, activates immune cells 
 
(Ahmed et al., 2009) 
GPR81 Mediates anti-lipolytic effects of insulin 
 
(Cai et al., 2008) 
Incretin Receptors 
GLP-1R Regulates glucose production and the action of insulin 
 
(Ayala et al., 2010) 
GIPR Stimulates insulin release 
 
(Miyawaki et al., 2002) 
Lysophospholipid Receptors 
GPR12 Regulates weight gain and energy expenditure  (Bjursell et al., 2006a) 
Melanin Concentrating Hormone Receptors 
MCH1 Regulates insulin sensitivity and/or secretion via a 
mechanism not dependent on decreased body weight 
 
(Bjursell et al.,2006b) 
Melanocortin Receptors 
MC3R Regulates energy homeostasis playing a critical role in 
weight regulation 
 
(Lee et al., 2002) 
MC4R Regulates energy homeostasis and food intake 
 
(Huszar et al., 1997) 
Melatonin Receptors 
MT1 Regulates glucose metabolism. KO mice display increased 
insulin resistance 
 
(Contreras-Alcantara 
et al., 2010) 
GPR50 Regulates thermogenesis and torpor. ob/ob mice display 
reduced receptor expression 
 
(Bechtold et al., 
2012) 
Metastin Receptor 
GPR54 Regulates endocrine function, weight gain and energy 
expenditure primarily in female mice 
 
(Tolson et al., 2014) 
Muscarinic Acetylcholine Receptors 
M3 Regulates food intake. Mice lacking the receptor display 
reduced food intake, reduced body weight and low leptin 
and insulin serum levels 
 
(Yamada et al., 2001) 
 
Neuropeptide Receptors 
NPY 
Receptors 
Control appetite and regulate insulin secretion (Chamorro et al., 
2002) 
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Table 1.3 GPCRs and type 2 diabetes. 
 
GPCR Effects mediated by receptor References 
Neuropeptide Receptors 
Orexin 
receptors 
 
Regulate appetite (Rodgers et al., 
2002) 
GPR7 Regulates energy homeostasis in male mice. KO male mice 
develop adult-onset obese phenotype exacerbated with a 
HFD  
 
(Ishii et al., 2003) 
Orphan Receptors 
GPR21 Coordinates macrophage pro-inflammatory activity. KO 
mice have improved glucose tolerance, insulin sensitivity 
and a modest lean phenotype 
 
(Gardner et al., 
2012)  
(Osborn et al., 2012) 
GPR26 Regulates energy homeostasis; GPR26 deficiency in the 
hypothalamus is associated with high genetic susceptibility 
to the onset of obesity  
 
(Chen, Liu, et al., 
2012) 
GPR116 Regulates systemic energy homeostasis; adipose tissue 
specific KO mice displayed glucose intolerance and insulin 
resistance 
 
(Nie et al., 2012) 
Serotonin Receptors 
5HT2C Regulates appetite. KO mice are overweight as a result of 
abnormal control of feeding behaviour 
 
(Tecott et al., 1995) 
5HT1A Regulates satiety. The receptor agonist stimulates food 
intake in lean control rats but inhibits feeding in obese rats 
up to 6 months of age 
 
(Voigt et al., 2002) 
Somatostatin Receptors 
SSTR2 Regulates hypoglycaemia-stimulated glucagon and 
corticosterone release in diabetic rats 
 
(Yue et al., 2012) 
SST5 Regulates pancreatic insulin secretion and contributes to 
the regulation of glucose homeostasis and insulin 
sensitivity 
 
(Strowski et al., 
2003) 
UDP Glucose Receptors 
GPR105 Regulates insulin secretion and immune cell chemotaxis. 
Conflicting reports on the consequences of receptor 
deletion on insulin signalling 
(Xu et al., 2012) 
(Meister et al., 2014) 
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1.7.6.1 GPR21 	
GPR21, an orphan GPCR has recently emerged as a novel target for the treatment of 
type 2 diabetes (Gardner et al., 2012, Osborn et al., 2012). Gardner and colleagues 
found GPR21 knockout mice fed on a high fat diet (HFD) to have a modest lean 
phenotype, increased insulin sensitivity, improved glucose tolerance and a reduction in 
pro-inflammatory markers when compared to wild type littermates.  In a simultaneous 
study, the Olefsky group (Osborn et al., 2012), reiterated these findings and proposed 
the involvement of GPR21 in coordinating macrophage pro-inflammatory activity in the 
context of obesity-induced insulin resistance.  In wild type mice, GPR21 mRNA was 
highly induced in the stromal vascular fraction (SVF) of adipose tissue from HFD mice 
but not in the lean counterparts, while knockout mice had a reduced percentage of M1 
macrophages in both control and HFD states.  Increased expression of GPR21 was 
observed in wild type M1 macrophages with lower expression in the anti-inflammatory 
M2 macrophages of the SVF.  Furthermore, the essential cytoskeletal reorganisation 
required for transmigration was absent in GPR21 knockout macrophages.  Overall, 
knockout mice demonstrated a decrease in pro-inflammatory gene expression and an 
increase in anti-inflammatory genes with a concurrent increase in insulin-stimulated Akt 
phosphorylation in liver and adipose tissue.  Moreover, wild type mice that received 
bone marrow transplantations from knockout mice demonstrated a similar phenotype to 
the GPR21 deficient mice.  Receptors such as GPR21 open new avenues for the 
discovery of next generation drugs to effectively treat obesity-induced type 2 diabetes.  
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1.8  Computational Drug Discovery 	
A major challenge in targeting GPCRs for the development of novel anti-diabetic 
therapies is the lack of experimentally elucidated high-resolution crystal structures.  
This proves even more irksome in the case of orphan receptors for which no 
endogenous ligands have yet been identified.  However, advances in homology 
modelling and ligand docking studies have vastly improved the development of targeted 
therapies towards such GPCRs (Stockert and Devi, 2015). 
1.8.1 Homology Modelling 
Homology modelling involves the development of a model of a protein of interest based 
on its amino acid sequence and a template protein structure of related homologous 
proteins.  A template is chosen using a BLASTP search of the Protein Data Bank 
(www.rcsb.org) (Altschul et al., 1990) with three criteria considered, the structure 
resolution, ligand type and percentage sequence identity to the target (Xiang, 2006).   
As crystal structures are available for less than 20 unique receptors in the rhodopsin-like 
class, the family in which GPR21 resides, (Fredriksson and Schio, 2005, Latek et al., 
2013), it is very difficult to achieve a sequence identity above 30 % with most GPCRs.  
Therefore, when working with these receptors, it is more important to have a high 
sequence identity between the template and target in the conserved seven 
transmembrane region, as this is likely to be a ligand binding region, while decreased 
sequence similarity in the external loops should not affect the success of the model 
(Bhattacharya et al., 2013).  The use of multiple templates may also increase the rate of 
success in these challenging cases (Latek et al., 2013).  
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Once a template has been selected, the next step is to align it with the target to identify 
regions that may be a consequence of functional, structural or evolutionary relationships 
between the sequences using an alignment tool such as Clustal W (Larkin et al., 2007).  
It is then important to satisfy the spatial restraints of the model, more specifically the 
modelling of loops using a database of loops or by ab initio methods, to resolve regions 
of the target sequence that are not aligned to a template.  These regions are most 
susceptible to errors, especially when there is a low sequence identity between the target 
and template (Michalsky et al., 2003).  The resulting structure is then analysed with a 
range of computational tools to determine the quality of the model (Fanelli and De 
Benedetti, 2011). 
1.8.2 Molecular Docking 	
When a satisfactory homology model has been constructed molecular docking can be 
employed to predict the predominant binding mode of a possible ligand with the 
protein.  In order to achieve this, it must be assumed that small molecules interact with 
the receptor and the binding site has been conserved in the template used to generate the 
model.  In the case of orphan receptors, blind docking can be undertaken with 
programmes such as LigPrep to prepare high quality, all atom, 3D structures which can 
be inputted into a docking tool such as Glide (Grid-based ligand docking with 
energetics) from the Schrödinger product suite (www.schrodinger.com).  The simplest 
approach to take is rigid-rigid docking where the protein and ligands are kept static.  
Glide searches for favourable interactions between the ligand and the homology model.  
Ranked ligands can then be screened through flexible docking to get a better 
representation of the possible interactions.  Once a clear picture is established, ligands 
can be altered to improve affinity and prevent clashes with the protein, and finally 
screened in a biological assay.  These methods have been successful in identifying 
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potent and selective ligands for numerous GPCRs (Evers and Klabunde, 2005, Dong et 
al., 2013, Jacobson 2013, Pappalardo et al., 2014, Stockert and Devi, 2015).  
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1.9 Aims and Objectives 	
Type 2 diabetes is a multifaceted metabolic disorder developing as a consequence of 
distorted cellular signalling.  This project aimed to identify novel therapeutic avenues 
for the treatment of this disease by elucidating the underlying mechanism of action of a 
successful, novel anti-diabetic compound, RTC-1, and by exposing the signalling 
mechanisms of a recently identified target, GPR21. 
 
Solidifying the mechanism of action of a novel compound is essential to the 
development of a prospective therapy for type 2 diabetes.  RTC-1 was designed to clear 
serum RBP levels in an attempt to modulate the development of insulin resistance. 
However, in vitro analysis revealed the ability of this compound to stimulate glucose 
uptake, an effect its predicted mechanism of action would not account for.  Through 
cellular analysis, the effects of RTC-1 were explored in respect to key aspects modified 
with the development of type 2 diabetes, namely glucose uptake, insulin resistance, 
adipogenesis and osteogenesis.  While a comparative study with the most common anti-
diabetic therapy, metformin, gave context to the influence of RTC-1. 
 
In a separate study, the signalling capabilities of a novel diabetic target, GPR21, were 
investigated with the hope of regulating its proposed effect on macrophage migration.   
In order to fully appreciate this GPCR in the context of insulin resistance, the G protein 
to which GPR21 couples to amplify signal potential was assessed, while the 
downstream consequences of receptor activation on insulin signalling, glucose uptake 
and macrophage migration were explored.  In addition to this, the influence of a novel 
compound designed through a computational approach to bind GPR21 was evaluated to 
determine if attenuating the effects of the receptor could prevent the development of 
insulin resistance through a previously unexplored mechanism. 
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2.1 Materials 	
All chemicals used were from Sigma-Aldrich unless otherwise stated.   
2.2 Cell Culture 	
All cell culture materials and reagents were kept sterile and used in a Class II biological 
safety cabinet.  All cell lines were maintained at 37 °C in a sterile, humidified, 5 % CO2 
atmosphere.  Foetal Bovine Serum (FBS) and horse serum were heat inactivated at 56 
°C for 30 minutes prior to use, to inactivate complement. 
2.2.1 Culture of Adherent Cells 	
Adherent cell lines (Table 2.1) were maintained in high glucose (4500 mg/ml) 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 100 µg/ml 
penicillin/streptomycin, 2 mM L-glutamine (complete medium) and 10 % (v/v) FBS.  
Cryo-preserved cells were rapidly thawed in a 37 °C water bath, washed with 10 ml 
complete medium containing 10 % (v/v) FBS and centrifuged to remove the cryo-
protectant, DMSO.  Cells were resuspended in complete medium supplemented with 10 
% (v/v) FBS and cultured in a T75 flask (Sarstedt) at 37 °C, in a humidified, 5 % CO2 
environment.  When 80 % confluency was reached, non-adherent cells were washed 
away with Dulbecco’s phosphate buffered saline (DPBS) (Gibco).  Remaining cells 
were detached from the flask by incubating with 0.25 % (v/v) trypsin-1 mM EDTA 
solution (Thermo Fisher Scientific), for 5 minutes at 37 °C.  Protease action was 
neutralised with the addition of complete medium supplemented with 10 % (v/v) FBS.  
Trypsin-EDTA was removed by centrifugation, cells were resuspended in complete 
medium with 10 % (v/v) FBS and counted using a haemocytometer.  Cells were seeded 
at an optimal density, as recommended by the supplier, and incubated at 37 °C with 5 % 
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CO2 until 80 % confluent.  Cells were then passaged once more, cryo-preserved or 
differentiated if required.  
Table 2.1 Adherent cell lines. 
Cell line Description Culture medium 
C2C12  Myoblast  High glucose DMEM (Thermo Fisher Scientific) 
 
cell line from  10 % FBS (Thermo Fisher Scientific) 
 
mouse skeletal  2 mM L-glutamine  (Thermo Fisher Scientific) 
 
muscle 100 µg/ml penicillin/streptomycin  (Thermo Fisher Scientific) 
   3T3-L1 Murine   High glucose DMEM (Thermo Fisher Scientific) 
 
pre-adipocytes 10 % FBS (Thermo Fisher Scientific) 
  
2 mM L-glutamine  (Thermo Fisher Scientific) 
  
100 µg/ml penicillin/streptomycin  (Thermo Fisher Scientific) 
   SH-SY5Y  Human  High glucose DMEM (Thermo Fisher Scientific) 
 
neuroblastoma  10 % FBS (Thermo Fisher Scientific) 
  
2 mM L-glutamine  (Thermo Fisher Scientific) 
  
100 µg/ml penicillin/streptomycin  (Thermo Fisher Scientific) 
   HEK293T Immortalised Human High glucose DMEM (Sigma-Aldrich) 
 
embryonic kidney 10 % FBS (Sigma-Aldrich) 
 
cell line containing 2 mM L-glutamine  (Thermo Fisher Scientific) 
 
the SV40 Large 100 µg/ml penicillin/streptomycin  (Thermo Fisher Scientific) 
 
T-antigen  
 
   BMDM Immortalised murine High glucose DMEM (Sigma-Aldrich) 
 
bone marrow 10 % FBS (Sigma-Aldrich) 
 
derived macrophage 2 mM L-glutamine  (Thermo Fisher Scientific) 
  
100 µg/ml penicillin/streptomycin  (Thermo Fisher Scientific) 
   J774 Murine BALB/cN  High glucose DMEM (Sigma-Aldrich) 
 
monocyte/macrophage 10 % FBS (Sigma-Aldrich) 
  
2 mM L-glutamine  (Thermo Fisher Scientific) 
  
100 µg/ml penicillin/streptomycin  (Thermo Fisher Scientific) 
 
CHO Chinese Hamster Ham’s F-12 Nutrient mixture (Sigma-Aldrich) 
 
Ovary cell line 10 % FBS (Sigma-Aldrich) 
  
2 mM L-glutamine  (Thermo Fisher Scientific) 
  
100 µg/ml penicillin/streptomycin  (Thermo Fisher Scientific) 
   COS-1 Kidney cell line from High glucose DMEM (Sigma-Aldrich) 
 
African green monkey 10 % FBS (Sigma-Aldrich) 
  
2 mM L-glutamine  (Thermo Fisher Scientifc) 
 
  100 µg/ml penicillin/streptomycin  (Thermo Fisher Scientific) 
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Table 2.1 Adherent cell lines. 
Cell line Description Culture medium 
A549  Human alveolar basal Ham’s F-12 Nutrient mixture (Sigma-Aldrich) 
 
epithelial cell line 10 % FBS (Sigma-Aldrich) 
  
2 mM L-glutamine  (Thermo Fisher Scientific) 
  
100 µg/ml penicillin/streptomycin  (Thermo Fisher Scientific) 
   HepG2 Human cell line from  High glucose DMEM (Thermo Fisher Scientific) 
 
a liver hepatocellular  10 % FBS (Thermo Fisher Scientific) 
 
carcinoma 2 mM L-glutamine  (Thermo Fisher Scientific) 
  
100 µg/ml penicillin/streptomycin  (Thermo Fisher Scientific) 
   MSC Murine mesenchymal  Minimal Essential Medium alpha (αMEM) (Sigma-Aldrich) 
 
stromal cells isolated 10 % FBS (Thermo Fisher Scientific) 
 
from the femur and 10 % Horse Serum (Gibco) 
 
tibia of 6 – 8 week old  2 mM L-glutamine  (Thermo Fisher Scientific) 
 female BALB/c mice  100 µg/ml penicillin/streptomycin  (Thermo Fisher Scientific) 
 
2.2.1.1 C2C12 Cell Culture and Differentiation 	
C2C12 cells were purchased from Sigma-Aldrich (91031101), seeded at a density of 
2x103 cells/cm2 and maintained as described in Section 2.2.1.  When 80 % confluent, 
differentiation into myotubes was induced with complete medium supplemented with 2 
% (v/v) horse serum (Gibco) for 3 days.  Fully differentiated cells were washed once 
with DPBS and stimulated with various compounds in complete medium supplemented 
with 0.1 % (v/v) horse serum.  Rotenone (R8875-5G), metformin (04635) and 
wortmannin (W3144) were obtained from Sigma-Aldrich.  TNF-α (315-01A) was 
supplied by PeproTech and Compound C (171264) was from Merck Millipore.  Insulin 
(Sigma-Aldrich, I9278) stimulations were carried out in filter sterilised (0.2 µm) Krebs 
Ringer Buffer containing glucose (KRBG); 136 mM NaCl, 20 mM HEPES, 4.7 mM 
KCl, 1 mM MgSO4, 1 mM CaCl2, 4.05 mM Na2HPO4, 0.95 mM NaH2PO4, 5 mM 
glucose, pH 7.4.   
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2.2.1.2 3T3-L1 Cell Culture and Differentiation 	
3T3-L1 cells were obtained from ATCC® (CL-173), seeded at a density of 2x104 
cells/cm2 and maintained as described in Section 2.2.1.  When 80 % confluent, 
differentiation into adipocytes was induced with complete medium supplemented with 
10 % (v/v) FBS, 10 µg/ml insulin, 0.5 mM IBMX and 1 µM dexamethasone.  After 2 
days, the medium was changed to complete medium containing 10 % (v/v) FBS and 10 
µg/ml insulin.  Every 2 days following, medium was changed to complete medium 
containing 10 % (v/v) FBS until 80 % of cells formed intracellular lipid droplets. 
Differentiated 3T3-L1 cells were stained for lipid accumulation as described by Kuri-
Harcuch and Green (1978).   Cells were washed twice with phosphate buffered saline 
(PBS) before fixing with 10 % (v/v) formalin for 20 minutes.  Cells were then washed 
three times with PBS and incubated for 20 minutes with filtered (0.2 µm) 1.5 mg/ml Oil 
Red O, prepared in 1:1 isopropanol:PBS.  Excess stain was removed by washing once 
with PBS and cells were visualised with an inverted light microscope.  To quantify lipid 
accumulation, Oil Red O was extracted with isopropanol and absorbance was measured 
at 520 nm with an ELx800TM microplate reader (Kasturi and Joshi, 1982). 
2.2.1.3 Murine Mesenchymal Stromal Cell (MSC) Culture and 
Differentiation 
 
MSC isolated from the femur and tibia of 6 – 8 week old female BALB/c mice were 
kindly donated as a live culture courtesy of Dr. Karen English.  Cells were maintained 
in complete αMEM supplemented with 10 % (v/v) FBS and 10 % (v/v) horse serum as 
described in Section 2.2.1 with an optimal seeding density of 1x105 cells/cm2.  When 80 
% confluent cells were differentiated into fat or bone cells.   
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Adipogenic differentiation was induced with MSC culture medium containing 5 µg/ml 
insulin, 50 µM indomethacin, 1 µM dexamethasone and 0.5 µM IBMX.  Fresh medium 
was added every 3 days for 21 days.  On day 21, cells were stained for lipid 
accumulation with Oil Red O (Section 2.2.1.2).   
 
Osteoblast differentiation was induced with MSC culture medium supplemented with 1 
mM dexamethasone, 20 mM β-glycerolphosphate, 50 µM L-ascorbic acid-2 phosphate 
and 50 ng/ml L-thyroxine sodium pentahydrate.  Fresh medium was added every 3 
days.  After 21 days, cells were stained for calcium deposition with Alizarin Red S 
prepared in dH2O (20 mg/ml).  Cells were washed twice with PBS before fixing with 10 
% (v/v) formalin for 20 minutes.  Cells were then washed three times with PBS and 
incubated with Alizarin Red S for 20 minutes.  Excess stain was removed by washing 
once with PBS and cells were visualised with an inverted light microscope.  Calcium 
deposition was quantified as described by Tavakol and colleagues (2012).  Alizarin Red 
S was extracted with 800 µl 10 % (v/v) acetic acid and agitated for 30 minutes at room 
temperature, cells were then scraped into a 1.5 ml tube and vortexed for 30 seconds.  
The solution was covered with 500 µl mineral oil, incubated for 10 minutes at 85 °C, 
then cooled on ice for 5 minutes.  Samples were centrifuged at 20,000 x g for 15 
minutes.  500 µl of the supernatant was added to 200 µl 10 % (v/v) ammonium 
hydroxide and absorbance was read at 405 nm on an ELx800TM microplate reader.    
2.2.2 Culture of RAW 264.7 Semi-Adherent Cells 	
RAW 264.7 semi-adherent macrophages derived from murine blood were kindly 
donated as a live culture courtesy of Dr. Sinead Miggin.  When 80 % confluent, 
adherent cells were detached with a cell scraper, centrifuged and resuspended in DMEM 
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supplemented with 10 % (v/v) FBS, 100 µg/ml penicillin/streptomycin and 2 mM L-
glutamine at a density of 3x104 cells/cm2.  
2.2.3 Culture of THP-1 Suspension Cells 	
THP-1, a human monocyte cell line was kindly donated as a live culture courtesy of 
Prof. Paul Moynagh.  Cells were seeded at a density of 2x105 cells/ml in RPMI-1640 
supplemented with 100 µg/ml penicillin/streptomycin, and 10 % (v/v) FBS.  Flasks 
were tilted at a 45° angle in the CO2 incubator to provide an optimal environment for 
growth.  When a density of 8x105 cells/ml was reached, cells were sub-cultured by 
centrifugation and resuspension at a density of 2x105 cells/ml. 
2.2.4 Cryo-preservation of Mammalian Cells 	
Following sub-culture, cell pellets were gently resuspended at a density of 2x106 cells in 
1 ml complete medium containing 10 % (v/v) FBS and 10 % (v/v) DMSO.  The cell 
suspension was transferred into Cryo-tubes (Nunc) and placed in a Mr. Frosty™ 
freezing container (Thermo Fisher Scientific) at -80 °C for 24 hours, which allowed a 
cooling rate of approximately -1 °C/minute.  Cryo-tubes were then placed in liquid 
nitrogen for long-term storage.   
2.3 Animals 	
Male C57BL/6J mice, aged 4 weeks (n=6) provided by Charles River, Calco, Lecco, 
Italy, were maintained on a pellet diet for 1 week, then randomly divided into two 
groups: normal diet (control, n=3) or a high fat high sugar diet (HFHS, 45 % kcal fat, 35 
% kcal carbohydrates and 20 % kcal protein, n=3) for 16 weeks.  Animals were housed 
at the University of Turin in a temperature-controlled environment with a 12 hour 
light/dark cycle.  Mice were sacrificed by cervical dislocation, epididymal fat pads were 
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removed and snap frozen in liquid nitrogen.  Samples were received on dry ice and 
stored at -80 °C until required.  Protocols were approved by the ‘Animal Use and Care 
Committee’ of the University of Turin and subsequently by the ethics committee of the 
National University of Ireland, Maynooth (BSRESC-2014-008).  Protocols were in 
accordance with the European Directive 2010/63/EU on the protection of animals used 
for scientific purposes. 
2.4 Molecular Biology Methods 
2.4.1 RNA Isolation and cDNA Synthesis 
2.4.1.1 RNA Isolation 	
Total RNA was extracted using TRIzol® Reagent (Invitrogen) according to the 
manufacturer’s protocol.  Tissue samples were homogenised in 1 ml TRIzol® using a 
handheld T10 Basic Homogeniser (IKA) and stored at -20 °C until required.  Samples 
were thawed on ice and 100 µl 1-bromo-3-chloropropane was added to each.  Samples 
were vortexed for 20 seconds and incubated at room temperature for 5 minutes.  
Samples were then centrifuged at 12,000 x g at 4 °C for 15 minutes resulting in the 
formation of three distinct layers.  The clear, aqueous upper layer containing the RNA 
was removed, ensuring the interphase containing DNA and the lower organic phase 
containing proteins were not disturbed.  RNA was precipitated with 500 µl isopropanol, 
samples were mixed by inversion, incubated at room temperature for 10 minutes and 
centrifuged at 12,000 x g at 4 °C for 15 minutes.  The resulting RNA pellet was washed 
twice with 1 ml 75 % (v/v) ethanol and centrifuged at 7,500 x g for 5 minutes at 4 °C.  
The supernatant was aspirated and the pellet was allowed to air dry before resuspension 
with 20 µl nuclease free water.  RNA concentration was determined using a Nanodrop 
2000 spectrophotometer (Thermo Fisher Scientific), which calculates absorbance at 260 
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nm and 280 nm.  A ratio between 1.8 and 2.0 indicated sufficient purity, samples 
outside this range were discarded and remaining samples were stored at -80 °C until 
required. 
2.4.1.2 DNase Treatment of RNA 	
To recover RNA contaminated with genomic DNA, samples were treated with DNase I 
(Invitrogen) as outlined by the manufacturer.  1 µl of amplification grade DNase I and 1 
µl of 10X DNase I reaction buffer were incubated with 2 µg RNA for 15 minutes at 
room temperature.  1 µl 25 mM EDTA was added and samples were incubated in a GS1 
Thermal Cycler (G-Storm) at 65 °C for 10 minutes, followed by cooling on ice to 
inactivate the DNase.  RNA was then reverse transcribed into cDNA. 
2.4.1.3 First Strand cDNA Synthesis 	
5X All-In-One RT MasterMix (Applied Biological Materials Inc.) was added to the 
RNA template and mixed by pipetting.  cDNA was synthesised by incubating samples 
in a GS1 Thermal Cycler (G-Storm) for 50 minutes at 42 °C. The reaction was 
terminated by heating samples at 85 °C for 5 minutes followed by chilling on ice.  
Samples were stored at -20 °C until required. 
2.4.2 Polymerase Chain Reaction (PCR) 
2.4.2.1 PCR to Confirm Synthesis of cDNA 	
A PCR using primers specific to the house keeping gene HPRT (Table 2.2) was used to 
confirm synthesis of cDNA.  A reaction mix was set up in a 0.2 ml PCR grade tube 
containing: 
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5 µl 5X MyTaq Reaction Buffer (Bioline) 
0.5 µl Forward primer (4 pM) 
0.5 µl Reverse primer (4 pM) 
0.3 µl MyTaq DNA Polymerase (Bioline) 
17.7 µl Nuclease free H2O 
1 µl cDNA (500 ng) 
 
Samples were run in a GS1 Thermal Cycler (G-Storm) for 2 minutes at 95 °C followed 
by 40 cycles of 95 °C for 45 seconds, 58 °C for 45 seconds and 72 °C for 45 seconds.  
Samples were then incubated at 72 °C for 10 minutes followed by cooling on ice.  To 
visualise nucleic acid products, samples were run on a 0.8 % (w/v) agarose gel. 
2.4.2.2 Agarose Gel Electrophoresis of DNA 	
0.8 % (w/v) agarose was dissolved in TAE buffer (40 mM Tris-acetate, 1 mM EDTA, 
pH 8.4) by heating in a microwave at a medium setting.  The solution was allowed to 
cool before the addition of the DNA visualisation agent, SYBR® Safe (Invitrogen, 
S33102), gels were left to set for 1 hour at room temperature prior to use.  Nucleic acid 
samples were mixed with a loading buffer (Thermo Fisher Scientific, R0631) and 
electrophoresed in TAE buffer at 100 volts constant.  DNA was visualised under UV 
light (254 nm) once sufficient migration and separation had occurred.  A 1 kb 
GeneRuler™ DNA ladder (Thermo Fisher Scientific, SM0313)  (Fig.  2.1) was used to 
estimate fragment length. 
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Figure 2.1 Distribution of DNA ladder used with DNA electrophoresis. 
 
2.4.2.3 Quantative Real Time PCR (qRT-PCR) 	
Template cDNA was used for qRT-PCR with specific primers (Table 2.2) to detect a 
gene of interest using the following reaction mixture: 
 
5 µl Fast start Universal SYBR Green Master - ROX (Roche) 
1 µl Forward primer (4 pM) 
1 µl Reverse Primer (4 pM) 
2 µl Nuclease Free H2O 
 
The reaction mixture was added to a specialised optical 96 well plate (Applied 
Biosystems) along with 1 µl template cDNA at 500 ng and sealed with an optically clear 
adhesive cover.  The plate was incubated at 95 °C for 5 minutes in the Applied 
Biosystems Step One™ real-time PCR instrument, accumulation of gene-specific 
products was measured continuously by means of fluorescence detection over 40 cycles.  
Each cycle consisted of a denaturing step of 95 °C for 15 seconds, an annealing step at 
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the appropriate temperature (Table 2.2) for 30 seconds, then extension at 72 °C for 30 
seconds.  This was followed by a melt curve cycle of 95 °C for 15 seconds, 55 °C for 15 
seconds and 95 °C for a final 15 seconds.  Intercalation of SYBR green into the dsDNA 
product was monitored after each step of primer annealing and elongation.  Melt curve 
analysis demonstrating one single melting peak eliminated the possibility of primer-
dimer associations, confirming the amplification of one specific product.  Relative 
quantification of target gene expression was evaluated using the delta Crossing 
Threshold (∆CT) method.  The Applied Biosystems Step One™ software generated the 
CT value for each sample, which records the cycle when sample fluorescence exceeds a 
chosen threshold above background fluorescence.  The ∆CT value was determined by 
subtracting the CT value of HPRT, the housekeeping gene, for each sample from the CT 
value of the target gene.  Fold change in the relative expression of the target was 
determined by calculating 2−(∆CTSample-∆CTControl). 
 
Table 2.2 Primers. 
Gene 
 
Forward Primer 5'-3' 
Reverse Primer 3'-5' 
Annealing 
Temperature (°C) 
HPRT 
 
AGGGATTTGAATCACGTTTG 
TTTACTGGCAACATCAACAG 
58 
 
TNF-α 
 
GGATGAGAAGTTCCCAAATG 
TGAGAAGATGATCTGAGTGTG 
 
57 
 
F4/80 
 
TTTCAAATGGATCCAGAAGG 
CAGAAGGAAGCATAACCAAG 
 
58.9 
 
 
 
2.4.3 Transformation of Competent Escherichia coli Cells 	
Competent TOP10 E. coli cells supplied by Invitrogen (C4040-03) were transformed 
with plasmid DNA according to the manufacturer’s protocol by heat shock.  5 µl of 
plasmid DNA was added to 50 µl of competent cells and incubated on ice for 30 
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minutes.  Cells were incubated at 42 °C for 30 seconds then placed on ice again.  After 2 
minutes, 250 µl of pre-warmed (37 °C) SOC medium was added (5 % (w/v) tryptone 
0.5 % (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 
20 mM glucose).  Cells were incubated at a 45° angle at 37 °C for 1 hour with constant 
shaking of 200 – 250 rpm.  Cells were then plated on Lysogeny Broth (LB) agar plates 
(1 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 1 % (w/v) NaCl, 1 % (w/v) agar, pH 
7.0), with the appropriate antibiotic for selection and left at 37 °C overnight. 
 
All vectors used (Table 2.3) confer ampicillin or kanamycin resistance to E. coli 
transformants.  Ampicillin was added to both liquid and solid medium at a final 
concentration of 100 µg/ml for selection and maintenance.  Kanamycin was added at a 
final concentration of 50 µg/ml. 
Table 2.3 Vectors. 
cDNA 
Clone 
Vector 
 
Antibiotic 
Resistance 
5' Restriction 
Site 
3' Restriction 
Site 
Insert 
Size (bp) 
eGFP pcDNA3 Ampicillin XhoI XbaI 700 
GPR21 pCMV6-Entry Kanamycin Sgfl Mlul 1050 
Gαq pcDNA3.1+ Ampicillin KpnI XhoI 1085 
Gα14 pcDNA3.1+ Ampicillin KpnI XhoI 1075 
Gα15/16 pcDNA3.1+ Ampicillin KpnI XhoI 1130 
 
2.4.4 Small Scale Isolation of DNA from E. coli 	
Successful colonies were isolated, transferred to 3 ml LB medium (1 % (w/v) tryptone, 
0.5 % (w/v) yeast extract, 1 % (w/v) NaCl, pH 7.0) with the appropriate antibiotic and 
incubated overnight at a 45° angle at 37 °C with shaking.  2 ml of each respective 
culture was centrifuged at 6,800 x g for 2 minutes and DNA was extracted from the 
bacteria using the GeneJET Plasmid Miniprep Kit (Thermo Fisher Scientific, K0503).  
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DNA concentration was assessed by reading absorbance at 260 nm and 280 nm using 
the Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific), where absorbance of 
1 unit at 260 nm is ~50 µg/ml.  The purified plasmid was then digested using the 
appropriate restriction enzyme to assess the presence of the desired insert. 
2.4.5 Diagnostic Restriction Digest 	
To confirm production of plasmid DNA incorporating the gene of interest a diagnostic 
restriction digest was performed.  1 µg of plasmid DNA was digested using 0.5 µl of 
each restriction enzyme.  Enzymes were used at a final concentration of 0.1 U/µl, in 1X 
reaction buffer with 100 ng/ml bovine serum albumin (BSA) (Enzymes and buffers 
were supplied by New England Biolabs).  The reaction was incubated overnight at 37 
°C.  The digested plasmid was then electrophoresed using a 0.8 % (w/v) agarose gel as 
described in Section 2.4.2.2.  The relative structure of the plasmid could then be 
confirmed, based on the observed banding pattern.   
2.4.6 Large Scale Isolation of DNA from E. coli 	
Plasmids were propagated by inoculating 50 ml LB medium containing the required 
selection antibiotic with 50 µl of the small scale E. coli culture (Section 2.4.4).  Cultures 
were grown at 37 °C for 16 hours with shaking.  Plasmids were purified using the 
S.N.A.P. Midiprep kit (Invitrogen, K1910-01), as per the manufacturer’s instructions.  
DNA was eluted with 750 µl sterile MilliQ water and DNA concentration was assessed 
using the Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific) reading 
absorbance at wavelengths of 260 nm and 280 nm.  DNA was aliquoted and stored at    
-20 °C until required. 
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2.4.7 Preparation of Glycerol Stocks 	
For long term storage, liquid cultures of E. coli transformed with the plasmid of interest 
were mixed with sterile glycerol (4:1, glycerol:E. coli) and frozen at -80 °C.   
2.5  Genetic Manipulation of Mammalian Cells 
2.5.1 Transient Transfection of HEK293T Cells 	
Cells were transfected with eGFP plasmid DNA using Lipofectamine® 2000 
(Invitrogen) according to the manufacturer’s protocol and visualised on an inverted 
Olympus CKX41 fluorescent microscope to determine optimal transfection conditions.  
HEK293T cells were seeded at 2.5x105 cells/ml in a 6 well plate and allowed to adhere 
for 24 hours at 37 °C.  For each well of a 6 well plate 2 µg plasmid DNA, or 1 µg of 
each plasmid DNA if co-transfecting, was incubated with 250 µl Opti-MEM® (Gibco).  
4 µl Lipofectamine® 2000 was incubated with 250 µl Opti-MEM® in a separate tube for 
5 minutes at room temperature.  The Lipofectamine® 2000/Opti-MEM® and DNA/Opti-
MEM® mix were then combined.  After a 20 minute incubation at room temperature, 
the solution was added drop-wise to the cells and left for 24 hours at 37 °C to allow 
incorporation of the plasmid DNA.   
2.5.2 Transient Transfection of 3T3-L1 Cells 	
Cells were transfected with eGFP plasmid DNA using Lipofectamine® 3000 
(Invitrogen) according to the manufacturer’s protocol and visualised with an inverted 
Olympus CKX41 fluorescent microscope to determine optimal transfection conditions.  
3T3-L1 pre-adipocytes were seeded at 1.25x105 cells/ml in a 6 well plate and allowed to 
adhere for 24 hours at 37 °C.  For each well of a 6 well plate, 2.5 µg plasmid DNA, or 
1.25 µg of each plasmid DNA if co-transfecting, was incubated with 125 µl Opti-
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MEM® (Gibco) and 10 µl P3000.  7 µl Lipofectamine® 3000 was incubated with 125 µl 
Opti-MEM® in a separate tube for 5 minutes at room temperature.  The Lipofectamine® 
3000/Opti-MEM® and DNA/P3000/Opti-MEM® mix were combined.  After a 5 minute 
incubation at room temperature the solution was added drop-wise to the cells.  Cells 
were left for 24 hours at 37 °C to incorporate the plasmid DNA then differentiated into 
adipocytes as described in Section 2.2.1.2. 
2.5.3 Transient Transfection of RAW 264.7 Cells 	
Cells were transfected with eGFP plasmid DNA using Lipofectamine® 3000 to 
determine optimal transfection conditions.  RAW 264.7 cells were seeded at a density of 
5x105 cells/ml in a 6 well plate and allowed to settle for 24 hours at 37 °C.  Cells were 
transfected with 4 µg plasmid DNA or 2 µg of each plasmid DNA if co-transfecting, per 
well of a 6 well plate as outlined in Section 2.5.2.  
2.6 Biochemical Techniques 
2.6.1 Protein Extraction 	
Cell culture vessels were placed on ice, medium removed and cells were washed three 
times with ice-cold PBS.  Cells were then scraped into 1 ml ice-cold PBS, transferred to 
a 1.5 ml tube and centrifuged at 650 x g for 5 minutes.  The PBS was aspirated and cell 
pellets were resuspended in HEPES lysis buffer; 50 mM HEPES pH 7.5, 150 mM NaCl, 
10 mM Na2HPO4, 50 mM NaF, 1 mM EDTA, 1.5 mM MgCl2, 2 mM Na3VO4, 1 mM 
Na4P2O7, 1X SigmaFAST protease inhibitor cocktail (Sigma-Aldrich), 10 % (v/v) 
glycerol, 1 mM PMSF and 1 % (v/v) Triton x-100.   
 
Frozen murine epididymal fat pads were homogenised in ice-cold HEPES lysis buffer at 
a ratio of 1:5 (w:v) using a T10 Basic handheld homogeniser (IKA).   
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Crude extracts were incubated for 1 hour at 4 °C with constant agitation.  Lysates were 
centrifuged at 17,000 x g for 10 minutes at 4 °C.  The insoluble pellet was discarded 
and the protein concentration of the supernatant was determined using the Pierce protein 
assay (Section 2.6.2.1).   
2.6.2 Protein Assays 	
As some chemicals are known to react with the components of a protein assay, two 
different protein assays were employed, depending on the buffer used to isolate protein 
samples.  A standard protein curve was prepared using BSA at 0, 50, 100, 200, 400, 
600, 800, and 1000 µg/ml.  Samples were diluted as required and 10 µl of each sample 
or standard was used in triplicate in a 96 well plate.  Absorbance values obtained for 
each sample were compared to that of the standard curve to ascertain protein 
concentration. 
2.6.2.1 Pierce Protein Assay 
 
150 µl of the Pierce protein assay reagent (PN22660) was added to each standard and 
sample in a 96 well plate and incubated at room temperature for 5 minutes with 
agitation.  The plate was analysed using a BIO-TEK EL800 plate reader at 630 nm. 
2.6.2.2 Bicinchoninic Acid Protein Assay 	
The bicinchoninic acid protein assay was carried out as described by Smith and 
colleagues (1985).  Copper sulphate was diluted 1:50 into bicinchoninic acid and 200 µl 
of this solution was added to each standard and sample in a 96 well plate.  The plate was 
incubated at 37 °C for 30 minutes and subsequently read using a BIO-TEK EL800 plate 
reader at 562 nm.   
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2.6.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 
SDS-PAGE was conducted using the Hoefer system according to the methods described 
by Laemmli (1970), to separate proteins by molecular mass weight.  Samples were 
diluted 1:4 in Laemmli buffer (300 mM Tris-HCl, 50 % (v/v) glycerol, 10 % (w/v) SDS, 
0.02 % (w/v) bromophenol blue, 10 % (v/v) β-mercaptoethanol, pH 6.8) and boiled at 
95 °C for 5 minutes before loading into the wells of an appropriate percentage 
polyacrylamide gel (Table 2.4) sufficiently covered with SDS running buffer (0.1 % 
(w/v) SDS, 25 mM Tris-Base and 192 mM glycine).  Samples of equal protein 
concentration were electrophoresed at 19 mA for approximately 2 hours along with a 
protein molecular weight marker (Thermo Fisher Scientific, SM1811)  (Fig.  2.2). 
 
Table 2.4 Polyacrylamide gels. 
Stock Solution 
 
 
 
 
 
10 % 
Resolving 
Gel – For 
proteins 
above  
30 kDa 
8 % 
Resolving 
Gel – For 
proteins 
above  
100 kDa 
6 % 
Resolving 
Gel – For 
proteins 
above  
200 kDa 
5 % 
Stacking 
Gel 
 
 
 
dH2O 4 ml 4.6 ml 5.3 ml 3.4 ml 
30 % acrylamide/bisacrylamide (ProtoGel) 3.3 ml 2.7 ml 2 ml 830 µl 
1.5 M Tris-HCl, pH 8.8 2.5 ml 2.5 ml 2.5 ml - 
1 M Tris-HCl, pH 6.8 - - - 630 µl 
10 % (w/v) SDS 100 µl 100 µl 100 µl 50 µl 
10 % (w/v) ammonium persulfate 100 µl 100 µl 100 µl 50 µl 
TEMED 4 µl 6 µl 8 µl 5 µl 
Total volume per gel 10 ml 10 ml 10 ml 5 ml 
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Figure 2.2 Distribution of molecular weight marker used with SDS-PAGE. 
2.6.3.1 Coomassie Brilliant Blue Staining 	
To visualise proteins, SDS-PAGE gels were fixed for 15 minutes in 40 % (v/v) ethanol, 
10 % (v/v) acetic acid for 15 minutes with agitation, this was repeated once.  Gels were 
then incubated with agitation for a minimum of 2 hours with 40 % (v/v) ethanol, 10 % 
(v/v) acetic acid, 0.1 % (w/v) Coomassie Brilliant Blue G250 (Ams Biotechnology, 
17524).  Gels were destained for 5 minutes in 40 % (v/v) ethanol, 10 % (v/v) acetic acid 
then immersed in 20 % (v/v) ethanol, 10 % (v/v) acetic acid until completely destained.  
Gels were washed in dH2O before imaging. 
2.6.3.2 Semi-Dry Electroblotting 	
Alternatively, separated proteins were transferred from SDS-PAGE gels onto a PVDF 
membrane (GE Healthcare) in a semi-dry transfer unit (Cleaver Scientific Ltd).  The 
PVDF membrane was pre-soaked in methanol, followed by ice-cold transfer buffer (48 
mM Tris-Base, 39 mM glycine, 0.375 % (w/v) SDS, 20 % (v/v) methanol) for 10 
minutes.  Gels were washed once with dH2O and soaked in ice-cold transfer buffer for 5 
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minutes before proteins were transferred to the membrane at 150 mA per gel for 30 
minutes.   
2.6.3.2.1  Western Blotting 	
Membranes were blocked with 5 % (w/v) BSA or non-fat dry milk (Marvel) in Tris-
buffered saline containing Tween-20 (TBST); 150 mM NaCl, 20 mM Tris-HCl, pH 7.6, 
0.1 % (v/v) Tween-20 for 1 hour at room temperature to prevent antibodies binding 
non-specifically.  Membranes were subsequently incubated with a primary antibody at 
an optimised dilution (Table 2.5) overnight at 4 °C.  The membranes were washed 3 
times with TBST, 5 minutes each time, to remove unbound antibody, before incubating 
with the appropriate secondary antibody conjugated with HRP for 2 hours at room 
temperature.  Membranes were then washed 3 times, 5 minutes each, with TBST and 
incubated with enhanced chemiluminescence (ECL) (Roche, 11500694001) for 2 
minutes.  Immunoreactive protein bands were visualised on UltraCruz™ 
Autoradiography Film (Santa Cruz Biotechnology). 
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Table 2.5 Western blotting antibodies.    
Antibody Dilution Diluent Company  
Insulin Receptor β  1:1000 5% Milk TBST Abcam (ab69508) 
Phospho-Insulin Receptor β Tyr1150/1151 1:1000 5% Milk TBST Cell Signaling (3024) 
IRS1  1:1000 5% Milk TBST Cell Signaling (3407) 
Phospho-IRS1 Tyr612  1:1000 5% BSA TBST Life Technologies (44-816G) 
Akt  1:1000 5% BSA TBST Cell Signaling (9272) 
Phospho-Akt Ser473 1:1000 5% BSA TBST Cell Signaling (9271) 
AS160  1:1000 5% BSA TBST Cell Signaling (2670) 
Phospho-AS160 Ser588  1:1000 5% BSA TBST Cell Signaling (8730) 
Phospho-AS160 Thr642  1:1000 5% Milk TBST Cell Signaling (8881) 
AMPKα  1:750 5% BSA TBST Cell Signaling (2532) 
Phospho-AMPKα Thr172  1:750 5% BSA TBST Cell Signaling (2531) 
ACC 1:1000 5% BSA TBST Cell Signaling (3662) 
Phospho-ACC Ser79  1:1000 5% BSA TBST Cell Signaling (3661) 
JNK 1:1000 5% BSA TBST Cell Signaling (9258) 
Phospho-JNK Thr183/Tyr185 1:1000 5% BSA TBST Cell Signaling (4668) 
Erk 1:1000 5% BSA TBST Cell Signaling (4695) 
Phospho-Erk Thr202/Tyr204 1:1000 5% BSA TBST Cell Signaling (4370) 
p38  1:1000 5% BSA TBST Cell Signaling (9212) 
Phospho-p38 Thr180/Tyr182 1:1000 5% BSA TBST Cell Signaling (4511) 
β-actin 1:40000 5% Milk TBST Abcam (ab8226) 
Myc 1:5000 5% Milk TBST Cell Signaling (2276) 
GPR21  1:1000 5% Milk TBST Abcam (ab139654) 
F4/80 1:1000 5% Milk TBST Abcam (ab74383) 
Anti-Rabbit IgG HRP Conjugate 1:2000 TBST Dako (P0448) 
Anti-Mouse IgG HRP Conjugate 1:5000 TBST Promega (W4021) 
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2.6.3.2.2  Re-probing PVDF Membranes 	
When optimising antibody concentrations or when investigating more than one protein, 
it was possible to reuse membranes once the initial primary antibody was removed.  
Membranes were incubated with Restore™ Western Blot Stripping Buffer (Thermo 
Fisher Scientific, 21059) for 15 minutes with agitation, and then washed 3 times for 5 
minutes with TBST to remove any remaining stripping buffer.  To determine complete 
removal of antibody, membranes were incubated with ECL and exposed to X-ray film.  
If the procedure was successful, membranes were washed once with TBST and re-
blocked in 5 % (w/v) BSA or milk in TBST for 1 hour at room temperature.  
Membranes were then probed with an alternative antibody following the procedure 
outlined in Section 2.6.3.2.1. 
2.6.4 PI3K Enzyme-Linked Immunosorbent Assay (ELISA) 	
A PI3K ELISA (Merck Millipore, 17-493) was used to assess the direct effect of 
compounds on the activity of the four class I PI3Ks (p110α, p110β, p110γ and p120δ).  
All reagents used were supplied with the kit.  Each class I PI3K was incubated with 
each compound (1 µM wortmannin, 10 µM RTC-1, 10 µM RTC-15, 500 µM 
metformin) for 10 minutes at room temperature.  5 µl of the 5X kinase reaction buffer 
was added to each well of a glutathione coated 96 well plate followed by 5 µl (50 µM) 
PIP2.  5 µl of the kinase/compound mix was then added to the plate and incubated for 1 
hour at room temperature.  Wells containing no kinase acted as a buffer control, while 
wells containing no compounds acted as a positive control for kinase activity.  25 µl of 
biotinylated-PIP3/EDTA (diluted 1:18 in TBST) was added to each well, excluding 
buffer control wells, followed by 50 µl of the capture protein, general receptor for 
phosphoinositides (GRP-1) containing a glutathione-s-transferase (GST) tag, (diluted 
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1:1000 in TBST) and incubated for 1 hour at room temperature.  The plate was washed 
4 times with 200 µl TBST then incubated with 50 µl/well streptavidin-HRP conjugate 
(diluted 1:2000 in TBST) for 1 hour at room temperature.  Wells were washed 5 times 
with 200 µl TBST then incubated with 100 µl TMB for no more than 20 minutes in the 
dark.  When a blue colorimetric change appeared, the reaction was stopped with the 
addition of 100 µl/well of a stop solution included in the kit.  Absorbance was read at 
450 nm using a BIO-TEK EL800 plate reader.  To calculate the percentage of PIP3 
relative to the biotinylated-PIP3 tracer, the absorbance values of positive wells 
containing the tracer only were set to 100.  All other signals were divided by the 
biotinylated-PIP3 average then multiplied by 100 to show the relative percentage to the 
positive signal.  As the capture protein, GRP-1, binds either PIP3 generated as part of 
the kinase reaction or the biotinylated-PIP3 tracer, a lower signal was indicative of 
higher kinase activity.   
2.7 Functional Assays 
2.7.1 Analysis of NADH:ubiquinone oxidoreductase Activity 
2.7.1.1 Isolation of Mitochondria from Rat Liver 	
Mitochondria were isolated from rat liver as outlined by Chappell and Hansford, (1972).  
The liver was washed three times with ice-cold isolation buffer (250 mM sucrose, 5 
mM Tris-HCl, 1 mM EGTA, pH 7), then minced in fresh, ice-cold isolation buffer and 
transferred to a glass potter (Potter S Homogeniser, Sartorius).  A Teflon pestle was 
used at 1,600 rpm to homogenise the liver in an ice-bath.  The resulting homogenate 
was centrifuged at 750 x g for 5 minutes at 4 °C, the supernatant was retained and 
centrifuged at 12,000 x g for 10 minutes at 4 °C.  The resulting pellet was resuspended 
in ice-cold isolation buffer supplemented with 2 % (w/v) fatty acid free BSA and 
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centrifuged at 12,000 x g for 10 minutes at 4 °C.  Supernatant was discarded and the 
pellet was resuspended in a minimal volume of isolation buffer.  Mitochondrial 
concentration was determined using the bicinchoninic acid procedure (Section 2.6.2.2).  
Mitochondria were stored at -20 °C until required. 
2.7.1.2 NADH:ubiquinone oxidoreductase Activity 	
Immediately before the assay, mitochondria were diluted in a hypotonic buffer (25 mM 
K2HPO4, 5 mM MgCl2) and permeabilised with three cycles of freezing in liquid 
nitrogen and thawing at room temperature.  The assay was carried out in a temperature 
controlled Shimadzu UV-2550 UV-VIS spectrophotometer, at 30 °C in a 1 ml cuvette 
(Spinazzi et al., 2012).  Permeabilised mitochondria were incubated with 50 mM 
K2HPO4 pH 7.5, 3 mg/ml fatty acid free BSA, 300 µM KCN and 100 µM NADH, 
baseline activity was measured at 340 nm for 1 minute.  The reaction was initiated with 
the addition of 60 µM ubiquinone and the resulting decrease in absorbance was 
followed for 3 minutes.  Varying concentrations of compounds of interest were then 
added and absorbance was measured for a further 3 minutes. To determine the 
percentage activity of NADH:ubiquinone oxidoreductase, the slope of the line obtained 
with the addition of ubiquinone was divided by the slope of the line produced with the 
addition of the compound to be tested.  This value was then expressed as a percentage 
relative to the value calculated for the vehicle control, DMSO, and the protein 
concentration of the mitochondrial sample.  Specificity of the assay was confirmed with 
the addition of rotenone, a known inhibitor of NADH:ubiquinone oxidoreductase. 
2.7.2 Analysis of Intracellular ATP Levels 	
A luminescent ATP detection assay (Abcam, ab113849) was performed according to 
the manufacturer’s instructions.  C2C12 cells were cultured in a black, clear bottomed 
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96 well plate at a density of 1x103 cells/100 µl.  Differentiated cells were stimulated 
with compounds of interest for various time points in triplicate.  Rotenone was used as a 
reference inhibitor, as it is known to significantly decrease ATP levels.  ATP standards 
were also prepared in the 96 well plate, in triplicate, with concentrations ranging from 
250 pM to 10 µM.  Cells were lysed with the addition of 50 µl of a detergent solution 
and incubated for 5 minutes at room temperature on an orbital shaker at 700 rpm.  50 µl 
of reconstituted substrate buffer (containing D-luciferin and luciferase) was added to the 
cells and incubated in the dark for 15 minutes on an orbital shaker at 700 rpm before 
luminescence was read on BMG labtech plate reader.  ATP concentration was 
determined via the ATP standard curve. 
2.7.3 Analysis of Glucose Transport 
2.7.3.1 Radioactive Glucose Uptake 	
Cellular glucose uptake was measured by scintillation counting of cellular [3H]-2-
deoxyglucose with slight modifications to the method described by Yun and colleagues 
(2009).  Cells were washed once with Krebs Ringer Buffer (KRB); 136 mM NaCl, 20 
mM HEPES, 4.7 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 4.05 mM Na2HPO4, 0.95 mM 
NaH2PO4, pH 7.4 warmed to 37 °C.  Cells were then incubated with 1 µCi/ml [3H]-2-
deoxyglucose (PerkinElmer, NET328A001MC) in KRB at 37 °C for 10 minutes.   To 
terminate the assay cells were washed 3 times with ice-cold KRB, then lysed in 0.1 % 
(w/v) SDS at 37 °C for 30 minutes.  Cell lysates were diluted 1:4 in β-scintillation fluid 
(Beta-Plate Scint, PerkinElmer).  Cellular incorporation of [3H]-2-deoxyglucose was 
quantified by a 1450 Microbeta Liquid Scintillation Counter (PerkinElmer), which 
expressed results in counts per minute (CPM).  Total protein content of each sample 
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was determined by the bicinchoninic acid procedure (Section 2.6.2.2) to define results 
as CPM/mg. 
2.7.3.2 Flow Cytometry Analysis of GLUT4 Translocation  	
C2C12 myotubes were dissociated with trypsin-EDTA solution as described in Section 
2.2.1.  Trypsin-EDTA was neutralised with complete medium containing 10 % (v/v) 
FBS and cells were centrifuged at 300 x g for 5 minutes.  Cell pellets were resuspended 
in Fc buffer (PBS containing 1 % (w/v) BSA and 1 mM EDTA), counted and further 
diluted to yield a density of 1x105 cells/100 µl.  Cells were pre-incubated with 1 µl 
Mouse BD Fc Block™ (BD Biosciences, 553142) for 30 min at 4 °C to prevent non-
specific binding.  Samples were divided into two tubes, 5 µl anti-GLUT4 (Santa Cruz 
Biotechnology, SC-1606) was added to one sample set.  The other sample set served as 
the negative control, used to monitor non-specific binding of the secondary antibody, 
and was incubated with buffer alone.  Cells were incubated for 30 minutes at 4 °C then 
washed by centrifuging at 300 x g for 5 minutes and resuspending the pellet in 100 µl 
Fc buffer.  All samples were incubated with 1.2 µl anti-goat IgG-FITC (Sigma-Aldrich 
F7367) for 30 minutes at 4 °C and washed twice before analysis by flow cytometry with 
an Accuri® C6 Flow Cytometer (BD Biosciences).   
2.7.4 Homogeneous Time Resolved Fluorescence (HTRF) Assays 
2.7.4.1 PIP3 HTRF Assay 	
A PIP3 HTRF assay (Merck Millipore, 17-495) was used to establish the effect of 
compounds of interest on the production of PIP3 in differentiated C2C12 cells.  After 
stimulation, cells were incubated with 500 µl 0.5 M trichloroacetic acid for 5 minutes 
on ice to precipitate cellular debris.  The cell suspension was centrifuged at 17,000 x g 
for 5 minutes at 4 °C, and the resulting pellet was washed with 500 µl 5 % (v/v) 
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trichloroacetic acid, 1 mM EDTA.  Neutral lipids were extracted by incubating the 
pellet with 1 ml 2:1 methanol:chloroform for 10 minutes at room temperature followed 
by centrifugation at 17,000 x g for 5 minutes at 4 °C.  This step was repeated once.  
Acidic lipids were then extracted by incubating the pellet with 500 µl 40:80:1 
chloroform:methanol:12 M HCl for 15 minutes at room temperature.  180 µl chloroform 
was added to each sample followed by 320 µl 0.1 M HCl.  Samples were vortexed, then 
centrifuged at 17,000 x g for 5 minutes at 4 °C resulting in the formation of two distinct 
layers.  The lower phase was transferred to a clean tube and 30 µl of methanol 
containing 0.1 M ammonium hydroxide was added.  Samples were dried in a vacuum 
evaporator and resuspended in 60 µl lipid recovery buffer supplied with the HTRF kit.  
To aid the resuspension process, samples were vortexed for 30 seconds then sonicated 
in a cooled sonication bath for 15 seconds.  The PIP3 detection solution was prepared as 
outlined in the manufacturer’s instructions and incubated at room temperature for 30 
minutes in the dark.  Standards and samples were added to a black 96 well plate in 
triplicate (25 µl/well) followed by 25 µl of the detection solution, the plate was sealed 
and incubated at room temperature for 4 hours with agitation.  The plate was then read 
on a BMG labtech plate reader with excitation at 340 nm and measurements of emission 
at 615 nm and 665 nm.  The fluorescence resonance energy transfer (FRET) ratios (665 
nm/615 nm) were converted to PIP3 concentrations by interpolating values from the 
PIP3 standard curve. 
2.7.4.2 IP1 HTRF Assay 
Cellular inositol 1-phosphate (IP1) levels were measured using an IP-one HTRF assay 
kit (Cisbio, 62IPAPEC) (Trinquet et al., 2006).  Sub-confluent HEK293T cells were 
detached from the cell culture dish by trypsinisation (Section 2.2.1) and resuspended in 
the appropriate volume of the assay stimulation buffer (10 mM HEPES, 1 mM CaCl2, 
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0.5 mM MgCl2, 4.2 mM, KCl, 146 mM NaCl, 5.5 mM glucose, 50 mM LiCl, pH 7.4) 
warmed to 37 °C, to achieve a concentration of 6x106 cells/ml.  7 µl of the cell 
suspension was added to each well of a white half volume 384 well plate (Greiner, 
781080) along with 7 µl of the compound to be tested, prepared at a 2X concentration.  
Triplicate samples were incubated at 37 °C for 2 hours.  3 µl IP-one-d2 conjugate  
(diluted 1:20 in IP-one lysis buffer) was added to each well followed by 3 µl anti-IP-one 
cryptate Tb conjugate (diluted 1:20 in IP-one lysis buffer), and incubated in the dark for 
1 hour at room temperature.  The plate was read on a BMG labtech plate reader with an 
excitation at 340 nm and emissions at 615 nm and 665 nm respectively.  The FRET 
ratios (665 nm/615 nm) were converted to IP1 concentrations by interpolating values 
from an IP1 standard curve.  
2.7.5 Macrophage Migration Assay 	
RAW 264.7 cells were detached from the culture vessel using a cell scraper and 
centrifuged at 600 x g for 5 minutes.  Cell pellets were resuspended in complete DMEM 
supplemented with 2 % (v/v) FBS at a density of 5x105 cells/ml.  750 µl of 2 % (v/v) 
FBS DMEM was added to a well of a 24 well plate and a 6.5 mm Transwell® insert 
with a 5.0 µm pore polycarbonate membrane (Corning®) was placed into the well.  250 
µl of the cell suspension was added to the upper chamber of the Transwell® insert and 
cells were incubated at 37 °C for 1 hour to acclimatise.  Medium was removed from the 
lower chamber and replaced with 3T3-L1 adipocyte conditioned medium, cells were 
then incubated for 4 hours at 37 °C.  To determine the migratory capacity of the cells, 
medium was removed from the Transwell® insert, which was subsequently washed 
twice with PBS then incubated in cold (-20 °C) methanol for 5 minutes to fix the 
migrating cells.   The polycarbonate membrane was then removed from the Transwell® 
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insert using a scalpel and incubated with 0.05 % (w/v) crystal violet dissolved in 0.1 M 
disodium tetraborate, pH 9.0 containing 2 % (v/v) ethanol for 20 minutes.  The 
membrane was washed three times with PBS before the crystal violet stain was eluted 
using 10 % (v/v) acetic acid with a 5 minute incubation.  The resulting solution was 
transferred to a 96 well plate and absorbance was read at 560 nm on an ELx800TM 
microplate reader.     
2.8  Statistical Analysis 	
Data are presented as mean ± the standard error of the mean (SEM).  The unpaired 
Student’s t-test was used to determine significance between two experimental groups.  
One-way analysis of variance (ANOVA) with a post-hoc Tukey test was used to 
determine significance among three or more groups.  One-way ANOVA with a post-hoc 
Dunnett test was used when comparing two or more groups to a control group.  
GraphPad Prism® 5 software was used to carry out the analysis.  Significance was 
denoted as p < 0.05; *, p < 0.01; **, p < 0.001; ***. 
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3.1 Introduction 	
The emerging limitations of current anti-diabetic strategies stress the need for novel 
therapeutics with well-defined mechanisms of action (Rochester and Akiyode, 2014).  
This study focuses on securing the mode of action of a novel compound, RTC-1 (Fig. 
3.1A), which demonstrated anti-diabetic properties in a murine dietary-induced model 
of type 2 diabetes. RTC-1 was developed following on from work conducted by 
Campos-Sandoval and colleagues (2011), where novel retinoid analogues were found to 
interrupt RBP interactions with TTR and STRA6 in a superior way to fenretinide in 
vitro.  This action holds potential as an anti-diabetic therapy as we propose that 
unbound RBP may be readily excreted, thus preventing the proposed negative effects of 
the protein on the insulin signalling pathway.  Through in silico screening of 
commercial databases, Dr. Gemma Kinsella found RTC-1, a non-retinoid compound, to 
interact with RBP.  Surface plasmon resonance analysis (Fig. 3.1B) then demonstrated 
the ability of this compound to inhibit RBP-TTR interactions, prompting in vivo 
analysis of the effects of the compound on the type 2 diabetic phenotype.  
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Figure 3.1 The effect of RTC-1 on RBP:TTR complex formation. 
(A) Structure of RTC-1.  (B) His-tagged RBP was immobilised on the surface of a 
sensor chip and exposed to retinol and TTR. The complex formation causes a change in 
the mass on the sensor chip resulting in a change in resonance units.  The addition of 10 
µM RTC-1 or fenretinide, both led to a decrease in this response, indicative of a 
disruption to the formation of the RBP:TTR complex.  SPR analysis was carried out in 
the University of Leeds by Prof. Colin Fishwick’s research group. 
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In an intervention study carried out by Dr. Clara Redondo, HFD-fed C57BL/6 mice 
exhibited reduced insulin sensitivity (Fig. 3.2A) and glucose tolerance (Fig. 3.2B), 
whereas HFD-fed mice that received 0.04 % (w/w) RTC-1 relative to the diet (~1 
mg/mouse/day), displayed improved glucose handling, not significantly different to that 
of the chow fed control mice.  Although there were no changes to food intake between 
mice on the HFD and the HFD supplemented with RTC-1, those receiving the novel 
compound maintained the bodyweight recorded at the time of RTC-1 administration, 
while those on the HFD alone continued to gain weight (Fig. 3.2C).  Given this effect, 
in vitro analyses of RTC-1 were conducted to give further insight into the potential of 
the novel compound as a pharmacological strategy for the treatment of insulin 
resistance and type 2 diabetes.  RTC-1 was found to dramatically increase glucose 
uptake in C2C12 muscle cells, an effect the action of the compound on RBP would not 
account for (Fig. 3.3). 
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Figure 3.2 RTC-1 intervention study in a dietary-induced mouse model of type 2 
diabetes. 
Mice received a HFD of 5450 kcal/kg for 16 weeks (n=16).  HFD-fed mice were then 
randomly divided into two groups with one cohort receiving a HFD supplemented with 
0.04 % (w/w) RTC-1 for a further 16 weeks (n=8).  (A) Mice fed either normal chow, 
HFD or HFD with RTC-1 were injected with a bolus of insulin and serum glucose 
levels were monitored for 2 hours.  (B) Mice were also injected with a bolus of glucose 
and serum glucose clearance was monitored for 2 hours.  (C) Total body weight was 
recorded for the duration of the experiment.  Images were kindly provided by Dr. 
Darren Martin. 
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Figure 3.3 The direct effect of RTC-1 on glucose uptake in C2C12 muscle cells. 	
C2C12 myotubes were stimulated with 10 µM RTC-1 or an equal volume of the vehicle 
control, DMSO, in complete medium supplemented with 0.1 % (v/v) horse serum for 16 
hours. Glucose uptake was measured via scintillation counting of cellular [3H]-2-
deoxyglucose.  Data presented as mean ± SEM are representative of multiple 
independent experiments performed in triplicate.  Using the unpaired Student’s t-test 
GraphPad Prism® 5 software demonstrates significance at p < 0.01; **. 
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In an attempt to establish the mechanism of action of this compound, a variety of targets 
known to positively impact the type 2 diabetic phenotype were investigated.  RTC-1 
displayed no effect on well-known diabetic targets such as GLP-1R or PPARγ nor did it 
induce secretion of insulin or GLP-1 from INS-1e and NCI-H716 cell lines respectively 
(Martin et al., 2016).  In a cell toxicity profile RTC-1 demonstrated no adverse reaction 
in vivo, it did not induce cell death in rat hepatocytes nor did it affect the hERG channel, 
a recognised preclinical safety test (Priest et al., 2008).  These results highlighted RTC-
1 as a promising anti-diabetic therapeutic, however in order to further develop this 
compound investigations into its precise mechanism of action were paramount.    
 
The observed effect of RTC-1 on glucose handling, weight gain and potentially energy 
balance suggested that AMPK may be a prime candidate through which RTC-1 could 
exert its effects.  AMPK is a central regulator of energy homeostasis that responds to 
increases in cellular AMP and ADP (Hardie et al., 1998).  Once activated, AMPK 
restores cellular energy balance by switching on ATP generating pathways such as 
glucose transport and fatty acid oxidation and by switching off ATP consuming 
pathways such as fatty acid synthesis and gluconeogenesis.  As altered glucose and lipid 
metabolism are central to type 2 diabetes, several anti-diabetic drugs are thought to 
target AMPK to alleviate this pathophysiology, including metformin, the current 
standard for the treatment of this disease (Coughlan et al., 2014, Inzucchi et al., 2015).  
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3.2  Aims and Objectives 	
The current study aimed to elucidate the mechanism of action of RTC-1 and the 
consequential effects on glucose uptake, insulin resistance, adipogenesis and 
osteogenesis using various in vitro analysis approaches.  In order to demonstrate a 
structure-activity relationship, a derivative of RTC-1, RTC-15, was analysed in the 
preliminary stages of this study. The effects of these novel compounds were also 
compared to that of metformin, the leading medication in the treatment of type 2 
diabetes, to gain insight into their effectiveness as a novel pharmacological approach for 
the treatment of insulin resistance and type 2 diabetes.  
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3.3 Results 
3.3.1 RTC-1 Demonstrates a Dramatic Effect on Glucose Uptake  	
As skeletal muscle accounts for up to 80 % of glucose uptake (Thiebaud et al., 1982), 
the C2C12 myoblast cell line, isolated from mouse skeletal muscle, was chosen to 
compare the effect of RTC-1 on glucose transport to that of insulin and metformin.  
Stimulation of differentiated C2C12 myotubes for 16 hours with increasing 
concentrations of RTC-1 led to a progressively significant increase in glucose uptake, as 
determined by the cellular levels of [3H]-2-deoxyglucose (Fig. 3.4A).  [3H]-2-
deoxyglucose, a derivative of glucose was used to monitor glucose uptake, as unlike 
glucose, it cannot be metabolised by the cell.  Following stimulations of cells with 1 
µM, 10 µM and 100 µM RTC-1, a meaningful increase in glucose uptake was evident 
and comparable to that of an acute insulin challenge (30 minute incubation with 100 nM 
insulin).  The action of metformin, although significant at 1 µM and 10 µM was only 
equivalent to a 100 nM insulin stimulation at concentrations above 100 µM (Fig. 3.4B).  
Based on these results optimal concentrations of RTC-1 (10 µM) and metformin (500 
µM) were selected to examine the influence of the compounds on glucose uptake over 
time.  Both RTC-1 (Fig. 3.5A) and metformin (Fig. 3.5B) led to an increase in glucose 
uptake, becoming significant at 4 hours, with the effect of RTC-1 surpassing that of 
metformin at the 6 hour time point.  Given this dramatic impact of RTC-1 on glucose 
transport, the long-term response to the compound was then evaluated.  Glucose uptake 
was stimulated in C2C12 myotubes with the addition of 10 µM RTC-1 for 16 hours.  
Cells were washed free of the compound and changes to glucose uptake were then 
examined.  At 6 and 12 hours post RTC-1 removal a significant increase in glucose 
uptake was observed.  Although this effect lessened at 24 and 48 hours, basal glucose 
levels were surpassed (Fig. 3.6).   
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Figure 3.4 Concentration dependent effects of RTC-1 and metformin on glucose 
uptake.   
 
C2C12 myotubes were stimulated with varying concentrations of (A) RTC-1 or (B) 
metformin for 16 hours in complete medium supplemented with 0.1 % (v/v) horse 
serum.  As a positive control, cells were incubated with 100 nM insulin in KRBG for 30 
minutes.  Glucose uptake was measured via scintillation counting of cellular [3H]-2-
deoxyglucose.  Data presented as mean ± SEM are representative of two independent 
experiments performed in triplicate.  One-way ANOVA with a post-hoc Dunnett test 
using GraphPad Prism® 5 software demonstrates significance at p < 0.05; * and p < 
0.001; ***. 
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Figure 3.5 Time dependent effects of RTC-1 and metformin on glucose uptake. 
 
C2C12 myotubes were stimulated for various times points ranging from 1 hour to 6 
hours with optimal concentrations of (A) RTC-1 (10 µM) and (B) metformin (500 µM) 
in complete medium containing 0.1 % (v/v) horse serum.  Changes in glucose uptake 
were evaluated via scintillation counting of cellular [3H]-2-deoxyglucose. Data 
presented as mean ± SEM are representative of three independent experiments 
performed in triplicate each time.  One-way ANOVA with a post-hoc Dunnett test using 
GraphPad Prism® 5 software demonstrates significance at p < 0.05; * and p < 0.01; **. 
 
 
Chapter 3: Elucidating the Mechanism of Action of a Novel Anti-Diabetic Compound  
 101 
 
Figure 3.6 The long-term effects of RTC-1-stimulated glucose uptake in cells 
washed free of the compound. 
 
C2C12 myotubes were stimulated with 10 µM RTC-1 in complete medium 
supplemented with 0.1 % (v/v) horse serum for 16 hours, then washed free of RTC-1 
with DPBS and incubated with fresh medium.  Changes in glucose uptake were 
evaluated via scintillation counting of cellular  [3H]-2-deoxyglucose at 6, 12, 24 and 48 
hours post medium change.  Data presented as mean ± SEM are representative of two 
independent experiments performed in triplicate each time.  One-way ANOVA with a 
post-hoc Dunnett test using GraphPad Prism® 5 software demonstrates significance at p 
< 0.05; * and p < 0.01; **. 
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3.3.2 RTC-1 and its Derivative, RTC-15, Induce GLUT4 
Translocation 	
In order to investigate the structure-activity relationship of RTC-1, a large number of 
compounds with alterations to the original structure of RTC-1 were tested for their 
capacity to induce glucose uptake.  Stimulation of C2C12 myotubes with 10 µM of one 
derivative, RTC-15 (Fig. 3.7A), led to a significant increase in glucose uptake, similar 
to the action of 100 nM insulin.  However, the response to RTC-15 did not exceed that 
observed with RTC-1 (Fig. 3.7B).   
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Figure 3.7 The effect of the RTC-1 derivative, RTC-15, on glucose uptake. 
 
(A) Structure of RTC-15. (B) C2C12 myotubes were incubated with 10 µM RTC-1 or 
10 µM RTC-15 in complete medium containing 0.1 % (v/v) horse serum for 6 hours.  
Cells were also stimulated with 100 nM insulin in KRBG for 30 minutes, as a positive 
control.  Glucose uptake was measured via scintillation counting of cellular [3H]-2-
deoxyglucose.  Data presented as mean ± SEM are representative of multiple 
experiments, performed in triplicate each time.  One-way ANOVA with a post-hoc 
Dunnett test using GraphPad Prism® 5 software demonstrates significance at p < 0.01; 
** and p < 0.001; ***.  
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As GLUT4 is the primary modulator of glucose uptake in response to insulin 
stimulation (Pessin et al., 1999), and has also been implicated in AMPK-induced 
glucose transport (Kurth-Kraczek et al., 1999), the effect of these novel compounds on 
GLUT4 translocation was investigated.  Under basal conditions, GLUT4 resides in 
intracellular storage vesicles until signalled to redistribute to the plasma membrane to 
facilitate increased uptake of glucose (Larance et al., 2008).  Through flow cytometry 
analysis, a significant increase in plasma membrane associated GLUT4 was observed in 
C2C12 cells stimulated with 10 µM RTC-1 or 10 µM RTC-15.  Cells incubated with 
500 µM metformin exhibited a level of GLUT4 cell surface expression similar to those 
exposed to the vehicle control, DMSO (Fig. 3.8).     
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Figure 3.8 The effect of RTC-1, RTC-15 and metformin on GLUT4 translocation.  
 
C2C12 myotubes were stimulated with 10 µM RTC-1, 10 µM RTC-15, 500 µM 
metformin or an equal volume of DMSO for 4 hours in complete medium containing 
0.1 % (v/v) horse serum.  Cells were incubated with a GLUT4 specific antibody 
followed by a FITC conjugated secondary antibody (red line).  As a control, cells were 
stained with the secondary antibody alone (black line).  Cells were analysed using flow 
cytometry with 10,000 events recorded.  (A) Data are presented in histograms of mean 
fluorescence intensity, representing two separate experiments.  (B) A bar chart 
represents the average percentage of membrane-associated GLUT4 relative to cells 
incubated with the fluorescent secondary antibody alone.  One-way ANOVA with a 
post-hoc Dunnett test using GraphPad Prism® 5 software demonstrates significance at p 
< 0.01; **. 
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3.3.3 RTC-1 and RTC-15 Activate AMPK 	
Given the effects of RTC-1 and RTC-15 on GLUT4 translocation, the next step was to 
examine the activation status of AMPK (Mu et al., 2001).  Phosphorylation of the 
catalytic α-subunit of AMPK at Thr172 was investigated in response to RTC-1, RTC-15 
and metformin, as phosphorylation at this residue is a recognised indicator of AMPK 
activation (Hawley et al., 1996, Stein et al., 2000).  After a 15 minute incubation, 10 
µM RTC-1 moderately induced the phosphorylation of AMPKα in C2C12 myotubes; 
this became amplified at 45 minutes and plateaued (Fig. 3.9A).  An increase in the 
phosphorylation of AMPKα was observed at 45 minutes post stimulation in response to 
10 µM RTC-15, this was augmented at 2 hours and the phosphorylation status of the 
kinase remained elevated for the duration of the time course (Fig. 3.9B).  A 500 µM 
metformin incubation augmented AMPKα phosphorylation after 15 minutes, 
phosphorylation increased again at 45 minutes and was sustained throughout the 
remainder of the time course (Fig. 3.9C).    
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Figure 3.9 Time dependent effects of RTC-1, RTC-15 and metformin on AMPKα 
phosphorylation. 
 
C2C12 myotubes were stimulated with (A) 10 µM RTC-1, (B) 10 µM RTC-15 or (C) 
500 µM metformin for 15 minutes up to 6 hours in complete medium with 0.1 % (v/v) 
horse serum.  Cells were lysed, subjected to SDS-PAGE and immunoblotted with 
antibodies against phospho-AMPKα Thr172 and native AMPKα.  β-actin was used as a 
loading control.  Data are representative of multiple independent experiments.   
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3.3.4 RTC-1 and RTC-15 Inhibit NADH:ubiquinone oxidoreductase 
Activity  
 
To determine if the effect of these compounds was as a result of a direct interaction with 
AMPK or of a regulating mechanism upstream of the protein, the influence of RTC-1 
and RTC-15 on the activity of NADH:ubiquinone oxidoreductase in mitochondria was 
investigated.  As metformin is believed to instigate its influence on AMPK in this way 
(Owen et al., 2000), the impact of the RTC compounds was again compared to that of 
metformin.  Before each assay the activity of mitochondria isolated from rat liver was 
assessed ± the addition of rotenone, a potent NADH:ubiquinone oxidoreductase 
inhibitor that obstructs NADH oxidation by blocking the ubiquinone binding site of the 
enzyme (Degli Esposti, 1998).  Using a temperature controlled spectrophotometer, 
NADH:ubiquinone oxidoreductase activity was initiated, and monitored, with the 
addition of 60 µM ubiquinone.  As more NAD+ was produced from NADH to generate 
a proton gradient a decrease in absorbance was observed, as NAD+ does not absorb at 
340 nm.  With the addition of 1 µM rotenone, the solution began to absorb again at 340 
nm, an indication of a decrease in NAD+ production (Fig. 3.10A).  The effect of a 
compound on NADH:ubiquinone oxidoreductase was determined by comparing activity 
before and after addition, relative to the vehicle control, DMSO (Fig. 3.10B).   
 
Utilising the same method, the addition of RTC-1 (Fig. 3.11A) and RTC-15 (Fig. 
3.11B) to disrupted mitochondria produced a dose-related inhibition of 
NADH:ubiquinone oxidoreductase activity.  This assay also allowed the IC50 of the 
compounds to be calculated; 27 µM for RTC-1 and 104 µM for RTC-15.  There was no 
apparent effect with metformin until the addition of the highest soluble concentration, 
10 mM (Fig. 3.11C).   
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Figure 3.10 The effect of rotenone on NADH:ubiquinone oxidoreductase activity. 
 
(A) Baseline activity of NADH:ubiquinone oxidoreductase in isolated mitochondria 
was measured at 340 nm for 1 minute.  The addition of 60 µM ubiquinone led to the 
oxidation of NADH to NAD+.  DMSO (black and red lines) demonstrated little effect on 
this process, while 1 µM of the specific NADH:ubiquinone oxidoreductase inhibitor, 
rotenone (blue and green lines), prevented the oxidation of NADH. (B) A bar chart 
represents the average percentage activity of NADH:ubiquinone oxidoreductase relative 
to the vehicle control, DMSO.  Using the unpaired Student’s t-test GraphPad Prism® 5 
software demonstrates a significant decrease in activity at p < 0.05; *. 
Chapter 3: Elucidating the Mechanism of Action of a Novel Anti-Diabetic Compound  
 110 
 
Figure 3.11 The effect of RTC-1, RTC-15 and metformin on NADH:ubiquinone 
oxidoreductase activity. 
 
Mitochondria isolated from rat liver were incubated with (A) RTC-1, (B) RTC-15 and 
(C) metformin at various concentrations. The effect of the compounds on 
NADH:ubiquinone oxidoreductase was determined by comparing activity before and 
after addition, relative to the vehicle control, DMSO.  Data are presented as mean ± 
SEM of at least three independent experiments.   A nonlinear regression curve of log 
[inhibitor] v response was calculated using GraphPad Prism® 5 software.  This 
estimated an IC50 value at 27 µM for RTC-1 and 104 µM for RTC-15, as indicated by 
the dashed line. 
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In a separate study carried out by Dr. Conor Breen, the effect of RTC-1 on oxygen 
consumption was examined to determine if the action of the compound was limited to 
NADH:ubiquinone oxidoreductase.  Intact rat liver mitochondria were incubated with 
an air-saturated medium (20 mM Tris-HCl, 80 mM KCl, 5 mM MgCl2, 0.5 M KH2PO4, 
pH 7.4) and oxygen consumption was monitored with a Clark electrode (Fig. 3.12).  
The complex I substrate (160 mM glutamate, 40 mM sodium malate) stimulated oxygen 
consumption as electrons from NADH entered the respiratory chain via 
NADH:ubiquinone oxidoreductase.  This increase was augmented with the addition of 
ADP, however 10 µM RTC-1 inhibited the process.  RTC-1 demonstrated no effect on 
complex II of the mitochondrial respiratory chain (succinate:ubiquinone 
oxidoreductase), as oxygen consumption was restored with the addition of 0.5 mM 
sodium succinate which provides electrons for succinate:ubiquinone oxidoreductase, 
bypassing NADH:ubiquinone oxidoreductase. 
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Figure 3.12 The effect of RTC-1 on oxygen consumption in isolated mitochondria.   
 
Isolated rat liver mitochondria were monitored for changes in oxygen consumption 
using a Clark electrode.  Glutamate/malate was used as a substrate to increase NADH 
levels.  The addition of 10 µM RTC-1 resulted in a drop in oxygen consumption, which 
was rescued with the complex II substrate, succinate.  Image kindly provided by Dr. 
Conor Breen. 
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As RTC-1 appeared to target NADH:ubiquinone oxidoreductase alone, the mode of 
action which impacts AMPK is believed to be due to the resultant decrease in ATP 
levels.  Using a luminescent ATP detection kit to look at cellular ATP levels directly, 
there was no apparent effect with C2C12 muscle cells when exposed to rotenone, RTC-
1, RTC-15 or metformin for 30 minutes (Fig. 3.13A).  However after 1 hour, a dramatic 
reduction in cellular ATP was observed with the addition of 25 µM rotenone.  A 
decrease in cellular ATP levels, although not significant, was also seen in cells 
incubated with 10 µM RTC-1 and 10 µM RTC-15, while 500 µM metformin 
demonstrated no effect on ATP levels (Fig. 3.13B).  RTC-1, RTC-15 and metformin all 
provoked a modest decrease in cellular ATP 4 hours post stimulation, again not 
statistically different from basal concentrations (Fig. 3.13C).  
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Figure 3.13 The impact of RTC-1, RTC-15 and metformin on cellular ATP levels. 
 
C2C12 myotubes were stimulated with 10 µM RTC-1, 10 µM RTC-15, 500 µM 
metformin or 25 µM rotenone in complete medium with 0.1 % (v/v) horse serum for 
(A) 30 minutes, (B) 1 hour and (C) 4 hours.  A luminescent ATP detection assay 
(Abcam, ab113849) was used according to the manufacturer’s instructions to monitor 
changes in ATP levels.  Data presented as mean ± SEM are representative of two 
independent experiments each performed in triplicate.  One-way ANOVA with a post-
hoc Dunnett test using GraphPad Prism® 5 software demonstrates significance at p < 
0.05; * and p < 0.001; ***. 
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3.3.5 RTC-1 and RTC-15-Induced Glucose Uptake is Dependent on 
AMPK Activation 
 
To confirm AMPK as the effector protein by which RTC-1 elicited its effects on 
glucose metabolism in vivo, C2C12 myotubes were incubated with the specific AMPK 
inhibitor, Compound C, at 10 µM for 1 hour prior to the addition of 10 µM RTC-1, 10 
µM RTC-15 or 500 µM metformin.  RTC-1, RTC-15 and metformin all significantly 
increased glucose uptake in C2C12 cells, the effect of which was dramatically 
attenuated by Compound C (Fig. 3.14).  Compound C failed to inhibit insulin-induced 
glucose uptake, demonstrating the selectivity of the inhibitor.   
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Figure 3.14 The effect of the AMPK inhibitor, Compound C, on insulin, RTC-1, 
RTC-15 and metformin-induced glucose uptake. 
 
C2C12 myotubes were incubated with 10 µM Compound C or an equal volume of the 
vehicle control, DMSO, in complete medium supplemented with 0.1 % (v/v) horse 
serum for 1 hour.  Cells were then stimulated with 100 nM insulin for 30 minutes or 10 
µM RTC-1, 10 µM RTC-15 and 500 µM metformin for 4 hours.  Glucose uptake was 
measured via scintillation counting of cellular [3H]-2-deoxyglucose.  Data presented as 
mean ± SEM are representative of three independent experiments performed in 
triplicate each time.  One-way ANOVA with a post-hoc Dunnett test using GraphPad 
Prism® 5 software demonstrates significance at p < 0.01; ** and p < 0.001; ***. 
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3.3.6 RTC-1 and RTC-15 Activate the Downstream Effector Proteins 
of AMPK; AS160 and ACC 
 
The activation of AMPK initiates a series of signalling events culminating in the uptake 
and oxidation of substrates important for ATP synthesis such as glucose. AS160 
mediates GLUT4 translocation to facilitate glucose uptake when phosphorylated at a 
number of residues, with Thr642 and Ser588 of particular importance (Sano, 2003, 
Geraghty et al., 2007, Schweitzer et al., 2012). Activated AMPK also leads to a 
decrease in ATP-consuming biosynthetic processes such as lipid synthesis through the 
phosphorylation of ACC at Ser79  (Park et al., 2002). 
Downstream of AMPK activation, RTC-1 was found to influence these main effector 
proteins of cell metabolism.  In a dose response experiment, a 16 hour stimulation of 
C2C12 muscle cells with 10 nM RTC-1 induced the phosphorylation of AMPKα and of 
AS160 at Thr642, which was enhanced with increasing concentrations of the compound.  
Phosphorylation of AS160 at Ser588 was also seen to increase in response to a 10 nM 
stimulation, albeit to a lesser extent.  RTC-1 triggered ACC phosphorylation moderately 
at 10 nM, with a more pronounced effect seen at concentrations of 100 nM and above 
(Fig. 3.15).  In response to metformin, the phosphorylation of AMPKα was augmented 
by a 16 hour, 10 nM stimulation of C2C12 myotubes, with phosphorylation peaking in 
response to 1 mM.  Metformin demonstrated little effect on the phosphorylation of 
AS160 at Thr642, while phosphorylation at Ser588 increased with a 1 mM stimulation.  
An increase in ACC phosphorylation was also observed at concentrations above 10 nM 
metformin (Fig. 3.16).  
Chapter 3: Elucidating the Mechanism of Action of a Novel Anti-Diabetic Compound  
 118 
 
Figure 3.15 Concentration dependent effects of RTC-1 on AMPK signalling. 
 
C2C12 myotubes were stimulated with varying concentrations of RTC-1 (10 nM – 100 
µM) for 16 hours in complete medium containing 0.1 % (v/v) horse serum.  Cells were 
lysed, subjected to SDS-PAGE and immunoblotted with antibodies against phospho-
AMPKα Thr172, phospho-AS160 Thr642 and Ser588, phospho-ACC Ser79, native 
AMPKα, AS160 and ACC.  β-actin was used as a loading control.  Data are 
representative of two independent experiments.   
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Figure 3.16 Concentration dependent effects of metformin on AMPK signalling. 
 
C2C12 myotubes were stimulated with varying concentrations of metformin (10 nM – 
10 mM) for 16 hours in complete medium containing 0.1 % (v/v) horse serum.  Cells 
were lysed, subjected to SDS-PAGE and immunoblotted with antibodies against 
phospho-AMPKα Thr172, phospho-AS160 Thr642 and Ser588, phospho-ACC Ser79, native 
AMPKα, AS160 and ACC.  β-actin was used as a loading control.  Data are 
representative of two independent experiments.   
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In a time course study, 10 µM RTC-1 (Fig. 3.17A), 10 µM RTC-15 (Fig. 3.17B) and 
500 µM metformin (Fig. 3.17C) all led to an increase in ACC phosphorylation 
corresponding to the phosphorylation pattern of AMPKα (Fig. 3.9). 
Time course analysis of AS160 demonstrated a 10 µM exposure to RTC-1 (Fig. 3.18A) 
to increase the phosphorylation status of AS160 at Thr642 within 15 minutes and at 
Ser588 at 45 minutes.  Phosphorylation at both residues diminished to basal levels after 2 
hours and increased again at the 6 hour time point.  A similar, although less intense 
profile of phosphorylation was observed in cells stimulated with 10 µM RTC-15 (Fig. 
3.18B).  Conversely, 500 µM metformin increased the phosphorylation of AS160 at 
both residues maximally within 15 minutes.  The phosphorylation at Thr642 diminished 
to basal levels at 2 hours, with the more pronounced phosphorylation at Ser588 
resembling basal activity at 45 minutes (Fig. 3.18C).  The pattern of AS160 
phosphorylation associated with RTC-1 and RTC-15 did not reflect that of AMPKα at 
the early times points, suggesting that these compounds may influence another regulator 
of AS160, the obvious candidate being Akt.  
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Figure 3.17 Time dependent effects of RTC-1, RTC-15 and metformin on ACC 
phosphorylation. 
 
C2C12 myotubes were stimulated with (A) 10 µM RTC-1, (B) 10 µM RTC-15 or (C) 
500 µM metformin for 15 minutes up to 6 hours in complete medium containing 0.1 % 
(v/v) horse serum.  Cells were lysed, subjected to SDS-PAGE and immunoblotted with 
antibodies against phospho-ACC Ser79 and native ACC.  Data are representative of 
three independent experiments.  
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Figure 3.18 Time dependent effects of RTC-1, RTC-15 and metformin on AS160 
phosphorylation. 
 
C2C12 myotubes were stimulated with (A) 10 µM RTC-1, (B) 10 µM RTC-15 or (C) 
500 µM metformin for 15 minutes up to 6 hours in complete medium containing 0.1 % 
(v/v) horse serum.  Cells were lysed, subjected to SDS-PAGE and immunoblotted with 
antibodies against phospho-AS160 Thr642 and Ser588 and native AS160.  Data are 
representative of three independent experiments. 
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3.3.7 RTC-1 and RTC-15 Activate Akt 	
The addition of 10 µM RTC-1 (Fig. 3.19A) to C2C12 myotubes resulted in a rapid 
increase in Akt phosphorylation within 15 minutes, this lessened after 30 minutes, 
subsiding to basal levels at 45 minutes and decreased further at 4 hours.  Similarly, 10 
µM RTC-15 (Fig. 3.19B) promptly increased Akt phosphorylation at 30 minutes, which 
sustained a high level of activity until the 4 hour time point.  Conversely, 500 µM 
metformin led to a progressive decrease in Akt phosphorylation over time (Fig. 3.19C). 
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Figure 3.19 Time dependent effects of RTC-1, RTC-15 and metformin on Akt 
phosphorylation. 
 
C2C12 myotubes were stimulated with (A) 10 µM RTC-1, (B) 10 µM RTC-15 or (C) 
500 µM metformin for 15 minutes up to 6 hours in complete medium containing 0.1 % 
(v/v) horse serum.  Cells were lysed, subjected to SDS-PAGE and immunoblotted with 
antibodies against phospho-Akt Ser473 and native Akt.  Data are representative of three 
independent experiments.   
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In an extended time course study, stimulation of C2C12 cells with 10 µM RTC-1 (Fig. 
3.20A) and 10 µM RTC-15 (Fig. 3.20B) led to a noticeable increase in Akt 
phosphorylation within 1 minute, which became saturated at 5 minutes and declined 
over the remainder of the time course.  This pattern was also reflected in the 
phosphorylation of AS160 in response to RTC-1 and RTC-15.  Both compounds led to 
an increase in AS160 phosphorylation after 1 minute, yet this effect began to diminish 
at Ser588 after 30 minutes and at Thr642 after 45 minutes in response to RTC-1.  RTC-15-
induced phosphorylation of AS160 subsided at Thr642 and at Ser588 after 45 minutes.   
Phosphorylation of AS160 at Thr642 returned at 6 hours and after 2 hours at Ser588 in 
response to RTC-1.  RTC-15 restored AS160 phosphorylation at Thr642 after 4 hours, 
with phosphorylation of AS160 at Ser588 augmented once more at the 6 hour time point.  
Again 500 µM metformin led to a decrease in Akt phosphorylation over time, appearing 
inhibitory at 2 hours.  Stimulation with metformin led to an increase in AS160 
phosphorylation at Thr642 and at Ser588 to a lesser extent after 1 minute, which 
diminished over time (Fig. 3.20C).   
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Figure 3.20 Time dependent effects of RTC-1, RTC-15 and metformin on Akt 
signalling. 
 
C2C12 myotubes were stimulated with (A) 10 µM RTC-1, (B) 10 µM RTC-15 or (C) 
500 µM metformin for 1 minute up to 16 hours in complete medium containing 0.1 % 
(v/v) horse serum.  Cells were lysed, subjected to SDS-PAGE and immunoblotted with 
antibodies against phospho-Akt Ser473, phospho-AS160 Thr642 and Ser588, native Akt 
and AS160.  β-actin was used as a loading control.  Data are representative of two 
independent experiments.   
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In an attempt to understand the role of this early phosphorylation of Akt in RTC-1-
stimulated glucose uptake, differentiated C2C12 cells were incubated with an inhibitor 
of Akt activity, wortmannin, for 1 hour prior to the addition of 10 µM RTC-1.  As a 
control, the effect on insulin-induced glucose uptake was also evaluated.  Pre-treatment 
with 1 µM wortmannin reduced basal glucose uptake and prevented insulin-stimulated 
glucose transport in C2C12 myotubes.  Wortmannin appeared to attenuate RTC-1-
induced glucose uptake at the early time point of 15 minutes, which corresponded to the 
activation of Akt.  At 1 hour, RTC-1 overcame the effects of wortmannin, returning 
glucose uptake to basal levels.  Glucose uptake increased again at 4 hours post RTC-1 
stimulation in the presence of wortmannin, and significantly so at 16 hours (Fig. 3.21). 
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Figure 3.21 The effect of wortmannin on insulin- and RTC-1-induced glucose 
uptake. 
 
C2C12 myotubes were treated with 1 µM wortmannin or an equal volume of the vehicle 
control, DMSO, in complete medium containing 0.1 % (v/v) horse serum for 1 hour.  
Control cells were incubated with 1 µM wortmannin for 17 hours to represent the 
effects of long-term exposure.  Cells were then stimulated with 100 nM insulin for 30 
minutes or 10 µM RTC-1 for 15 minutes up to 16 hours.  Glucose uptake was measured 
via scintillation counting of cellular [3H]-2-deoxyglucose. Data presented as mean ± 
SEM are representative of at least three experiments performed in triplicate each time.  
One-way ANOVA with a post-hoc Dunnett test using GraphPad Prism® 5 software 
demonstrates a significant increase in glucose uptake at p < 0.05; * p < 0.01; ** and p < 
0.001; ***.  A significant decrease in glucose uptake at p < 0.05 is indicated by #. 
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3.3.8 RTC-1 Does Not Directly Influence PI3K, the Major Regulator 
of Akt Activity 
 
As PI3K lies directly upstream of Akt, the effect of the compounds on this regulator of 
Akt activation was evaluated.  Using a PI3K ELISA, in which the capture protein, GRP-
1, binds PIP3 generated as part of the kinase reaction or the biotinylated-PIP3 tracer, 
wherein a lower signal was indicative of increased PI3K activity.  Wortmannin (1 µM), 
used as a control, diminished PI3K activity with p110α, p110δ and p120γ.  However, 
RTC-1 (10 µM), RTC-15 (10 µM) and metformin (500 µM) did not alter PI3K activity 
with the four class I PI3Ks, p110α, p110β, p110δ and p120γ (Fig. 3.22). 
As basal kinase activity appeared low in this assay, the direct effect of the compounds 
on PIP3 production was next examined.  Lipids were extracted from C2C12 myotubes 
stimulated with 1 µM wortmannin, 100 nM insulin, 10 µM RTC-1, 10 µM RTC-15 or 
500 µM metformin and cellular PIP3 abundance was determined using a HTRF PIP3 
assay.  No change was detected upon exposure to RTC-1, RTC-15 or metformin.  
Insulin provoked an increase in PIP3, while wortmannin significantly reduced cellular 
PIP3 concentration (Fig. 3.23).   
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Figure 3.22 The effect of RTC-1, RTC-15 and metformin on PI3K activity.  
 
Each kinase isoform (A) p110α, (B) p110β, (C) p110δ and (D) p120γ was incubated 
with each compound (1 µM wortmannin, 10 µM RTC-1, 10 µM RTC-15, 500 µM 
metformin) for 10 minutes at room temperature then processed according to PI3K 
ELISA (Merck Millipore, 17-493).  Data are presented as mean ± SEM, n=4.  One-way 
ANOVA with a post-hoc Dunnett test using GraphPad Prism® 5 software denotes 
significance at p < 0.05; *, with an increase in relative percentage to biotinylated-PIP3 
(B-PIP3) characteristic of reduced kinase activity. 
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Figure 3.23 The effect of RTC-1, RTC-15 and metformin on PIP3 production. 
 
C2C12 myotubes were incubated with 1 µM wortmannin, 100 nM insulin, 10 µM RTC-
1, 10 µM RTC-15 or 500 µM metformin for 1 hour.  Lipids were extracted and cellular 
PIP3 abundance was determined using a HTRF PIP3 assay (Merck Millipore, 17-495).  
Data are presented as mean ± SEM, n=4.  One-way ANOVA with a post-hoc Dunnett 
test using GraphPad Prism® 5 software denotes significance at p < 0.05; *. 
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3.3.9 RTC-1 Prevents TNF-α-Induced Insulin Resistance in C2C12 
Muscle Cells 
 
The powerful anti-diabetic effects of RTC-1 in vivo prompted exploration into the 
bearing this compound may have on an in vitro model of insulin resistance.  Treatment 
of C2C12 myotubes with 40 ng/ml TNF-α prevented insulin-induced glucose uptake, a 
response that could be attenuated with the addition of 10 µM RTC-1 (Fig. 3.24A).  500 
µM metformin improved glucose uptake following a 2 hour exposure to TNF-α, 
although not to the same extent as RTC-1 (Fig. 3.24B).   
 
In parallel with this, TNF-α prevented insulin-induced phosphorylation of IRS1, Akt 
and AS160 at Thr642 and Ser588, all of which were counteracted by the addition of 10 
µM RTC-1 (Fig. 3.25A).  Although the response of the insulin signalling pathway to 
TNF-α was modest, the effect of metformin on this system appeared weak, echoing the 
outcome of the glucose uptake assay (Fig. 3.25B).   
 
As TNF-α is known to provoke the inhibition of insulin signalling through the action of 
JNK, the influence of the compounds on the phosphorylation of JNK and the other 
MAPKs was assessed.  RTC-1 did not impede TNF-α-induced phosphorylation of JNK, 
Erk or p38 (Fig. 3.26A).  In contrast, metformin counteracted the influence of TNF-α on 
the three MAPKs investigated (Fig. 3.26B).  
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Figure 3.24 Glucose uptake analysis of the effect of RTC-1 and metformin on TNF-
α-induced insulin resistance. 
 
C2C12 myotubes were incubated with 40 ng/ml TNF-α for 2 hours in complete medium 
supplemented with 0.1 % (v/v) horse serum ± (A) 10 µM RTC-1 or (B) 500 µM 
metformin for a further 4 hours.  Cells were then stimulated with 100 nM insulin for a 
final 30 minutes.  Changes to glucose uptake were evaluated by measuring cellular 
[3H]-2-deoxyglucose content.  Data presented as mean ± SEM are representative of at 
least three experiments performed in triplicate.  Using the unpaired Student’s t-test 
GraphPad Prism® 5 software demonstrates a significant increase in glucose uptake at p 
< 0.01; ** and p < 0.001; ***.   
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Figure 3.25 Western blot analysis of the effect of RTC-1 and metformin on TNF-α-
induced insulin resistance. 
 
C2C12 myotubes were incubated with 40 ng/ml TNF-α for 2 hours in complete medium 
supplemented with 0.1 % (v/v) horse serum ± (A) 10 µM RTC-1 or (B) 500 µM 
metformin for a further 4 hours.  Cells were then stimulated with 100 nM insulin for a 
final 30 minutes.  Cells were lysed, subjected to SDS-PAGE and immunoblotted with 
antibodies against phospho-insulin receptor β Tyr1150/1151, phospho-IRS1 Tyr612, 
phospho-Akt Ser473, phospho-AS160 Thr642 and Ser588, native insulin receptor β, IRS1, 
Akt and AS160.  β-actin was used as a loading control.  Data are representative of two 
independent experiments.   
 
 
Chapter 3: Elucidating the Mechanism of Action of a Novel Anti-Diabetic Compound  
 135 
 
Figure 3.26 The effect of RTC-1, metformin and TNF-α on the phosphorylation of 
the MAPKs. 
 
C2C12 myotubes were incubated with 40 ng/ml TNF-α for 2 hours in complete medium 
supplemented with 0.1 % (v/v) horse serum ± (A) 10 µM RTC-1 or (B) 500 µM 
metformin for a further 4 hours.  Cells were then stimulated with 100 nM insulin for a 
final 30 minutes.  Cells were lysed, subjected to SDS-PAGE and immunoblotted with 
antibodies against phospho-JNK Thr183/Tyr185, phospho-Erk Thr202/Tyr204, phospho-p38 
Thr180/Tyr182, native JNK, Erk and p38.  β-actin was used as a loading control.  Data are 
representative of two independent experiments. 
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3.3.10 RTC-1 Compliments the Action of Insulin 	
In an effort to elucidate the mechanism by which RTC-1 ameliorated insulin-induced 
glucose transport in the presence of TNF-α, the effect of the compound on insulin-
stimulated glucose uptake alone was evaluated.  Both insulin and RTC-1 produced a 
marked increase in glucose uptake in C2C12 muscle cells.  The combination of RTC-1 
and insulin surpassed the response to these molecules alone (Fig. 3.27).   
 
To determine if RTC-1 was demonstrating insulin sensitising properties, the impact of 
the compound on insulin-induced phosphorylation of the insulin signalling pathway was 
examined.  As expected, insulin stimulation alone amplified the phosphorylation of the 
insulin receptor, IRS1, Akt and AS160 in C2C12 myotubes.  There was no indication of 
RTC-1 altering the phosphorylation status of the insulin receptor, IRS1 or Akt in cells 
incubated with the compound alone. However, RTC-1 augmented AS160 
phosphorylation at Thr642 and at Ser588, presumably via AMPK activation at this later 
time point.  In cells stimulated with RTC-1 followed by insulin, no significant change 
was seen in the phosphorylation of the insulin receptor or IRS1 when compared to the 
action of insulin.  However, an increase in the phosphorylation of Akt and of AS160 at 
Thr642 and at Ser588, beyond that of insulin stimulation alone, was seen following 
treatment with RTC-1 and insulin (Fig. 3.28). 
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Figure 3.27 The effect of RTC-1 on insulin-induced glucose uptake. 
 
C2C12 myotubes were stimulated with 10 µM RTC-1 for 4 hours in complete medium 
containing 0.1 % (v/v) horse serum, cells were then incubated with KRBG ± 100 nM 
insulin for 30 minutes.  Changes to glucose uptake were established by measuring the 
cellular levels of [3H]-2-deoxyglucose.  Data are representative of two independent 
experiments presented as mean ± SEM.  One-way ANOVA with a post-hoc Tukey test 
using GraphPad Prism® 5 software indicates a significant increase in glucose uptake at 
p < 0.05; * and p < 0.001; ***.   
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Figure 3.28 The effect of RTC-1 on insulin-induced phosphorylation of the insulin 
signalling pathway. 
 
C2C12 myotubes were stimulated with 10 µM RTC-1 for 4 hours in complete medium 
containing 0.1 % (v/v) horse serum, cells were then incubated with KRBG ± 100 nM 
insulin for 30 minutes.  Following this, cells were lysed, proteins separated by SDS-
PAGE and immunoblotted with antibodies against phospho-insulin receptor β 
Tyr1150/1151, phospho-IRS1 Tyr612, phospho-Akt Ser473, phospho-AS160 Thr642 and 
Ser588, native insulin receptor β, IRS1, Akt and AS160.  β-actin was used as a loading 
control.  Data are representative of two independent experiments.   
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3.3.11 RTC-1 Prevents Adipogenesis 	
As RTC-1-treated mice exhibited a reduction in weight gain, the influence of the 
compound on the process of adipogenesis was examined in vitro to further explore this 
effect.  In the 3T3L-1 preadipocyte cell line induction medium caused extensive 
morphological changes resulting in the accumulation of intracellular lipid droplets.  
Using Oil Red O as an aid to visualisation, RTC-1 was seen to potently inhibit the 
process of adipogenesis when added at the time of induction (Fig. 3.29A).  Conversely, 
metformin demonstrated little effect on adipogenesis, which the quantification of the 
Oil Red O stain revealed to be insignificant (Fig. 3.29B).  Western blot analysis was 
then employed to determine if AMPK played an influential role in this observation 
through the action of ACC, as inhibition of this regulator of fatty acid synthesis, which 
can be achieved through AMPK-induced phosphorylation, has been found to inhibit 
adipogenesis (Cordonier et al., 2015).  Incubation of 3T3-L1 cells with RTC-1 for the 
duration of the differentiation process augmented AMPKα and ACC phosphorylation.  
A moderate increase in the phosphorylation of AMPKα and a considerable increase in 
ACC phosphorylation was observed in cells stimulated with metformin (Fig. 3.30).   
 
The influence of the compounds on fully differentiated 3T3-L1 adipocytes was then 
investigated.  Both RTC-1 and metformin instigated a slight decrease in lipid 
accumulation as visualised by Oil Red O staining (Fig. 3.31A).  However, 
quantification of the stain revealed no significant change in lipid content in response to 
the compounds when compared to the vehicle control, DMSO (Fig. 3.32B).  At the 
protein level, the phosphorylation status of AMPKα and ACC, were marginally 
increased in response to RTC-1 and metformin when compared to differentiated 3T3-L1 
adipocytes incubated with DMSO (Fig. 3.33).   
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Figure 3.29 Visual analysis of the effect of RTC-1 and metformin on 3T3-L1 
adipocyte differentiation. 
 
3T3-L1 preadipocytes were cultured in control medium or adipogenic medium in the 
presence or absence of 10 µM RTC-1 or 500 µM metformin.  Medium was changed 
every 48 hours.  (A) Lipid accumulation was visualised after day 8 of differentiation by 
Oil Red O staining.  Images are representative of two independent experiments.  Cells 
were visualised with a x100 magnification.  (B) Total lipid content was quantified by 
eluting the Oil Red O stain with isopropanol and measuring absorbance at 520 nm.  
One-way ANOVA with a post-hoc Tukey test using GraphPad Prism® 5 software 
denotes significance at p < 0.001; ***. 
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Figure 3.30 The effect of RTC-1 and metformin on AMPKα and ACC 
phosphorylation in 3T3-L1 adipocytes. 
 
3T3-L1 preadipocytes were cultured in control medium or adipogenic medium in the 
presence or absence of 10 µM RTC-1 or 500 µM metformin.  Medium was changed 
every 48 hours.  On day 8, cells were lysed, subjected to SDS-PAGE and 
immunoblotted with antibodies against phospho-AMPKα Thr172, phospho-ACC Ser79 
and native AMPKα and ACC.  β-actin was used as a loading control.  Data are 
representative of two independent experiments. 
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Figure 3.31 Visual analysis of the effect of RTC-1 and metformin on fully 
differentiated 3T3-L1 adipocytes. 
 
Fully differentiated adipocytes were stimulated with 10 µM RTC-1 or 500 µM 
metformin.  Medium was changed every 48 hours.  (A) Lipid accumulation was 
visualised microscopically with a x100 magnification using an Oil Red O stain.  Images 
are representative of two independent experiments.  (B) Total lipid content was 
quantified by eluting the Oil Red O stain with isopropanol and measuring absorbance at 
520 nm.  One-way ANOVA with a post-hoc Tukey test using GraphPad Prism® 5 
software denotes significance at p < 0.001; ***. 
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Figure 3.32 The effect of RTC-1 and metformin on AMPKα and ACC 
phosphorylation in fully differentiated 3T3-L1 adipocytes. 
 
3T3-L1 preadipocytes were cultured in control medium or adipogenic medium.  Fully 
differentiated adipocytes were stimulated with 10 µM RTC-1 or 500 µM metformin, 
with fresh medium added every 48 hours.  On day 8, cells were lysed, subjected to 
SDS-PAGE and immunoblotted with antibodies against phospho-AMPKα Thr172, 
phospho-ACC Ser79 and native AMPKα and ACC.  β-actin was used as a loading 
control.  Data are representative of two independent experiments. 
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To determine if this response translated into other cell types, murine MSC, which 
readily differentiate into fat cells given the appropriate conditions, were incubated with 
RTC-1 or metformin throughout the differentiation process.  MSC incubated with 
adipogenic medium containing DMSO underwent morphogenesis with the formation of 
large intracellular lipid droplets.  RTC-1 reduced the capacity of MSC to differentiate 
into adipocytes, while cells incubated with metformin exhibited intracellular lipid 
droplets similar to the control (Fig. 3.33A).  Quantification of the stain demonstrated the 
significant influence of the adipogenic medium on MSC differentiation, an effect that 
RTC-1 markedly reduced, metformin however, demonstrated less force (Fig. 3.33B).  
Analysis of the AMPK pathway revealed that 10 µM RTC-1 impacted on the 
phosphorylation of both AMPKα and ACC substantially, while 500 µM metformin 
exhibited little effect (Fig. 3.34). 
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Figure 3.33 Visual analysis of the effect of RTC-1 and metformin on murine MSC 
adipogenesis. 
 
MSC isolated from the femur and tibia of 6 – 8 week old female BALB/c mice were 
cultured in control medium or adipogenic medium in the presence or absence or 10 µM 
RTC-1 or 500 µM metformin for 21 days.  (A) Lipid accumulation was visualised 
microscopically with a x100 magnification using an Oil Red O stain.  Images are 
representative of three independent experiments.  (B) Total lipid content was quantified 
as described in Section 2.2.1.2.  One-way ANOVA with a post-hoc Tukey test using 
GraphPad Prism® 5 software denotes significance at p < 0.05; *. 
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Figure 3.34 The effect of RTC-1 and metformin on AMPKα and ACC 
phosphorylation in murine MSC during adipogenesis. 
Murine MSC were cultured in control medium or adipogenic medium in the presence or 
absence or 10 µM RTC-1 or 500 µM metformin for 21 days.  Cells were lysed, 
subjected to SDS-PAGE and immunoblotted with antibodies against phospho-AMPKα 
Thr172, phospho-ACC Ser79 and native AMPKα and ACC.  β-actin was used as a 
loading control.  Data are representative of two independent experiments. 
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3.3.12 RTC-1 Augments MSC Osteogenesis 	
To ensure RTC-1 did not negatively alter other lineages of cellular differentiation the 
effect of the compound on MSC bone differentiation was also examined.  Visualisation 
of Alizarin Red S demonstrated the modest response of MSC to the process of 
osteoblast differentiation when compared to undifferentiated cells (Fig. 3.35A). 
However, quantification of the stain revealed a significant increase in mineralisation in 
cells incubated with the osteogenic medium (Fig. 3.35B).  While metformin appeared to 
marginally increase the process of differentiation, cells incubated with RTC-1 assumed 
the osteogenic morphology more readily, which quantification of the stain revealed to 
be significant.  As the activation of AMPK is known to positively regulate osteoblast 
mineralisation (Kanazawa et al., 2009), the role of RTC-1 and metformin in augmenting 
the phosphorylation of this effector protein was investigated.  Differentiated control 
cells displayed increased phosphorylation of AMPKα when compared to 
undifferentiated cells, while cells stimulated with metformin marginally improved the 
level of activity, RTC-1 was found to augment this response considerably (Fig. 3.36). 
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Figure 3.35 Visual analysis of the effect of RTC-1 and metformin on murine MSC 
osteogenesis. 
 
Murine MSC were cultured in control medium or osteogenic medium in the presence or 
absence or 10 µM RTC-1 or 500 µM metformin for 21 days.  (A) Calcium deposition 
stained with Alizarin Red S was visualised microscopically with a x100 magnification.  
(B) Total mineral deposition was quantified as described in Section 2.2.1.3.  One-way 
ANOVA with a post-hoc Tukey test using GraphPad Prism® 5 software denotes 
significance at p < 0.001; ***, n=3. 
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Figure 3.36 The effect of RTC-1 and metformin on AMPKα phosphorylation in 
murine MSC during osteogenesis. 
 
Murine MSC were cultured in control medium or osteogenic medium in the presence or 
absence or 10 µM RTC-1 or 500 µM metformin for 21 days.  Cells were lysed, 
subjected to SDS-PAGE and immunoblotted with antibodies against phospho-AMPKα 
Thr172 and native AMPKα.  β-actin was used as a loading control.  Data are 
representative of three independent experiments.   
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3.4  Discussion 	
This study has delved into the underlying mechanism by which RTC-1 restored normal 
glucose disposal, augmented insulin sensitivity and prevented weight gain in a murine 
diet-induced model of type 2 diabetes.  The structure of this novel compound has been 
demonstrated to be central to its activity as a derivative of RTC-1, RTC-15, produced 
similar results to the parent compound in vitro.  Comparing the action of this novel 
compound to that of metformin, RTC-1 demonstrated very superior effects in amending 
some of the many in vitro representations of the pathophysiology of type 2 diabetes. 
3.4.1 Consequences of RTC-1-Induced Inhibition of NADH: 
ubiquinone oxidoreductase Activity 	
Both RTC-1 and RTC-15 have been found to inhibit NADH:ubiquinone oxidoreductase 
activity with respective IC50 values of 27 µM and 104 µM.  Although metformin is 
believed to directly stimulate glucose uptake through AMPK, activated by the inhibition 
of NADH:ubiquinone oxidoreductase (Owen et al., 2000), it failed to significantly alter 
NADH:ubiquinone oxidoreductase activity at the concentrations assayed.  Studies 
carried out by Jenkins and colleagues (2013), found metformin to be a weak inhibitor of 
NADH:ubiquinone oxidoreductase, with an IC50 of 27 mM.   In line with this finding, 
Bridges and colleagues (2014), observed metformin to be the weakest of the five 
pharmacologically relevant biguanides in attenuating complex I catalysis, demonstrating 
an IC50 of 19.4 ± 1.4 mM in bovine heart mitochondria, 22.6 ± 4.3 mM in Pichia 
pastoris mitochondria and 60.7 ± 8.5 mM in the mitochondria of E. coli.  As these 
predicted IC50 values exceed the maximal soluble concentration possible in the assay 
employed in this study, it is unsurprising that metformin did not appear to perturb 
NADH:ubiquinone oxidoreductase activity.    
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The action of RTC-1 appears to be restricted to NADH:ubiquinone oxidoreductase as 
oxidative phosphorylation could be restored with the addition of succinate, the complex 
II substrate.  This has also been observed to be true of metformin (Hinke et al., 2007, 
Wheaton et al., 2014).  These compounds, incapable of uncoupling the energy 
harnessing process of mitochondria outright, appear to cause little detrimental damage 
to the cell.  Nonetheless, any potential resultant transient decrease in cellular ATP and 
rise in cellular ADP and AMP could provoke the activation of AMPK.  
RTC-1 and RTC-15 stimulate the phosphorylation of AMPKα, and its downstream 
effector proteins, AS160 and ACC in a more pronounced manner to metformin despite 
the 50-fold higher dose of the common anti-diabetic therapy, echoing the previous 
finding in terms of drug potency.  The enhanced influence of RTC-1 and RTC-15 
resonates through to their impact on glucose transport, with RTC-1 demonstrating signs 
of longevity as glucose uptake is elevated for some time after cells have been washed 
free of the compound.  This may be due in part to the lipophilic properties of RTC-1, 
which also reflects its ability to provoke these effects at relatively low concentrations.   
As patients often demonstrate poor adherence to the multitude of daily doses required of 
metformin to effectively regulate glycaemic control (Donnan et al., 2002, García-Pérez 
et al., 2013), the enhanced potency of RTC-1 should promote its use as a more 
manageable therapeutic regime, particularly when its low toxicity profile is also 
considered. 
3.4.2 RTC-1-Induced Activation of Akt 	
Along with being almost 1,000-fold more efficacious than metformin in the inhibition 
of NADH:ubiquinone oxidoreductase, the enhanced effects of RTC-1 on a direct 
modulator of glucose uptake, AS160, may also lie with its influence on the activity of 
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Akt.  RTC-1 was found to stimulate the phosphorylation of Akt and of AS160 in a 
superior manner to metformin, predominantly at Thr642, a critical consensus site in 
facilitating GLUT4 translocation.  As insulin-stimulated phosphorylation of AS160 at 
Thr642 is impaired in patients with type 2 diabetes (Middelbeek et al., 2013), the 
multifaceted action of RTC-1 through Akt strengthens its potential as a promising anti-
diabetic therapy.  However, the direct role RTC-1 plays in the augmenting the 
phosphorylation of Akt remains obscure as this novel compound and its derivative 
demonstrated no impact on the major upstream regulator of Akt, PI3K.  It is therefore 
likely the RTC compounds influence another aspect of Akt activation.    
Although most modulators of Akt activity rely on PI3K dependent relocalisation of Akt 
to the plasma membrane via the PH domain (Toker and Marmiroli, 2014), 
diphosphoinositol pentakisphosphate (IP7), synthesised by a family of three inositol 
hexaphosphate kinases (IP6Ks) (Stephens et al., 1993), has recently emerged as an Akt 
regulator competing with this mechanism (Chakraborty et al., 2010).  In Dictyostelium 
discoideum, IP7 has been shown to compete with PIP3 at PH domains, preventing PIP3 
signalling (Luo et al., 2003).  Prasad and colleagues (2011), specifically demonstrated 
the ability of IP7 to compete with PIP3 at the PH domain of Akt, negatively regulating 
PIP3-mediated cellular functions in neutrophils.  Furthermore, IP6K1 knockout mice 
which have depleted IP7 levels, demonstrate a lean phenotype and have elevated Akt 
activity in response to insulin stimulation (Chakraborty et al., 2010).   
 
IP6K’s have a Km for ATP between 1 and 1.4 mM, making IP7 synthesis very sensitive 
to fluctuations in ATP levels (Wunderberg and Mayr, 2012). The effect of the RTC 
compounds on NADH:ubiquinione oxidoreductase activity and subsequently 
intracellular ATP levels, may therefore, inhibit the function of IP6K to promote Akt 
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activation.  Although further experimentation would be required to confirm this, it is 
instructive that the IP6K inhibitor TNP, which decreases IP7 production to activate Akt, 
demonstrates similar effects to RTC-1 in that it also increases the phosphorylation of 
AMPKα and ACC (Sun et al., 2015).  While the activation of Akt appears promising to 
attenuate the symptoms of type 2 diabetes, stimulation of Akt as a therapeutic target 
must be tightly regulated as hyperactivation of this protein is thought to be involved in 
the development of many human cancers (Kumar et al., 2013).  The role of the RTC 
compounds is encouraging in this regard as RTC-induced activation of Akt and 
consequentially AS160, is very short lived and is rapidly replaced by AMPK-dependent 
activation of AS160 to further promote glucose uptake.   
3.4.3 Akt and AMPK-Mediated Signalling  	
The action of the RTC compounds in stimulating glucose transport appears to be 
stringently regulated.  The initial surge of RTC-1-induced glucose uptake is thought to 
be dependent on Akt activation, as wortmannin was seen to effectively inhibit glucose 
uptake after a 15 minute exposure of C2C12 myotubes to RTC-1, while this impact 
lessened at the later time points.  This initial effect on Akt, whether through the 
inhibition of IP6K or by other means, is quickly attenuated, followed by the activation 
of AMPK, indicative of a feedback relationship between the two proteins.  A reduction 
in ATP levels, such as that triggered by the inhibition of NADH:ubiquinone 
oxidoreductase is known to destabilise the phosphorylation state of Akt by exposing 
phosphorylated sites to phosphatases (Chan et al., 2011, Lin et al., 2012).  Furthermore, 
Akt has been shown to phosphorylate rat AMPK at Ser485, which renders the kinase 
inactive (Horman et al., 2006).  The intricate relationship between Akt and AMPK may 
be fundamental to the power of the RTC compounds in stimulating glucose uptake.  As 
the initial activity of Akt subsides, so too does that of AS160, only to return under the 
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influence of AMPK.  The latter surge in glucose uptake appears to be dependent on the 
action of AMPK as it was effectively attenuated with the addition of Compound C.   
A proteomics study conducted by Dr. Pamela Young (Young et al., 2016), reinforces 
the potent downstream effects of the RTC compounds in targeting metabolomic 
proteins to restore cellular energy balance.  Notably, RTC-15 was found to increase the 
expression of triose phosphate isomerase, a protein that contributes to the process of 
glycolysis, of Annexin A2, a calcium binding protein involved in the fusion of plasma 
secretory vesicles, such as those of GLUT4, with the plasma membrane and of ECH1, 
an auxiliary enzyme of β-oxidation involved in preparing unsaturated fatty acids for 
fatty acid oxidation. 
3.4.4 RTC-1-Induced Effects on Insulin Signalling 	
To better understand the anti-diabetic properties of RTC-1, the pro-inflammatory 
cytokine TNF-α was used to mimic an insulin resistant state in vitro.  TNF-α prevented 
insulin-induced glucose uptake by increasing the phosphorylation of the MAPKs thus 
leading to the inhibition of key components of the insulin signalling pathway.  Both 
RTC-1 and metformin overcame the influence of TNF-α, improving glucose uptake; 
RTC-1 elicited a more efficacious response at a much lower concentration.  At the 
protein level, metformin did not noticeably attenuate the impact of TNF-α on the insulin 
signalling pathway.  However, metformin markedly reduced the phosphorylation of 
JNK, Erk and p38.  The modest impact of metformin on this system may lie with its 
ability to constrain the phosphorylation of the MAPKs, as small molecule inhibitors of 
JNK have been found to restore insulin sensitivity in a mouse model of type 2 diabetes 
(Stebbins et al., 2008).  Additionally, metformin has been reported to inhibit the action 
of the MAPKs (Isoda et al., 2006, Simon-Szabó et al., 2014).  However, controversy 
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remains in this area as Kumar and Dey (2002), found that metformin increased p38 
phosphorylation, having no effect on Erk or JNK.  Furthermore, Lee and colleagues 
(2012) observed that metformin positively impacted on the phosphorylation of JNK.  As 
metformin demonstrated little effect in restoring the signalling capabilities of insulin, 
the influence of metformin on AMPK alone may have led to the moderate increase in 
glucose uptake in the presence of TNF-α.  Given the fact that metformin demonstrates 
no effect on the insulin signalling pathway in diabetic patients (Kim et al., 2002, 
Karlsson et al., 2005), nor does it act as an insulin sensitizer in mouse skeletal muscle 
(Turban et al., 2012), it seems likely that the modest influence of metformin bypasses 
the insulin signalling pathway.  
 
RTC-1 on the other hand, demonstrated no effect on the MAPKs yet restored insulin-
induced glucose uptake in a much more successful and significant manner to metformin. 
As RTC-1 was found to augment the signalling capabilities of insulin in cells stimulated 
with TNF-α, the enhanced effect of this compound was postulated to lie in its ability to 
also act as an insulin sensitizer.  Although RTC-1 demonstrated no direct effect on the 
insulin signalling pathway, in the presence of this compound the action of insulin 
significantly improved downstream of Akt.  However, the longer-lasting potent effects 
of RTC-1 on AMPK may have given rise to the increase in AS160 phosphorylation 
which enhanced glucose uptake.  Nonetheless, as RTC-1 was observed to restore 
insulin-induced phosphorylation of IRS1 in the presence of TNF-α, a protein it probably 
does not directly interact with, an unresolved element of the influence of RTC-1 
remains.  Analysis of other downstream targets of TNF-α that negatively impact on 
insulin signalling such as IKKβ and SOCS3, may give further insight into the regulatory 
effect of RTC-1 on TNF-α-induced insulin resistance.  Given that the inhibition of 
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IP6K1 either through knockout studies or by pharmacological intervention has been 
suggested to increase insulin sensitivity (Mackenzie and Elliott, 2014), the proposed 
impact of RTC-1 on this system to regulate Akt activity may explain the apparent 
insulin sensitising effects of the compound. 
3.4.5 The Anti-Adipogenic Effects of RTC-1 	
As obesity is a major contributor to the genesis of type 2 diabetes, the reduction in 
weight gain observed in RTC-1 HFD-fed mice warranted further exploration.  RTC-1 
was found to potently block adipogenesis in 3T3-L1 preadipocytes and murine MSC 
with a concurrent rise in AMPKα and ACC phosphorylation.  Direct pharmacological 
attenuation of ACC (Levert et al., 2002) or transient inhibition through the 
phosphorylation of Ser79 via AMPK (Ejaz et al., 2009) has been found to attenuate the 
lipogenic activity of ACC and effectively inhibit adipogenesis.  Although a significant 
decrease in adipogenesis was not observed with the addition of metformin, despite the 
increase in ACC phosphorylation, several studies have demonstrated the anti-
adipogenic abilities of metformin and other AMPK activating molecules (Giri et al., 
2006, Ahn et al., 2008, Zhou et al., 2009, Molinuevo et al., 2010, Vingtdeux et al., 
2011).  RTC-1 and metformin were found to moderately reduce lipid accumulation in 
fully differentiated 3T3-L1 adipocytes with a modest increase in AMPKα and ACC 
phosphorylation.  This finding correlates with the effects of RTC-1 in vivo as the 
compound prevented HFD-fed mice from gaining weight, yet it did not appear to reduce 
pre-established adipose tissue.  
3.4.6 The Impact of RTC-1 on Osteogenesis 	
RTC-1-induced phosphorylation of AMPKα positively altered the osteogenic 
differentiation process of murine MSC.  As patients with diabetes often present with 
Chapter 3: Elucidating the Mechanism of Action of a Novel Anti-Diabetic Compound  
 157 
osteoporosis (Krakauer et al., 1995), this result proves particularly meaningful given the 
fact that administration of the anti-diabetic, roziglitizone, results in significant bone loss 
(Rzonca et al., 2004).  In line with studies of osteoblastic differentiation in MC3T3-E1 
cells (Kanazawa et al., 2008) and rat bone marrow progenitor cells (Molinuevo et al., 
2010), quantification of Alizarin Red S also demonstrated a modest increase in 
osteogenesis associated with metformin-induced AMPK activation.  Consistent with 
this, a role for AMPK signalling in skeletal physiology has been demonstrated by Shah 
and colleagues (2010).  Primary rat calvaria osteoblasts cultured in the presence of 
AMPK activators, AICAR and metformin exhibit a dose-dependent increase in 
trabecular bone nodule formation, while AMPKα knockout mice demonstrate smaller 
cortical and trabecular bone compartments when compared to wild type mice.  AMPK 
is believed to influence this process of differentiation by increasing the expression of 
eNOS and bone morphogenetic protein 2 (Kanazawa et al., 2009), both of which are 
critical in the regulation of bone mass and bone turnover by modulating osteoblast 
function (Yamaguchii et al., 2000, Armour et al., 2001).  
3.4.7 Summary 	
This study has established the basis for the anti-diabetic and anti-obesity effects a novel 
compound exhibited in a dietary-induced murine model of type 2 diabetes (Fig. 3.37). 
RTC-1-induced inhibition of NADH:ubiquinone oxidoreductase leads to a transient 
decrease in cellular ATP levels which may reduce IP6K-induced IP7 production to 
promote Akt activation and sensitise the cell to the action of insulin.  This transient 
alteration to cellular energy also facilitates the activation of AMPK with a successive 
decrease in Akt activity and increase in the phosphorylation of AS160 and ACC.  The 
superior impact of RTC-1 on glucose transport, insulin resistance, adipogenesis and 
osteogenesis when compared to metformin, advocates this novel molecule as a powerful 
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therapy capable of regulating many facets of the pathophysiology of type 2 diabetes. 
 
Figure 3.37 Proposed mechanism of action of RTC-1. 
RTC-1 inhibits NADH:ubiquinone oxidoreductase activity, transiently decreasing 
cellular ATP levels.  This may prevent IP6K-induced IP7 synthesis, sensitising the cell 
to the action of insulin-stimulated PIP3 production, which can promote glucose transport 
through Akt.  The likely build up of ADP may then be sensed by adenylate kinase, 
which converts two molecules of ADP into one ATP and one AMP molecule.  The rise 
cellular ADP and AMP promotes AMPK phosphorylation and leads to a decrease in 
Akt activity.  Activated AMPK restores cellular energy balance by stimulating glucose 
transport through the action of AS160 and by reducing fatty acid synthesis as it inhibits 
ACC, thus preventing the conversion of acetyl-CoA to malonyl-CoA. 
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4.1 Introduction 	
Type 2 diabetes is primarily caused by a systemic insulin resistant state to which 
obesity is a major contributing factor.  Increasing visceral adipose tissue provokes a 
chronic, low-grade, inflammatory response that negatively impacts on the insulin 
signalling pathway (Weyer et al., 2001, Kahn et al., 2006, Qatanani and Lazar, 2007, 
Emanuela et al., 2012, Osborn and Olefsky, 2012).  The rapidly rising incidence of 
type 2 diabetes, along with variable subject responses and the increasing limitations 
of current therapies, urge the need for innovative, effective strategies to prevent the 
development and progression of this condition (Rochester and Akiyode, 2014).  
GPCRs represent a rich source of drug targets for many disease states.  These seven 
transmembrane receptors, the largest family of proteins in the genome, convey major 
external signals to the internal environment of the cell, with approximately 30 – 40 
% of all marketed drugs targeting these versatile proteins (Ma and Zemmel, 2002, 
Lappano and Maggiolini, 2011, Tautermann, 2014).   
 
GPR21, an orphan GPCR, has recently emerged as a potential novel target for the 
treatment of type 2 diabetes (Gardner et al., 2012, Osborn et al., 2012).  GPR21 
knockout mice fed on a HFD demonstrated increased insulin sensitivity, improved 
glucose tolerance and a reduction in pro-inflammatory markers when compared to 
wild type littermates.  Both the identity of the ligand for this receptor and the precise 
mechanism by which it mediates this action remain unclear.  Analysis of the G 
protein to which GPR21 couples to amplify signal potential is key to understanding 
the activity and downstream consequences of receptor activation.  It has been 
suggested that GPR21 couples with Gαq (Bresnick et al., 2003) and specifically 
Gα15/16 (Xiao et al., 2008).  Selective GPCR coupling to Gαq proteins leads to the 
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activation of PLC, which cleaves PIP2 into the secondary messengers, DAG and IP3 
(Fig. 4.1).  The membrane-bound DAG activates PKC, whereas the soluble IP3 binds 
to its receptor in the endoplasmic reticulum triggering the release of Ca2+.  
Downstream of this, a wide range of intracellular pathways can be activated, 
including the MAPK cascade (Naor et al., 2000, Chan and Wong, 2004, Goldsmith 
and Dhanasekaran, 2007), of which JNK is an established contributor to the 
development of insulin resistance (Aguirre et al., 2000). 
 
 
Figure 4.1 Gαq signalling. 	
Upon GPCR activation, a G protein binds to the receptor, which facilitates the 
exchange of bound GDP for GTP on the α-subunit.  The active GTP bound G protein 
then dissociates from the receptor forming a Gα monomer and a Gβγ dimer to 
modulate downstream effector proteins.  The Gαq family comprises four subtypes; 
Gαq, Gαq/11, Gα14 and Gα15/16 which activate PLC, an enzyme that catalysis the 
hydrolysis of PIP2 into DAG and IP3.  DAG directly activates PKC while IP3 
released into the cytoplasm mobilises Ca2+ from intracellular stores to influence PKC 
before it is rapidly metabolised into IP2 and subsequently IP1.  PKC signals to a 
variety of proteins including MAPKKKs, which phosphorylate MAPKKs; highly 
specific activators of the MAPKs; Erk, p38 and JNK.  
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4.2  Aims and Objectives 
 
This study aimed to elucidate the signalling mechanisms of GPR21 and the role it 
may play in obesity-associated type 2 diabetes.  Given the impact of knocking out 
this receptor in vivo and the potential role it may play in the development of insulin 
resistance, moderating the effects of GPR21 with novel compounds may hold great 
promise as a prospective therapy for type 2 diabetes.  As the structure of GPR21 is 
unknown, homology modelling and ligand docking studies were employed to 
identify potential small molecules capable of binding GPR21 and attenuating the 
downstream effects of the receptor. 
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4.3 Results 
4.3.1 Increased Expression of GPR21 is Observed in the Adipose 
Tissue of HFHS-Fed Mice 
 
Western blot analysis of the epididymal fat pads of wild type C57BL/6J mice, a 
meaningful indicator of obesity-related diabetes, revealed a substantial increase in 
GPR21 expression in HFHS-fed mice when compared to chow fed control mice (Fig. 
4.2A).  A concurrent increase in the content of the macrophage marker F4/80 was 
also observed in HFHS-fed mice (Fig. 4.2B).  As the epididymal fat pads of the mice 
demonstrated differential expression of standard housekeeping proteins such as β-
actin, Coomassie brilliant blue was used to confirm equal protein loading between 
groups (Fig. 4.2C).  A rise in F4/80 expression was also seen at the mRNA level 
(Fig. 4.2D) along with a notable increase in the pro-inflammatory cytokine TNF-α in 
HFHS-fed mice (Fig. 4.2E).   
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Figure 4.2 Analysis of the epididymal fat pads of chow fed and HFHS-fed mice. 
 
Epididymal fat pads of chow fed and HFHS-fed C57BL/6J mice were lysed, proteins 
separated by SDS-PAGE and expression of (A) GPR21 and (B) the macrophage 
marker F4/80, were evaluated by Western blotting.  Representative Western blots are 
shown along with relative densities obtained with ImageJ software, presented as 
mean ± SEM, n=3.  (C) A representative Coomassie brilliant blue stained gel was 
used to confirm equal loading of the extracted proteins.  qRT-PCR was also used to 
assess the mRNA levels of (D) F4/80 and (E) TNF-α, relative to the housekeeping 
control, HPRT.  Using the unpaired Student’s t-test, GraphPad Prism® 5 software 
demonstrates significance at p < 0.05; * and p < 0.01; **. 
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4.3.2 GPR21 is a Ubiquitously Expressed Protein 	
In an attempt to better understand this receptor, the expression profile of GPR21 in 
various cell lines was analysed through Western blotting (Fig. 4.3).  Upon short 
immunoblotting exposure, GPR21 was not detected in C2C12 muscle cells, in THP-
1 monocytes or in the macrophage cell lines J774, RAW 264.7 and BMDM.  
Relatively low levels of the receptor were observed in A549 alveolar basal epithelial 
lung cells, CHO cells and SH-SY5Y neuroblastoma cells.  COS-1 and HEK293T 
kidney cells expressed a greater amount of GPR21, with more again detected in 
HepG2 liver cells.  The greatest abundance of GPR21 by far was found in 
differentiated 3T3-L1 adipocytes.  However, with a longer exposure time it was clear 
the monocytes and various macrophage cell lines were not completely devoid of the 
receptor, with C2C12 muscle cells also potentially exhibiting expression of GPR21.  
 
 
 
 
 
Figure 4.3 Western blot analysis of GPR21 expression in various cell lines. 
 
The indicated cell lines were grown to confluency, lysed, subjected to SDS-PAGE 
and immunoblotted with antibodies against GPR21 with short (SE) and long (LE) 
exposures.  β-actin was used as a loading control.  Data presented are representative 
of two independent experiments.  
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4.3.3 GPR21 cDNA can be effectively Transfected into HEK293T, 
RAW 264.7 and 3T3-L1 cells 
In order to explore the potential of an increase in GPR21 levels, overexpression of 
the receptor in a cell line was carried out.  HEK293T cells were selected as the 
primary cell for this study, as this human cell line expresses the SV40 large T 
antigen, which can bind to SV40 enhancers of expression vectors, yielding increased 
protein production.  Given the differential expression profile of GPR21 in adipocytes 
and macrophages, resident cells of the epididymal fat pads, transfection efficiencies 
with RAW 264.7 macrophages and 3T3-L1 adipocytes were also investigated.  To 
determine optimal transfection conditions HEK293T cells were transiently 
transfected with eGFP using Lipofectamine® 2000, whereas RAW 264.7 
macrophages and 3T3-L1 preadipocytes were transfected with eGFP using 
Lipofectamine® 3000 (Fig. 4.4A).  Cells transiently transfected under the indicated 
conditions were found to successfully express GPR21 as confirmed by Western 
blotting for the myc tag incorporated into the C-terminus of the receptor (Fig. 4.4B).   
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Figure 4.4 Optimisation of cell line transfection. 
HEK293T, RAW 264.7 and 3T3-L1 cells were seeded at the indicated densities and 
left to adhere for 24 hours.  Cells were then transfected with various ratios of eGFP: 
Lipofectamine® 2000 or Lipofectamine® 3000 as outlined in the manufacturer’s 
instructions.  (A) HEK293T and RAW 264.7 cells were left for 24 hours at 37 °C 
then imaged with an inverted Olympus CKX41 fluorescent microscope.  3T3-L1 
cells demonstrating expression of the plasmid after 24 hours were differentiated as 
outlined in Section 2.2.1.2.  Cells were visualised microscopically every two days 
and imaged on day six of the differentiation process.  (B) Using the outlined, 
optimised conditions, cells were transfected with GPR21 or the empty vector 
pCMV6-Entry.  After 24 hours, or at the end of the differentiation process in the case 
of 3T3-L1 adipocytes, cells were lysed, subjected to SDS-PAGE and immunoblotted 
for the myc tag incorporated into the C-terminus of GPR21 to confirm expression.  
β-actin was used as a loading control. 
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4.3.4 GPR21 is a Constitutively Active Receptor, Signalling 
Preferentially Through Gα15/16 
As HEK293T cells transiently expressed GPR21 with the greatest efficiency, they 
were selected to investigate the G protein to which GPR21 couples, to give further 
insight into the consequences of an increase in receptor expression.  HEK293T cells 
were transiently transfected with GPR21 along with the cDNAs of the α-subunits of 
the Gq family members; Gαq, Gα14, and Gα15/16, as these effector proteins have been 
suggested to couple with the receptor (Bresnick et al., 2003, Xiao et al., 2008).  
Mammalian receptors activating Gαq family members apparently do not discriminate 
between Gαq and Gαq/11 (Offermanns et al., 1994), therefore, the influence of Gαq/11 
on GPR21 activity was not investigated.  
Analysis of IP1 production with a FRET based IP-one assay was used as a surrogate 
of the transient Gαq secondary messenger IP3, since the degradation of this 
metabolite of IP3 can be prevented with the addition of lithium chloride (Trinquet et 
al., 2006).  An increase in endogenous IP1 was observed in HEK293T cells 
transfected with GPR21 alone and in the absence of a ligand when compared to cells 
transfected with the empty vector, an indication of a constitutively active receptor.  
Each of the Gαq subtypes led to an increase in basal IP1 production when co-
transfected with the empty vector pCMV6-Entry.  When GPR21 was coupled with 
Gαq a significant increase in IP1 was observed.  Although transfection with Gαq 
stimulated the greatest production of IP1, Gα15/16 was found to significantly augment 
GPR21-induced release of IP1.  Gα14 did not appear to markedly influence GPR21-
induced production of IP1 (Fig. 4.5). 
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Figure 4.5 GPR21 activity in HEK293T cells. 
 
HEK293T cells were seeded at 2.5x105 cells/ml in a 6 well plate, after 24 hours cells 
were transiently transfected with 4 µl Lipofectamine® 2000: 2 µg GPR21 plasmid 
DNA or the empty vector pCMV6-Entry.  When co-transfecting cells with Gαq, 
Gα15/16 and Gα14, 1 µg of each plasmid DNA was used.  After 24 hours cells were 
trypsinised, resuspended at a density of 6x106 cells/ml in IP-one stimulation buffer 
and processed according to the IP-one assay protocol (Cisbio, 62IPAPEC).  IP1 
concentrations were then extrapolated from an IP1 standard curve.  One-way 
ANOVA with a post-hoc Tukey test using GraphPad Prism® 5 software denotes 
significance at p < 0.05; * and p < 0.001; ***.  Data presented as mean ± SEM are 
representative of at least three independent experiments.  
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To confirm GPR21 was explicitly signalling through Gαq, HEK293T cells 
overexpressing GPR21 were incubated with increasing concentrations of the PLC 
inhibitor U73122 (Smith et al., 1990), as PLC is the crucial intermediate protein 
between Gαq signalling and the production of IP3.  Since the receptor appeared most 
active when co-expressed with Gα15/16, the effect of the inhibitor on GPR21 when 
coupled with Gα15/16 was concurrently investigated.  Cells transfected with pCMV6-
Entry and pCMV6-Entry coupled with Gα15/16 were also stimulated with U73122 as a 
control.  The PLC inhibitor demonstrated little effect on endogenous IP1 production 
in these control cells.  However, in cells overexpressing GPR21, a dose dependent 
decrease in IP1 production was observed (Fig. 4.6A), a response more evident when 
GPR21 was coupled with Gα15/16 (Fig. 4.6B).   
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Figure 4.6 The effect of the PLC inhibitor, U73122, on GPR21-induced IP1 
production in HEK293T cells. 
 
HEK293T cells were transiently transfected with (A) pCMV6-Entry or GPR21 and 
(B) pCMV6-Entry coupled with Gα15/16 or GPR21 coupled with Gα15/16.  After 24 
hours cells were trypsinised and resuspended at a density of 6x106 cells/ml in IP-one 
stimulation buffer.  Cells were then incubated with the PLC inhibitor U73122 
(Sigma-Aldrich, U6756) in IP-one stimulation buffer and processed according to the 
IP-one assay protocol.  IP1 concentrations were extrapolated from an IP1 standard 
curve and GraphPad Prism® 5 software was used to generate a non-linear sigmoidal 
dose response curve.  Data presented as mean ± SEM are representative of two 
independent experiments performed in triplicate each time.   
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4.3.5 Overexpression of GPR21 leads to the Activation of the 
MAPKs 	
Downstream of the Gαq secondary messenger PLC, a wide range of intracellular 
pathways can be activated, including the MAPK cascade.  Overexpression of GPR21 
led to a significant increase in the phosphorylation of the MAPKs Erk, p38 and JNK 
when compared to cells transfected with pCMV6-Entry.  The effect of GPR21 on the 
MAPKs was reduced in cells incubated with complete medium containing 10 % 
(v/v) FBS in comparison to serum starved cells (Fig. 4.7A).  When coupled with 
Gα15/16 (Fig. 4.7B), GPR21 again led to an increase in the phosphorylation of Erk, 
p38 and JNK.  In the presence of 10 % (v/v) FBS, the phosphorylation status of the 
MAPKs was unaltered.   
 
To determine if the activation of the MAPKs was dependent on GPR21 signalling 
through Gαq to activate PLC, HEK293T cells overexpressing GPR21 were incubated 
with 10 µM U73122 in serum free complete medium.  The PLC inhibitor reduced the 
effect of the receptor on the MAPKs, with the influence of U73122 on JNK 
phosphorylation slightly inferior to that of the JNK inhibitor SP600125 (Fig. 4.8). 
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Figure 4.7 The effect of GPR21 overexpression on the phosphorylation of the    
MAPKs in HEK293T cells. 
 
HEK293T cells transiently transfected with (A) pCMV6-Entry or GPR21 and (B) 
pCMV6-Entry coupled with Gα15/16 or GPR21 coupled with Gα15/16 were incubated 
for 24 hours in complete medium in the presence or absence of 10 % (v/v) FBS.  
Cells were lysed and subjected to SDS-PAGE followed by immunoblotting with 
antibodies against phospho-Erk Thr202/Tyr204, phospho-p38 Thr180/Tyr182, phospho-
JNK Thr183/Tyr185, native Erk, p38 and JNK.  Myc was used to confirm GPR21 
expression and β-actin was used as a loading control.  Data are representative of two 
independent experiments. 
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Figure 4.8 The effect of U73122 on GPR21-induced phosphorylation of the 
MAPKs in HEK293T cells. 
 
HEK293T cells were transiently transfected with the empty vector pCMV6-Entry or 
GPR21 and left for 24 hours to incorporate plasmid DNA.  Cells were then 
stimulated with 10 µM U73122, a PLC inhibitor, 10 µM SP600125, a JNK inhibitor 
(Sigma-Aldrich, S5567) or an equal volume of the vehicle control, DMSO for 24 
hours in serum free complete medium.  Cells were lysed and subjected to SDS-
PAGE followed by immunoblotting with antibodies against phospho-Erk 
Thr202/Tyr204, phospho-p38 Thr180/Tyr182, phospho-JNK Thr183/Tyr185, native Erk, 
p38 and JNK.  Myc was used to confirm GPR21 expression and β-actin was used as 
a loading control.  Data are representative of two independent experiments. 
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4.3.6 GPR21 Negatively Impacts the Insulin Signalling Pathway 
 
As overexpression of GPR21 in HEK293T cells led to a significant increase in JNK 
phosphorylation, an acknowledged negative regulator of the insulin signalling 
cascade, the direct effect of receptor overexpression on this pathway was 
investigated (Fig. 4.9A).  HEK293T cells transfected with the empty vector pCMV6-
Entry as a control, exhibited basal phosphorylation of the principal proteins of the 
insulin signalling pathway.  Control cells also responded to the 1 hour 100 nM 
insulin stimulation, leading to an increase in the phosphorylation of the insulin 
receptor, IRS1, Akt and AS160 at both residues, Thr642 and Ser588 critical for GLUT4 
translocation to facilitate glucose transport.  Conversely, cells overexpressing 
GPR21 demonstrated reduced basal phosphorylation of Akt and AS160.  
Furthermore, cells did not respond to insulin-induced stimulation of the insulin 
receptor itself, diminishing the activity of the signalling pathway.  
 
Incubation of cells transfected with the empty vector with complete medium 
containing 10 % (v/v) FBS, increased the phosphorylation of AS160 at Thr642 
marginally, yet had little bearing on the activation of the other proteins of the 
signalling cascade.  However, the effect of GPR21 overexpression on this pathway 
was curtailed in the presence of FBS.  The phosphorylation of the insulin receptor, 
IRS1, Akt and AS160 were seen to increase when compared to GPR21-expressing 
cells incubated with serum free medium.  Nonetheless, the phosphorylation status of 
these proteins remained below that of cells transfected with pCMV6-Entry.   
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A similar result was observed when GPR21 was coupled with Gα15/16 (Fig. 4.9B), 
while cells co-expressing pCMV6-Entry and Gα15/16 responded to the action of 
insulin. Additionally, the impact of serum containing complete medium in 
weakening the effect of GPR21 on the insulin signalling pathway was less effective 
when the receptor was coupled with Gα15/16.   
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Figure 4.9 Western blot analysis of the effect of GPR21 on insulin signalling in 
HEK293T cells. 
 
HEK293T cells transiently transfected with (A) pCMV6-Entry or GPR21 and (B) 
pCMV6-Entry coupled with Gα15/16 or GPR21 coupled with Gα15/16 were incubated 
for 24 hours in complete medium in the presence or absence of 10 % (v/v) FBS, then 
stimulated with 100 nM insulin for 1 hour in KRBG.  Cells were lysed and subjected 
to SDS-PAGE followed by immunoblotting with antibodies against phospho-insulin 
receptor β Tyr1150/1151, phospho-IRS1 Tyr612, phospho-Akt Ser473, phospho-AS160 
Thr642 and Ser588, native insulin receptor β, IRS1, Akt and AS160.  Myc was used to 
confirm GPR21 expression and β-actin was used as a loading control.  Data are 
representative of two independent experiments. 
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As a consequence of a hindered insulin signalling pathway, overexpression of 
GPR21 also led to a significant decrease in glucose uptake both basally and under 
insulin stimulation.  Although this response was weakened in cells incubated with 
complete medium supplemented with 10 % (v/v) FBS, glucose uptake did not return 
to the level of counterpart cells transfected with the empty vector.  Complete 
medium supplemented with 10 % (v/v) FBS demonstrated no effect in augmenting 
glucose uptake in control cells transfected with pCMV6-Entry (Fig. 4.10A).  
HEK293T cells expressing GPR21 coupled with Gα15/16 also displayed a reduction in 
basal and insulin-induced glucose uptake when compared to cells transfected with 
pCMV6-Entry coupled with Gα15/16.  Similarly, complete medium supplemented 
with 10 % (v/v) FBS undermined the impact of GPR21 coupled with Gα15/16, while 
exhibiting no effect on glucose uptake in control cells transfected with pCMV6-
Entry and Gα15/16 (Fig. 4.10B). 
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Figure 4.10 The effect of serum on glucose uptake in HEK293T cells 
overexpressing GPR21. 
 
HEK293T cells transiently transfected with (A) pCMV6-Entry or GPR21 and (B) 
pCMV6-Entry coupled with Gα15/16 or GPR21 coupled with Gα15/16 were incubated 
for 24 hours in the presence or absence of 10 % (v/v) FBS, then stimulated with 100 
nM insulin for 1 hour in KRBG.  The effect on glucose uptake was established by 
measuring cellular levels of [3H]-2-deoxyglucose.  Data presented as mean ± SEM 
are representative of two independent experiments. One-way ANOVA with a post-
hoc Tukey test using GraphPad Prism® 5 software conveys a significant increase in 
glucose uptake at p < 0.05; * and p < 0.01; **.  A significant decrease in glucose 
uptake is denoted at p < 0.05; #, p < 0.01; ## and p < 0.001; ###.  
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4.3.7 The Constituents of FBS may Influence GPR21 Activity  	
To further explore the effect of FBS on the phosphorylation events observed in 
response to GPR21 overexpression, transfected HEK293T cells were incubated with 
complete medium containing increasing concentrations of FBS for 24 hours prior to 
insulin stimulation (Fig. 4.11).  In serum free medium and medium containing 6 % 
(v/v) FBS, overexpression of GPR21 reduced insulin-induced phosphorylation of the 
insulin receptor.  When GPR21 transfected cells were incubated with complete 
medium containing 12 % (v/v), 25 % (v/v) and 50 % (v/v) FBS the effect of GPR21 
on the insulin receptor was abated.  In serum free medium, overexpression of GPR21 
led to an obvious decrease in insulin-induced phosphorylation of IRS1, an effect that 
was attenuated with increasing concentrations of FBS.  GPR21 also lessened insulin-
induced phosphorylation of Akt in serum free medium, however with increasing 
concentrations of FBS the response to insulin became augmented.  Further down the 
signalling pathway, the inhibitory effect of GPR21 on AS160 at Thr642 was evident 
both basally and upon insulin stimulation in serum starved cells. However, this 
response was reduced in GPR21-expressing cells incubated with complete medium 
containing 6 % (v/v) FBS.  While cells expressing GPR21 incubated with 12 % (v/v) 
and 25 % (v/v) FBS demonstrated a reduction in basal AS160 phosphorylation at 
Thr642, insulin-induced phosphorylation was comparable to cells transfected with the 
empty vector.  The phosphorylation status of AS160 at Thr642 was also equivalent to 
the basal levels observed with control cells when incubated in complete medium 
supplemented with 50 % (v/v) serum.  Insulin-induced phosphorylation of AS160 at 
Thr642 appeared to be reduced under these conditions, although the band present may 
have bleached due to the intensity.  Overall the overexpression GPR21 demonstrated 
little effect on the phosphorylation of AS160 at Ser588. hhhhhhhhhhhhhhhhhhhhhhh
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Figure 4.11 Western blot analysis of the effect of serum on insulin signalling in HEK293T cells overexpressing GPR21 in HEK293T cells. 
 
HEK293T cells transiently transfected with pCMV6-Entry or GPR21 were incubated for 24 hours with complete medium containing concentrations of 
FBS ranging from 0 – 50 % (v/v).  Cells were then stimulated with 100 nM insulin for 1 hour in KRBG, lysed and subjected to SDS-PAGE.  
Membranes were immunoblotted with antibodies against phospho-insulin receptor β Tyr1150/1151, phospho-IRS1 Tyr612, phospho-Akt Ser473, phospho-
AS160 Thr642 and Ser588, native insulin receptor β, IRS1, Akt and AS160.  Myc was used to confirm GPR21 expression and β-actin was used as a 
loading control. Data are representative of two independent experiments.  	
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The direct effect of FBS on GPR21 activity was then assessed through the impact on 
the activation of the MAPKs and IP1 production, to determine if the influence on the 
insulin signalling pathway was merely as a result of residual serum derived insulin 
present in the medium.   
 
Looking at the same sample set, phosphorylation of Erk was markedly increased in 
cells transfected with GPR21 in the presence and absence of insulin, yet only in 
serum free medium.  Basal phosphorylation of Erk in cells transfected with pCMV6-
Entry also subsided with increasing serum concentrations.  Transfection of 
HEK293T cells with GPR21 led to a considerable increase in the phosphorylation of 
p38 in serum free medium and medium supplemented with 6 % (v/v) and 12.5 % 
(v/v) FBS.  However GPR21-induced phosphorylation of p38 was reduced in cells 
incubated with concentrations of FBS above 25 %.  HEK293T cells overexpressing 
GPR21 incubated with serum free medium demonstrated an increase in JNK 
phosphorylation, while phosphorylated JNK remained undetected in cells transfected 
with the empty vector.  The effect of GPR21 on JNK diminished gradually when 
cells were incubated with medium containing increasing concentrations of FBS (Fig. 
4.12).   	
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Figure 4.12 Western blot analysis of the effect of increasing serum concentration of GPR21 activation of the MAPKs in HEK293T cells. 
 
HEK293T cells transiently transfected with pCMV6-Entry or GPR21 were incubated for 24 hours in complete medium containing FBS at 
concentrations ranging from 0 – 50 % (v/v).  Cells were then stimulated with 100 nM insulin for 1 hour in KRBG, lysed and subjected to SDS-PAGE 
with antibodies against phospho-Erk Thr202/Tyr204, phospho-p38 Thr180/Tyr182, phospho-JNK Thr183/Tyr185, native Erk, p38 and JNK.  Myc was used to 
confirm GPR21 expression and β-actin was used as a loading control.  Data are representative of two independent experiments. 	
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Table 4.1 Summarising the influence of GPR21 overexpression on protein 
phosphorylation.   
 
Phospho- - 6 % (v/v) FBS 
12.5 % (v/v) 
FBS 
25 % (v/v) 
FBS 
50 % (v/v) 
FBS Protein 
Insulin Signalling Cascade         
Insulin Receptor  - + ++ ++ +++ 
IRS1    + ++ ++ + ++ 
Akt    + ++ +++ +++ +++ 
AS160 Thr642 - + + ++ ++ 
MAPKs 
Erk +++ + - - - 
p38 +++ +++ ++ + + 
JNK ++ + - - - 
 
 
With regards to IP1 levels, GPR21-induced IP1 production decreased significantly when 
cells were incubated FBS (Fig. 4.13A).  In HEK293T cells overexpressing GPR21 
coupled with Gα15/16 IP1 production decreased gradually with increasing concentrations 
of serum and markedly so at 50 % (v/v) FBS (Fig. 4.13B).  
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Figure 4.13 IP1 production in HEK293T cells overexpressing GPR21 in response to 
FBS.   
 
HEK293T cells were transiently transfected with (A) pCMV6-Entry or GPR21 and (B) 
pCMV6-Entry coupled with Gα15/16 or GPR21 coupled with Gα15/16.  After 24 hours 
cells were trypsinised and resuspended at a density of 6x106 cells/ml in IP-one 
stimulation buffer.  Cells were then incubated with IP-one stimulation buffer containing 
FBS at concentrations ranging from 0 – 50 % (v/v) and processed according to the IP-
one assay protocol.  IP1 concentrations were extrapolated from an IP1 standard curve 
and GPR21 activity was determined by dividing the concentration of IP1 produced in 
cells expressing GPR21 by the concentration of IP1 produced in cells transfected with 
the empty vector.  The effect of the compounds was defined relative to cells incubated 
with serum free medium.  Data presented as mean ± SEM are representative of two 
independent experiments, n=2.  One-way ANOVA with a post-hoc Dunnett test using 
GraphPad Prism® 5 software denotes significance at p < 0.01; ** and p < 0.001; ***. 
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4.3.8 A Novel Compound, GRA2, Reduces the Activity of GPR21 	
As the crystal structure of GPR21 remains unknown and no native interacting ligands 
for the orphan receptor have been identified to date, the development of a structural 
homology model was undertaken to design novel, small molecule ligands to bind 
GPR21 to modulate its downstream effects.  Dr. Gemma Kinsella developed the GPR21 
homology model (Fig. 4.14) using the Modeller software embedded in Biovia 
Discovery Studio (Biovia Software Inc.).  A sequence alignment was constructed 
between the amino acid sequence of the GPCR templates 2RH1 (Cherezov et al., 2007) 
and 4GBR (Zou et al., 2012), with human GPR21 (Swissprot accession code Q99679).  
Using this alignment, 1,000 different models were generated with a refinement protocol 
applied to the loop regions (Fiser and Sali, 2003a, 2003b) and disulphide bonds were 
formed between Cys102 and Cys181.  The final model was selected using the Modeller 
objective score and a selection of protein assessment tools 
(http://services.mbi.ucla.edu/SAVES/, Laskowski et al., 1996, Wiederstein and Sippl, 
2007). 
 
Utilising the developed model, Dr. Gemma Kinsella screened large compound 
databases such as Specs (www.specs.net) in silico through molecular docking studies 
using the FRED docking engine and OMEGA conformational databases from OpenEye 
Scientific Software  (Perola and Charifson, 2004, McGaughey et al., 2007, Hawkins et 
al., 2010, McGann, 2011).  From the ranked list of 11 compounds, 8 were screened 
experimentally in vitro for their ability to alter GPR21-induced production of IP1 (Fig. 
4.15).  Although the hit compounds did not significantly modify GPR21-induced 
production of IP1 at the concentrations assayed, one compound, GRA2 appeared to 
negatively influence the effect of GPR21.   
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Figure 4.14 Homology model of GPR21 incorporating the predicted binding site of 
a lead compound, GRA2. 
 
A Homology Model of GPR21 was designed using the Modeller software embedded in 
Biovia Discovery Studio based on its amino acid sequence and a template protein 
structure of related homologous proteins.  Image kindly generated by Dr. Gemma 
Kinsella using PyMOL (www.pymol.org).   
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Figure 4.15 The effect of hit compounds on IP1 production in HEK293T cells 
overexpressing GPR21. 
 
HEK293T cells were transiently transfected with the empty vector pCMV6-Entry or 
GPR21 plasmid DNA.  After 24 hours cells were trypsinised and resuspended at a 
density of 6x106 cells/ml in IP-one stimulation buffer.  Cells were then incubated with 
the hit compounds at a final concentration of 10 µM or an equal volume of vehicle 
control, DMSO, in IP-one stimulation buffer for 2 hours at 37 °C.  IP1 concentrations 
were extrapolated from an IP1 standard curve and GPR21 activity was determined by 
dividing the concentration of IP1 produced in cells expressing GPR21 by the 
concentration of IP1 produced in cells transfected with the empty vector.  The effect of 
the compounds was defined relative to the DMSO control.  Data presented as mean ± 
SEM are representative of two independent experiments performed in triplicate each 
time. 
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In a dose response assay, the reaction to GRA2 was not significant in HEK293T cells 
transfected with GPR21 alone, with a mild decrease in cellular IP1 observed at 1 mM 
only (Fig. 4.16A).  However, in cells overexpressing GPR21 coupled with Gα15/16,  the 
more pronounced IP1 production was markedly inhibited by GRA2 at 100 nM, an effect 
which plateaued at 1 µM  supressing the activity of GPR21 (Fig. 4.16B).  GRA2 did not 
influence basal IP1 levels of control cells transfected with pCMV6-Entry or pCMV6-
Entry coupled with Gα15/16.  
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Figure 4.16 Dose response analysis of GRA2 on IP1 production in HEK293T cells 
overexpressing GPR21. 
 
HEK293T cells were transiently transfected with (A) GPR21 or pCMV6-Entry and (B) 
pCMV6-Entry coupled with Gα15/16 or GPR21 coupled with Gα15/16.  After 24 hours 
cells were trypsinised and resuspended at a density of 6x106 cells/ml in IP-one 
stimulation buffer.  Cells were then incubated with the lead compound, GRA2 at 
various concentrations in IP-one stimulation buffer.  IP1 concentrations were 
extrapolated from an IP1 standard curve and GraphPad Prism® 5 software was used to 
generate a non-linear sigmoidal dose response curve.  Data presented as mean ± SEM 
are representative of two independent experiments performed in triplicate each time. 
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4.3.9 GRA2 Protects Against the Effects of GPR21 on the Insulin 
Signalling Pathway  
 
To determine if the impact of this compound resonated through to the downstream 
effects of GPR21 on insulin signalling, transfected HEK293T cells were incubated with 
GRA2 for 24 hours followed by an acute insulin stimulation.  In the presence of the 
vehicle control DMSO, HEK293T cells overexpressing GPR21 demonstrated 
significantly reduced phosphorylation of the insulin receptor in response to insulin 
when compared to cells transfected with the empty vector.  Overexpression of GPR21 
also diminished basal and insulin-stimulated phosphorylation of IRS1, Akt and AS160 
at Thr642 and at Ser588 when compared to cells transfected with pCMV6-Entry.  
Conversely, cells overexpressing GPR21 incubated with 10 µM GRA2, demonstrated 
no negative impact on insulin-stimulated phosphorylation of its receptor, with the effect 
of insulin comparable to that of cells transfected with the empty vector.  Cells 
overexpressing GPR21 treated with GRA2 also demonstrated a level of IRS1 and Akt 
activity similar to that displayed by cells transfected with pCMV6-Entry.  Although 
treatment with GRA2 attenuated the effect of GPR21 on AS160 when compared to the 
DMSO control, the phosphorylation status of the protein at Thr642 and at Ser588 was still 
below that of cells transfected with the empty vector.  HEK293T cells transfected with 
pCMV6-Entry also demonstrated a slight response to GRA2, in that phosphorylation of 
the components of the insulin signalling cascade increased somewhat (Fig. 4.17A).  
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A similar effect was observed in HEK293T cells co-transfected with GPR21 and Gα15/16 
(Fig. 4.17B).  Phosphorylation of the insulin receptor, IRS1, Akt and AS160 at both 
critical residues were decreased in HEK293T cells expressing GPR21 coupled with 
Gα15/16.  In the presence of 10 µM GRA2, the effect of GPR21 on the insulin receptor, 
IRS1, Akt and AS160 at Thr642 was reduced.  GRA2 also exhibited a positive action on 
control cells, marginally increasing the phosphorylation of the insulin receptor, IRS1 
and AS160 at Thr642 in cells transfected with pCMV6-Entry coupled with Gα15/16. 
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Figure 4.17 Western blot analysis of the effect of GRA2 on the insulin signalling   
pathway in HEK293T cells overexpressing GPR21. 
 
HEK293T cells transiently transfected with (A) GPR21 or (B) GPR21 coupled with 
Gα15/16.   Cells were stimulated with 10 µM GRA2 or an equal volume of DMSO in 
serum free complete medium for 24 hours.  Cells were then stimulated with 100 nM 
insulin for 1 hour in KRBG, lysed and subjected to SDS-PAGE followed by 
immunoblotting with antibodies against phospho-insulin receptor β Tyr1150/1151, 
phospho-IRS1 Tyr612, phospho-Akt Ser473, phospho-AS160 Thr642 and Ser588, native 
insulin receptor β, IRS1, Akt and AS160.  Myc was used to confirm GPR21 expression 
and β-actin was used as a loading control.  Data are representative of two independent 
experiments. 
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These effects carried through to the downstream glucose uptake response.  HEK293T 
cells transfected with pCMV6-Entry reacted positively to a 100 nM insulin stimulation 
with a comparable increase in glucose uptake observed in the presence of DMSO and 
10 µM GRA2 (Fig. 4.18A).  Conversely, cells expressing GPR21 demonstrated a 
reduction in basal glucose uptake in the presence of DMSO, and a reduced response to 
insulin.  Treatment of HEK293T cells expressing GPR21 with 10 µM GRA2 for 24 
hours led to a significant improvement in basal and insulin-stimulated glucose uptake.   
 
In cells transfected with pCMV6-Entry coupled with Gα15/16 a comparable outcome to 
the empty vector alone was detected. Cells overexpressing GPR21 with Gα15/16 
demonstrated reduced basal and insulin-stimulated glucose uptake. While 10 µM GRA2 
improved glucose uptake in cells overexpressing GPR21 with Gα15/16, the effect was not 
significant (Fig. 4.18B).    
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Figure 4.18 The effect of GRA2 on glucose uptake in HEK293T cells 
overexpressing GPR21.   
 
HEK293T cells transiently transfected with (A) GPR21 or (B) GPR21 coupled with 
Gα15/16 were incubated with 10 µM GRA2 or an equal volume of DMSO in serum free 
complete medium for 24 hours.  Cells were then stimulated with 100 nM insulin for 1 
hour in KRBG.  The effect on glucose uptake was established by measuring cellular 
levels of [3H]-2-deoxyglucose.  Data presented as mean ± SEM are representative of 
two independent experiments.  One-way ANOVA with a post-hoc Tukey test using 
GraphPad Prism® 5 software denotes significance at p < 0.05; *. 
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4.3.10 GPR21 induces Macrophage Migration 	
As GPR21 has been implicated in the promotion of macrophage infiltration into adipose 
tissue to encourage the genesis of type 2 diabetes (Osborn et al., 2012), the effect of 
GPR21 overexpression in 3T3-L1 adipocytes and RAW 264.7 macrophages was 
investigated.  Since 3T3-L1 adipocytes exhibited the highest native level of GPR21, the 
effect of augmented expression, through transfection, on 3T3-L1 conditioned medium 
to induce macrophage migration was investigated.  Conditioned medium was harvested 
from 3T3-L1 adipocytes transfected with pCMV6-Entry, GPR21, and pCMV6-Entry or 
GPR21 coupled with Gα15/16 in the presence and absence of GRA2.  RAW 264.7 
macrophages did not demonstrate a significant increase in migratory capacity in 
response to conditioned medium from 3T3-L1 adipocytes transfected with GPR21 or 
GPR21 coupled with Gα15/16 (Fig. 4.19).  The novel compound GRA2 similarly 
produced no effect on the migratory ability of the macrophages in this system. 
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Figure 4.19 The effect of GPR21 on RAW 264.7 migration towards 3T3-L1 
adipocyte conditioned medium.  
 
3T3-L1 adipocytes were transiently transfected with pCMV6-Entry, GPR21, pCMV6-
Entry coupled with Gα15/16 or GPR21 coupled with Gα15/16.  Fully differentiated 
adipocytes were incubated with 10 µM GRA2 or DMSO for 24 hours to generate 
conditioned medium.  RAW 264.7 macrophages were placed in a 5.0 µm Transwell® 
insert at a density of 5x105 cells/ml in complete medium supplemented with 2 % (v/v) 
FBS and equilibrated in a 24 well plate with complete medium containing 2 % (v/v) 
FBS for 1 hour at 37 °C.  Untransfected RAW 264.7 were allowed to migrate towards 
conditioned medium generated from transfected 3T3-L1 adipocytes displaying large 
lipid droplets ± 10 µM GRA2.  After a 4 hour incubation at 37 °C, migratory cells were 
quantified as described in Section 2.7.5.  
 
 
 
pC
MV
6-E
ntr
y
GP
R2
1
pC
MV
6-E
ntr
y G
α 15
/16
  
GP
R2
1 G
α 15
/16
0.0
0.2
0.4
0.6
0.8
1.0
+ GRA2
- GRA2
A
bs
or
ba
nc
e 5
60
 n
m
                    Chapter 4: GPR21, A Novel Target for Obesity-Associated Type 2 Diabetes   
 
  
198 
Given that GPR21 did not appear to influence the production of soluble factors to 
promote macrophage chemotaxis, the direct effect of the receptor on RAW 264.7 
migration towards 3T3-L1 conditioned medium was evaluated. RAW 264.7 
macrophages overexpressing GPR21 demonstrated an increased aptitude for migration, 
as did cells overexpressing GPR21 coupled with Gα15/16.  When RAW 264.7 cells were 
exposed to GRA2, the compound provoked a minor curtailment of GPR21-induced 
migration, whilst a significant decrease was observed in cells expressing GPR21 
coupled with Gα15/16 (Fig. 4.20A).   
 
As JNK has been implicated in the process of macrophage accumulation in adipose 
tissue (Han et al., 2013) and can be activated downstream of proteins involved in the 
promotion of cytoskeletal reorganisation to facilitate macrophage migration, the effect 
of GRA2 on GPR21-induced phosphorylation of JNK in RAW 264.7 macrophages was 
examined and was found to decrease in the presence of the novel compound (Fig. 
4.20B). 
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Figure 4.20 The direct effect of GRA2 on the migratory capacity of RAW 264.7 
cells overexpressing GPR21. 
 
RAW 264.7 macrophages were transfected with pCMV6-Entry, GPR21, pCMV6-Entry 
coupled with Gα15/16 or GPR21 coupled with Gα15/16.  (A) After 24 hours cells were 
transferred into a 5.0 µm Transwell® insert and stimulated with 10 µM GRA2 in 
complete medium supplemented with 2 % (v/v) FBS then positioned into a 24 well plate 
containing 3T3-L1 conditioned medium.  After a 4 hour incubation at 37 °C, migratory 
cells were quantified as described in Section 2.7.5.  One-way ANOVA with a post-hoc 
Tukey test using GraphPad Prism® 5 software denotes a significant increase in 
migration at p < 0.01; ** and p < 0.001; ***.  A significant decrease in migration is 
indicated at p < 0.05; #, n=3.  (B) Alternatively, cells incubated with 10 µM GRA2 for 4 
hours were lysed, subjected to SDS-PAGE and immunoblotted with antibodies against 
phospho-JNK Thr183/Tyr185 and native JNK.  Myc was used to confirm GPR21 
expression and β-actin was used as a loading control.   
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4.4 Discussion 	
Analysis of the expression profile and signalling capabilities of GPR21 has given 
further insight into mechanisms by which this orphan GPCR may contribute to the 
development of the type 2 diabetic phenotype.   
4.4.1 The Effects of Enhanced GPR21 Expression 	
Increased expression of GPR21 in the epididymal fat pads of wild type HFHS-fed mice 
was found to correlate with a rise in the macrophage marker F4/80, along with an 
increase in TNF-α expression.  As well as being a marker gene for pro-inflammatory 
M1 type macrophages, TNF-α is known to contribute to the development of insulin 
resistance (Uysal et al., 1997, Lumeng et al., 2007).  Western blot analysis of various 
cell lines demonstrated an abundance of GPR21 present in adipocytes whilst reduced 
expression of the receptor was found in the three macrophage cell lines tested.  
Although the adipocytes displayed the highest levels of GPR21, macrophages cannot be 
discounted as a source of the increased receptor expression in the epididymal fat pads of 
HFHS-fed mice as the macrophage cell lines investigated were not specifically 
polarised into either the M1 or M2 type subset.  This differentiation may be significant 
as Osborn and colleagues (2012), observed a marked increase in GPR21 mRNA levels 
in M1 type macrophages when compared to M2 type macrophages.  As the macrophage 
cell lines investigated were not polarised into either subset it is not possible to ratify 
unambiguously the source of the increased GPR21 expression in the HFHS-fed mice.  
 
Confirming the signalling capabilities of GPR21 was fundamental to understanding the 
consequence of the observed increase in receptor expression.  As studies indicate that 
GPR21 may signal through Gq type G protein α-subunits (Bresnick et al., 2003, Xiao et 
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al., 2008), the effect of the receptor on IP1 production was investigated.  Analysis of 
this stable downstream metabolite of IP3, which accumulates upon Gαq receptor 
activation, suggests that GPR21 overexpressed in HEK293T cells can adopt the active 
conformation necessary to couple and activate Gαq type G proteins.  GPR21 was 
observed to stimulate this signal transduction in the absence of a ligand, a hallmark of a 
constitutively active receptor.  Co-expression with the specific members of the Gαq, 
family revealed a functional interaction between GPR21 and Gα15/16, as receptor-
induced IP1 production increased most significantly when co-transfected with Gα15/16.     
Although the greatest increase in cellular IP1 was observed in cells co-expressing 
GPR21 and Gαq, this is believed to be a consequence of Gαq expression alone, as this 
protein provoked a significant increase in cellular IP1 when expressed without the 
receptor.  Incubation of transfected HEK293T cells with the PLC inhibitor, U73122, 
blocked GPR21-induced production of IP1, confirming the selectivity of the effect of 
GPR21 on this signalling cascade. 
4.4.2 The Downstream Consequences of Gαq Activation 
The Gαq class of G proteins play a pivotal role in the regulation of many proteins central 
to the development of insulin resistance.  In 3T3-L1 adipocytes Gαq/11 has been shown 
to increase insulin-induced glucose uptake in a potentially PI3K dependent manner 
(Imamura et al., 1999), while β-cell specific inactivation of the genes encoding Gαq and 
Gαq/11 results in impaired glucose tolerance and insulin secretion in mice (Sassmann et 
al., 2010).  However, stimulation of the Gαq pathway by the prostaglandin receptor EP1, 
leads to MAPK activation and the production of pro-inflammatory cytokines involved 
in the genesis of insulin resistance such as IL-6 and TNF-α (Sun and Ye, 2012). 
Furthermore, studies with Gαq/11 have demonstrated reduced insulin-induced 
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phosphorylation of Akt in HeLa cells overexpressing this G protein α-subunit (Ueda et 
al., 2004).  These results demonstrate that the influence of Gαq type G proteins on 
glucose homeostasis is not only receptor, but also cell specific. 
Downstream of PLC, distinctive Gαq signalling systems have been found to activate the 
MAPKs; Erk, p38 and JNK (Naor et al., 2000).  Focusing on this pathway, GPR21 was 
found to significantly increase the phosphorylation of Erk, p38 and JNK in a PLC-
dependent manner.  However, in the presence of complete medium containing 
increasing concentrations of FBS, GPR21-induced phosphorylation of the MAPKs was 
attenuated, intimating the possibility of a native inverse agonist for the constitutively 
active receptor in the serum.  JNK is known to negatively regulate insulin signalling and 
is abnormally elevated in dietary and genetic murine models of obesity (Hirosumi et al., 
2002).  Possibly as a consequence of increased JNK activity, HEK293T cells 
overexpressing GPR21 displayed an impaired insulin signalling pathway, both basally 
and under insulin stimulation.  The regulatory effect of FBS on GPR21 activity was 
carried through to this signalling cascade and the consequential effect on glucose 
uptake.  In cells overexpressing both GPR21 and Gα15/16 the effect of serum was 
reduced, suggesting that the increased activity of GPR21 when coupled with Gα15/16 
may lead to a “hyper activated” signalling pathway that may not easily subside in the 
presence of any potential regulatory factor in the serum.  As increasing serum 
concentrations led to a decrease in IP1 production and a decline in MAPK 
phosphorylation, it is possible that a regulatory ligand for GPR21 present in the serum 
also led to the reduced impact of the receptor on the insulin signalling pathway rather 
than it arising as a consequence of residual serum derived insulin.  
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4.4.3 The Potential of a Ligand for GPR21 	
The prospect of an endogenous inverse agonist suggests that the effect of GPR21 may 
be tightly regulated under normal physiological conditions and only becomes 
deleterious when uncontrolled, as in a state of obesity.  The identification of natural 
ligands for orphan receptors, such as GPR21 may provide insight into the regulatory 
mechanism of the receptor as well as lead to the discovery of novel molecules not 
previously recognised as extracellular mediators.  So-called reverse pharmacology has 
led to the deorphanisation of about 300 GPCRs and the discovery of several novel 
ligands (Chung, Funakoshi and Civelli, 2008).  However, as this method can prove to be 
a lengthy and demanding endeavor, the onset of homology modelling and ligand 
docking studies has revitalised the drug discovery field, enabling high throughput 
screening of receptors (Flohr et al., 2002, Evers and Klabunde, 2005, Kufareve et al., 
2011).  Given the influence of GPR21 on insulin signalling, a molecule that binds 
GPR21 and blocks its constitutive activity in a similar manner to the prospective native 
ligand could be a very powerful new anti-diabetic therapy.   
Constitutively active orphan GPCRs, such as GPR21 provide a direct route to drug 
discovery as their functionality can be understood without the need to identify 
endogenous ligands (Chalmers and Behan, 2002).  Virtual screening of an in house 
model of GPR21 identified 11 hit compounds with the potential to bind the receptor.  Of 
the 8 compounds screened in vitro, GRA2, demonstrated prospective abilities as an 
inverse agonist of GPR21 as it reduced IP1 accumulation in HEK293T cells 
overexpressing the receptor.  Unfortunately, this compound displayed reduced solubility 
at higher concentrations and the effect on IP1 waned.  The diminished effect on IP1 
production could also arise through β-arrestin-mediated internalisation of the ligand 
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bound-receptor, following prolonged incubation with a high concentration of the 
compound.  Nevertheless, at the more soluble concentration of 10 µM GRA2 improved 
the signalling responses to insulin in cells overexpressing GPR21 and GPR21 coupled 
with Gα15/16, following through to a modest restoration of glucose uptake.  Cells 
transfected with the empty vector also displayed enhanced phosphorylation of the 
proteins involved in the insulin signalling cascade in response to GRA2.  This may be 
as a consequence of the compound acting on native GPR21 expressed in HEK293T 
cells, obstructing the dampening effects of the receptor on the insulin signalling 
pathway.  
4.4.4 The Role of GPR21 in Macrophage Migration 	
The marked effect of GPR21 on JNK activity was noteworthy, as increased expression 
of this MAPK in macrophage cells has been reported to promote HFD-induced 
accumulation of adipose tissue macrophages.  Macrophage specific deletion of JNK has 
been observed to decrease the expression of macrophage marker genes, Cd68 and F4/80 
in the adipose tissue of HFD-fed mice (Han et al., 2013).  Furthermore, Osborn and 
colleagues (2012), found markedly fewer adipose tissue macrophages in GPR21 
knockout mice than in wild type counterparts, while GPR21 knockout macrophages also 
displayed reduced migration towards chemokine rich medium.  Complementing this 
study, RAW 264.7 macrophages overexpressing GPR21 displayed an enhanced 
migratory capacity towards 3T3-L1 conditioned medium.  Although Osborn and 
colleagues (2012), discovered fewer macrophages to migrate towards conditioned 
medium harvested from GPR21 knockout adipocytes, conditioned medium generated 
from 3T3-L1 adipocytes overexpressing GPR21 did not influence macrophage 
migration.  The latter finding suggests GPR21 might not control macrophage migration 
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by upregulating the production of classical chemoattractants such as MCP-1 and LTB4 
(Kamei et al., 2006, Li et al., 2015).  It may therefore be plausible to speculate that 
GPR21 could be a novel control point coordinating, amongst other possibilities, the 
rearrangement of the actin cytoskeleton to promote macrophage migration into adipose 
tissue.   
A range of extracellular signals are known to induce cytoskeletal reorganisation to 
mediate cellular chemotaxis through GPCRs, receptor tyrosine kinases, PI3K isoforms 
and small GTPases (Jones, 2000).  The activation of small GTPases controls cell 
migration through the regulation of the actin cytoskeleton and the MAPK pathways 
(Hall, 1998).  The MAPKs JNK, Erk and p38 have all been observed play crucial roles 
in cell migration as the inhibition of these proteins can prevent migration in many cell 
types (Huang, Jacobson and Schaller, 2004).  Notably, the Rho family of small GTPases 
have been found to signal downstream of Gαq (Seasholtz, Majumdar and Brown, 1999, 
Chikumi et al., 2002, Vogt et al., 2003). Moreover, Gαq deficient neutrophils and 
dendritic cells display reduced chemotactic responses (Shi et al., 2007).  PKC isoforms, 
which can be activated downstream of the Gαq family, have been found to directly 
associate with microfilaments (Larsson, 2006) and regulate focal adhesion components 
(Fogh et al., 2014), to mediate cytoskeleton changes that facilitate cell migration.  It 
may be plausible to speculate that GPR21 could promote cytoskeletal reorganisation 
through its action on Gα15/16, leading to the observed increase in RAW 264.7 migration.  
This reinforces the findings of Osborn and colleagues (2012), who demonstrated that 
GPR21 knockout macrophages did not undergo crucial cytoskeletal rearrangements to 
promote transmigration.  
The direct effect of GRA2 in attenuating GPR21-promoted migration reinforces the 
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hypothesis that it may have the ability to act as an anti-diabetic therapy.  Strengthening 
the potential of GRA2-related inhibition of GPR21-induced JNK activation, 
macrophage specific JNK deficiency has been shown to prevent the accumulation of 
adipose tissue macrophages expressing the M1 surface markers CD11c+ and CD206− 
and to reduce the expression of genes associated with M1 polarisation; CD11c, IL-1β, 
Il-6, NOS2, TNF-α (Han et al., 2013).  Analysis of macrophage cell surface markers 
following GPR21 overexpression and GRA2 treatment may give further insight into 
whether the receptor may also influence macrophage polarisation to the pro-
inflammatory M1 subset and if this novel compound may have a regulatory impact.  
Taken together, these results demonstrate the pivotal role GPR21 signal transduction 
through Gα15/16 may play in the development of type 2 diabetes, giving insight into a 
novel means of controlling adipose tissue macrophage accumulation.  
4.4.5 Summary 	
Under normal physiological conditions, this constitutively active GPCR may be tightly 
regulated to facilitate macrophage migration in reaction to an antigen driven immune 
response.  However, obesity-induced type 2 diabetes potentially dysregulates GPR21; 
an increase in GPR21 expression, an increase in an endogenous agonist or a reduction in 
an inverse agonist could all exacerbate the effects of this receptor.  Downstream of 
Gα15/16, the potentiated pro-inflammatory signal activates the MAPKs, inhibits the 
insulin signalling pathway and may promote macrophage migration through the 
induction of cytoskeletal reorganisation (Fig. 4.21).  Whatever the primary cause of the 
GPR21 effect in vivo, an inverse agonist such as the one identified in this study could 
restore the signalling potential of insulin to reinstate normal glucose homeostasis.  
Structure-activity relationship studies of the identified compound should yield 
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compounds with increased affinity for the receptor and hence increased biological 
efficacy to curtail the development of type 2 diabetes.  	
 
 
Figure 4.21 Proposed role of GPR21 in the development of type 2 diabetes. 
 
The constitutively active GPR21 recruits and activates Gα15/16, which facilitates the 
hydrolysis of PIP2 into DAG and IP3 through the action of PLC.  Both DAG and IP3 
activate PKC, which signals to and activates the MAPK cascade.  PKC has also been 
implicated in the promotion of cytoskeletal reorganisation to stimulate cell migration.  
Gαq proteins have been found to activate the Rho family of small GTPases that 
stimulate the activity of the MAPKs and regulate intracellular actin dynamics to 
promote cell migration, among other functions.  Activated JNK has been proposed to 
promote macrophage accumulation in adipose tissue and is known to phosphorylate 
IRS1 of the insulin signalling cascade at Ser307 preventing insulin-induced tyrosine 
phosphorylation of its substrate.  Due to the potential of a native inverse agonist in 
serum, the pro-inflammatory signal transduction of GPR21 is believed to be tightly 
regulated under normal physiological conditions.  However in a state of obesity, GPR21 
activity is uncontrolled and becomes deleterious, promoting macrophage migration into 
adipose tissue and insulin resistance, potentially through the action of JNK. 
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5.1 Synopsis 	
Type 2 diabetes is a complex metabolic condition provoked primarily by obesity-
induced insulin resistance. Distinct routes may be taken to attenuate the 
pathophysiology of this condition, such as augmenting key metabolic regulators to 
overturn the damaging effects of insulin resistance and directly targeting the root cause, 
which many believe to be obesity-induced inflammation.  The work undertaken in this 
project has aided in resolving the mechanism of action of a successful anti-diabetic 
compound, RTC-1 and has given insight into the underlying mechanisms by which the 
novel diabetic target, GPR21 exerts its effects.  Although the original aims of this 
project were achieved, several questions surfaced over the course of this study, which 
warrant further investigation.   
5.2 Cellular Effects of RTC-1 	
The ability of RTC-1 to inhibit RBP binding, the purpose for which it was designed, 
may have contributed to the dramatic effect of the compound on insulin sensitivity in 
vivo.  However, as a result of this study the anti-diabetic and anti-obesity effects of 
RTC-1 have been largely attributed to the activation of AMPK as a consequence of the 
inhibition of NADH:ubiquinone oxidoreductase.  Although the inhibition of the 
mitochondrial respiratory chain was traditionally believed to be detrimental to the cell 
(Degli Esposti, 1998), more recent studies have illustrated over-activation of 
mitochondria as a potential risk for insulin resistance, suggesting the protective benefits 
of inhibition (Pospisilik et al., 2007, Vernochet et al., 2012, Quintens et al., 2013).  
RTC-1 demonstrated a superior effect to metformin in this regard, which may lie with 
the structural differences of the compounds.  Metformin is largely hydrophilic and 
reliant on organic cation transporters to enter the cell (Rena et al., 2013), while the 
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lipophilic properties of RTC-1 allow easier target engagement.  The compounds may 
also occupy distinctive regions of the mitochondrial respiratory chain to alter cellular 
energy balance.  Studies by Wheaton and colleagues (2014), found metformin to 
reversibly inhibit mitochondrial NADH:ubiquinone oxidoreductase.  Although the exact 
binding site remains unknown, this group have speculated that metformin does not act 
on the same site as the irreversible NADH:ubiquinone oxidoreductase inhibitor 
rotenone, as metformin did not substantially increase H2O2 release from mitochondria, 
whereas rotenone augmented this significantly.  Recently, Madiraju and colleagues 
(2014), observed that metformin bound non-competitively to an intermediate 
mitochondrial respiratory chain component, mitochondrial glycerophosphate 
dehydrogenase (mGPD).  mGPD controls cytoplasmic NADH levels and is involved in 
lipid and glucose synthesis (Mráček et al., 2013), thereby providing an alternative mode 
by which metformin may exert its downstream effects.  Based on some structural 
similarities to ubiquinone, RTC-1 could possibly bind the ubiquinone cleft of 
NADH:ubiquinone oxidoreductase to reduce the activity of the complex.  Molecular 
docking and binding simulations may give further insight into the binding capacity of 
RTC-1.  In addition to the observed consequential effects on glucose uptake and lipid 
synthesis, RTC-1 may also elicit long-term beneficial effects on dysregulated pancreatic 
β-cells through AMPK-induced autophagy (Quan et al., 2012, Rubinsztein et al., 2012).  
Analysis of an autophagy marker, such as the microtubule-associated protein 1 light 
chain 3, may help to ascertain whether RTC-1-induced activation of AMPK also 
promotes autophagy.  
 
Although more potent than metformin, the prospect of RTC-1 inducing the rare, yet 
most damaging physiological condition associated with metformin, lactic acidosis, is 
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unlikely.  RTC-1 does not impair the process of oxidative phosphorylation entirely, as 
oxygen consumption can be restored with the addition of the succinate:ubiquinone 
oxidoreductase substrate.  Free protons resulting from ATP hydrolysis can, therefore, be 
processed, albeit less efficiently, reducing the possibility of acidosis.  Furthermore, 
metformin-induced lactic acidosis may not exclusively arise as a consequence of 
NADH:ubiquinone oxidoreductase inhibition.  The effect of metformin on mGPD may 
contribute to the development of lactic acidosis, as this disrupts the conversion of 
lactate to glucose.  Moreover, high therapeutic levels of metformin have been observed 
to reduce lactate clearance by the liver (Lalau et al., 2015).  Nevertheless, the effect of 
RTC-1 on lactate production should be investigated as this compound is explored as a 
novel anti-diabetic therapy.  
 
While the superior effect of RTC-1 on glucose uptake may be attributed to the enhanced 
action on NADH:ubiquinone oxidoreductase to promote AMPK activation, the 
influence of RTC-1-induced phosphorylation of Akt cannot be discounted as a 
contributory factor.  As RTC-1 demonstrated no effect on the major regulator of Akt 
activity, PI3K, it is possible that RTC-1-stimulated decreases in ATP levels may 
prevent IP6K-induced IP7 synthesis to relieve the inhibitory effect of this inositol 
pyrophosphate on Akt activation.  The effects of the IP6K inhibitor, TNP, further 
support this concept, as it has been observed to enhance Akt, AMPK and ACC 
phosphorylation, however, this compound demonstrates no inhibitory effect on 
NADH:ubiquinone oxidoreductase activity (Sun et al., 2015).  TNP also reduces 3T3-
L1 adipogenesis (Chakraborty et al., 2010), although this impact does not approach the 
effectiveness of RTC-1, emphasising the potential of this novel compound.  HPLC 
analysis of cellular IP7 levels will give further insight as to whether this is a mechanism 
Chapter 5: Discussion 
 
  
212 
by which RTC-1 may augment Akt activation and improve insulin sensitivity (Saiardi et 
al., 2002).  Furthermore, the inhibition of IP7 associated with the IP6K inhibitor, TNP, 
has been observed to improve cardiac function, a notable outcome as mitochondrial 
dysfunction associated with insulin resistance can promote the development of 
cardiovascular diseases, the leading cause of death among patients with diabetes (Sun et 
al., 2015).  If studies demonstrate that RTC-1 modulates intracellular IP7 levels, it 
would be interesting to determine if cardiomyocyte apoptosis can also be regulated. 
 
5.3 GPR21 Signal Transduction 	
Although Gq coupled GPCRs are usually stimulatory towards insulin, it is clear the 
influence of these proteins cannot be generalised, given that the Gq coupled 
gonadotropin releasing hormone receptor has been observed to inhibit insulin release 
from rat islets (Amisten et al., 2013).  In this study the Gq coupled GPCR, GPR21, was 
found to be a constitutively active receptor that promoted macrophage migration and the 
activation of the MAPKs, which can negatively impact on the insulin signalling 
pathway.  Expression of this receptor was observed to be upregulated in HFHS-fed mice 
and correlated with an increase in epididymal fat pad macrophages, consistent with a 
role for this receptor in obesity-associated type 2 diabetes.  Intriguingly, the effects of 
GPR21 on MAPK activation and insulin signalling could be attenuated with increasing 
concentrations of serum, advocating the potential of an endogenous regulatory ligand 
for the receptor.  Employing GPR21 induced IP1 production as a functional screen for 
fractionated serum samples, followed by mass spectrometry analysis of those that 
attenuate GPR21 activity may assist in the identification of this regulatory ligand.  
Furthermore, analysis of the effects of diabetic serum on GPR21 activity may give 
insight into the role of this receptor in the development of type 2 diabetes. 
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The adverse contributions of visceral adipose tissue inflammation to the progression of 
type 2 diabetes are stark. Unsurprisingly, therefore, the prospect of targeting 
inflammatory mediators to arrest the pathogenesis of this condition has gained 
significant attention.  Initial studies with the IL-1 receptor antagonist, anakinra, 
demonstrated the beneficial effects of an anti-inflammatory agent on insulin resistance 
as a reduction in inflammatory markers correlated with an extended improvement in 
insulin action.  Although adverse effects occurred with the daily injections of anakinra, 
the benefits of targeting inflammation to regulate insulin resistance have been realised 
and antagonists for IL-1β are currently under investigation (Donath, 2014).  
Virtual screening of an in house homology model of GPR21 led to the identification a 
novel compound, GRA2, with potential anti-diabetic properties as it was found to 
attenuate the downstream effects of the constitutively active GPCR on macrophage 
migration and JNK activation.  Targeting macrophage infiltration into adipose tissue has 
the potential to slow the progressive decline in insulin secretion and responsiveness 
associated with type 2 diabetes.  In a phase 2 clinical trial, Hanefeld and colleagues 
(2012), found promise with the MCP-1 receptor antagonist in this regard, as glycated 
haemoglobin levels were seen to decrease in obese type 2 diabetic patients.  It remains 
unclear if GPR21-related JNK activation promotes migration or if it could be activated 
as a consequence of another mediator of cytoskeletal reorganisation.  F-actin staining of 
GPR21-overexpressing RAW 264.7 macrophages may reveal if GPR21-induced signal 
transduction promotes cytoskeletal reorganisation to form the branched morphology 
necessary for migration.  Furthermore, treatment of macrophages overexpressing 
GPR21 with specific inhibitors for proteins downstream of Gαq signalling that have 
been found to regulate cell migration, such as PKC (Inhibitor-calphostin C) may give 
further insight into the role GPR21 plays in macrophage migration.  
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Nevertheless, GRA2 holds promise as an anti-diabetic agent, as along with regulating 
migration and JNK phosphorylation in RAW 264.7 macrophages, it also counteracted 
the effects of GPR21 to augment insulin signalling and glucose uptake.  Although there 
are currently no anti-diabetic therapies marketed to regulate JNK activity, the effects of 
the insulin sensitising thiazolidinedione, rosiglitazone may also involve the modulation 
of this kinase.  Díaz-Delfín, Morales and Caelles (2007), found rosiglitazone to inhibit 
the elevated JNK activity associated with obesity to restore insulin-induced IRS1 
tyrosine phosphorylation.  Modulating JNK activity to restore insulin sensitivity is 
therefore a promising tactic to target type 2 diabetes and may account for the underlying 
in vitro effects of GRA2 on GPR21-induced insulin resistance.  Analysis of the effects 
of GPR21 overexpression in JNK deficient cells may reveal if the impact of the receptor 
on migration and insulin signalling are dependent on the MAPK.  Furthermore, the 
analysis of other key negative regulators of insulin signalling, namely IKKβ and 
SOCS3, in response to GPR21 overexpression would help consolidate the influence of 
this receptor in the development of insulin resistance. 
5.4 Conclusion 
 
The work presented in this thesis has contributed to a better understanding of the ways 
in which the type 2 diabetic phenotype may be regulated.  Given the complexity of the 
factors contributing to the development of this condition, an amalgamation of therapies 
directed at versatile targets, such as those discussed in this study, may be the best 
approach to treat type 2 diabetes.  
  
  
215 
 
 								
Chapter 6             
Bibliography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6: Bibliography 
 
  
216 
Aguirre, V., Uchida, T., Yenush, L., Davis, R., and White, M. F., 2000. The c-Jun NH2-
terminal kinase promotes insulin resistance during association with insulin receptor 
substrate-1 and phosphorylation of Ser307. The Journal of Biological Chemistry, 
275 (12), 9047–9054. 
Ahmed, K., Tunaru, S., Langhans, C. D., Hanson, J., Michalski, C. W., Kölker, S., 
Jones, P. M., Okun, J. G., and Offermanns, S., 2009. Deorphanization of GPR109B 
as a receptor for the β-oxidation intermediate 3-OH-octanoic acid and its role in 
the regulation of lipolysis. The Journal of Biological Chemistry, 284 (33), 21928–
21933. 
Ahn, J., Lee, H., Kim, S., Park, J., and Ha, T., 2008. The anti-obesity effect of quercetin 
is mediated by the AMPK and MAPK signaling pathways. Biochemical and 
Biophysical Research Communications, 373 (4), 545–549. 
Alers, S., Loffler,  A. S., Wesselborg, S., and Stork, B., 2012. Role of AMPK-mTOR-
Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks. 
Molecular and Cellular Biology, 32 (1), 2–11. 
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J., 1990. Basic 
local alignment search tool. Journal of Molecular Biology, 215 (3), 403–410. 
Amisten, S., Salehi, A., Rorsman, P., Jones, P. M., and Persaud, S. J., 2013. An atlas 
and functional analysis of G-protein coupled receptors in human islets of 
Langerhans. Pharmacology and Therapeutics, 139 (3), 359–391. 
Armour, K. E., Armour, K. J., Gallagher, M. E., Gödecke,  A., Helfrich, M. H., Reid, D. 
M., and Ralston, S. H., 2001. Defective bone formation and anabolic response to 
exogenous estrogen in mice with targeted disruption of endothelial nitric oxide 
synthase. Endocrinology, 142 (2), 760–766. 
Chapter 6: Bibliography 
 
  
217 
Aronoff, S. L., Berkowitz, K., Shreiner, B., and Want, L., 2004. Glucose Metabolism 
and Regulation: Beyond Insulin and Glucagon. Diabetes Spectrum, 17 (3), 183–
190. 
Ayala, J. E., Bracy, D. P., James, F. D., Burmeister, M. A., Wasserman, D. H., and 
Drucker, D. J., 2010. Glucagon-like peptide-1 receptor knockout mice are 
protected from high-fat diet-induced insulin resistance. Endocrinology, 151 (10), 
4678–4687. 
Bailey, C. J., Path, M. R. C., and Turner, R. C., 1996. Metformin. The New England 
Journal of Medicine, 334 (9), 547–579. 
Bando, H., 2005. Phosphorylation of the 6-Phosphofructo-2-Kinase/Fructose 2,6-
Bisphosphatase/PFKFB3 Family of Glycolytic Regulators in Human Cancer. 
Clinical Cancer Research, 11 (16), 5784–5792. 
Bechtold, D. A., Sidibe, A., Saer, B. R. C., Li, J., Hand, L. E., Ivanova, E. A., Darras, 
V. M., Dam, J., Jockers, R., Luckman, S. M., and Loudon, A. S. I., 2012. A role 
for the melatonin-related receptor GPR50 in leptin signaling, adaptive 
thermogenesis, and torpor. Current Biology, 22 (1), 70–77. 
Becker-Zimmermann, K., Berger, M., Berchtold, P., Gries, F. A., Herberg, L., and 
Schwenen, M., 1982. Treadmill training improves intravenous glucose tolerance 
and insulin sensitivity in fatty Zucker rats. Diabetologia, 22 (6), 468–474. 
van Bennekum, A. M., Wei, S., Gamble, M. V, Vogel, S., Piantedosi, R., Gottesman, 
M., Episkopou, V., and Blaner, W. S., 2001. Biochemical Basis for Depressed 
Serum Retinol Levels in Transthyretin-deficient Mice. The Journal of Biological 
Chemistry, 276 (2), 1107–1113. 
Berridge, M. J. and Irvine, R. F., 1984. Inositol trisphosphate, a novel second messenger 
Chapter 6: Bibliography 
 
  
218 
in cellular signal transduction. Nature, 312 (5992), 315–321. 
Berry, D. C. and Noy, N., 2012. Signaling by vitamin A and retinol-binding protein in 
regulation of insulin responses and lipid homeostasis. Biochimica et Biophysica 
Acta, 1821 (1), 168–76. 
Bhattacharya, S., Lam, A. R., Li, H., Balaraman, G., Niesen, M. J. M., and Vaidehi, N., 
2013. Critical Analysis of the Successes and Failures of Homology Models of G-
protein coupled receptors: Homology modeling of GPCRs: Success and failures. 
Proteins, 81 (5), 729–739. 
Biovia Software Inc., Discovery Studio Modeling Environment, Release 2.5, San 
Diego: Accelrys Software Inc., 2007. 
Birnbaumer, L., Abramowitz, J., and Brown, A. M., 1990. Receptor-effector coupling 
by G proteins. Biochimica et Biophysica Acta, 1031 (2), 163–224. 
Bjursell, M., Gerdin, A. K., Jönsson, M., Surve, V. V., Svensson, L., Huang, X. F., 
Törnell, J., and Bohlooly-Y, M., 2006a. G protein-coupled receptor 12 deficiency 
results in dyslipidemia and obesity in mice. Biochemical and Biophysical Research 
Communications, 348 (2), 359–366. 
Bjursell, M., Gerdin, A., Ploj, K., Svensson, D., Svensson, L., Oscarsson, J., Snaith, M., 
Törnell, J., and Bohlooly-Y, M., 2006b. Malanin-Concentrating Hormone 
Receptor 1 deficiency Increases Insulin Sensitivity in Obese Leptin Defieient Mice 
Without Affecting Body Weight. Diabetes, 55 (3), 725–733. 
Bouvier, M., 2013. Unraveling the structural basis of GPCR activation and inactivation. 
Nature Structural and Molecular Biology, 20 (5), 539–41. 
Bresnick, J. N., Skynner, H. A., Chapman, K. L., Jack, A. D., Zamiara, E., Negulescu, 
Chapter 6: Bibliography 
 
  
219 
P., Beaumont, K., Patel, S., and McAllister, G., 2003. Identification of signal 
transduction pathways used by orphan G protein-coupled receptors. Assay Drug 
Dev Technol, 1 (2), 239–249. 
Bridges, H. R., Jones, A. J. Y., Pollak, M. N., and Hirst, J., 2014. Effects of metformin 
and other biguanides on oxidative phosphorylation in mitochondria. The 
Biochemical Journal, 487, 475–487. 
Bultot, L., Guigas, B., Von Wilamowitz-Moellendorff, A., Maisin, L., Vertommen, D., 
Hussain, N., Beullens, M., Guinovart, J. J., Foretz, M., Viollet, B., Sakamoto, K., 
Hue, L., and Rider, M. H., 2012. AMP-activated protein kinase phosphorylates and 
inactivates liver glycogen synthase. The Biochemical Journal, 443 (1), 193–203. 
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., and Shoelson, S. 
E., 2005. Local and systemic insulin resistance resulting from hepatic activation of 
IKK-β and NF-κB. Nature Medicine, 11 (2), 183–90. 
Cai, T. Q., Ren, N., Jin, L., Cheng, K., Kash, S., Chen, R., Wright, S. D., Taggart, A. K. 
P., and Waters, M. G., 2008. Role of GPR81 in lactate-mediated reduction of 
adipose lipolysis. Biochemical and Biophysical Research Communications, 377 
(3), 987–991. 
Campos-Sandoval, J. A., Redondo, C., Kinsella, G. K., Pal, A., Jones, G., Eyre, G. S., 
Hirst, S. C., and Findlay, J. B. C., 2011. Fenretinide derivatives act as disrupters of 
interactions of serum retinol binding protein (sRBP) with transthyretin and the 
sRBP receptor. Journal of Medicinal Chemistry, 54, 4378–4387. 
Carbone, F., La Rocca, C., and Matarese, G., 2012. Immunological functions of leptin 
and adiponectin. Biochimie, 94 (10), 2082–2088. 
Carey,  A. L., Steinberg, G. R., Macaulay, S. L., Thomas, W. G., Holmes,  A. G., 
Chapter 6: Bibliography 
 
  
220 
Ramm, G., Prelovsek, O., Hohnen-Behrens, C., Watt, M. J., James, D. E., Kemp, 
B. E., Pedersen, B. K., and Febbraio, M. A., 2006. Interleukin-6 Increases Insulin-
Stimulated Glucose Disposal in Humans and Glucose Uptake and Fatty Acid 
Oxidation In Vitro via AMP-Activated Protein Kinase. Diabetes, 55 (10), 2688–
2697. 
Carling, D. and Viollet, B., 2015. Beyond Energy Homeostasis: the Expanding Role of 
AMP-Activated Protein Kinase in Regulating Metabolism. Cell Metabolism, 21 
(6), 799–804. 
Chakraborty, A., Koldobskiy, M. A., Bello, N. T., Maxwell, M., Potter, J. J., Juluri, K. 
R., Maag, D., Kim, S., Huang, A. S., Dailey, M. J., Saleh, M., Snowman, A. M., 
Moran, T. H., Mezey, E., and Snyder, S. H., 2010. Inositol pyrophosphates inhibit 
Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell, 143 (6), 
897–910. 
Chalmers, D. T. and Behan, D. P., 2002. The use of constitutively active GPCRs in drug 
discovery and functional genomics. Nature Reviews Drug Discovery, 1 (8), 599–
608. 
Chamorro, S., Della-Zuana, O., Fauchere, J. L., Feletou, M., Galizzi, J. P., and Levens, 
N., 2002. Appetite suppression based on selective inhibition of NPY receptors. 
International Journal of Obesity, 26 (3), 281–298. 
Chan, A. S. L. and Wong, Y. H., 2004. Gβγ signaling and Ca2+ mobilization co-operate 
synergistically in a Sos and Rac-dependent manner in the activation of JNK by Gq-
coupled receptors. Cellular Signalling, 16 (7), 823–836. 
Chan, T. O., Zhang, J., Rodeck, U., Pascal, J. M., Armen, R. S., Spring, M., Dumitru, C. 
D., Myers, V., Li, X., Cheung, J. Y., and Feldman, A. M., 2011. Resistance of Akt 
Chapter 6: Bibliography 
 
  
221 
kinases to dephosphorylation through ATP-dependent conformational plasticity. 
Proceedings of the National Academy of Sciences of the United States of America, 
108 (46), E1120–E1127. 
Chappell, J. B. and Hansford, R. G., 1972. Preparation of mitochondria from animal 
tissues and yeasts. Subcellular Components: Preparation and Fractionation, 77–
91. 
Chawla, A., Nguyen, K. D., and Goh, Y. P. S., 2012. Macrophage-mediated 
inflammation in metabolic disease. Nature Reviews Immunology, 11 (11), 738. 
Chen, D., Liu, X., Zhang, W., and Shi, Y., 2012. Targeted inactivation of GPR26 leads 
to hyperphagia and adiposity by activating AMPK in the hypothalamus. PLoS 
ONE, 7 (7), 1–10. 
Chen, L., Magliano, D. J., and Zimmet, P. Z., 2012. The worldwide epidemiology of 
type 2 diabetes mellitus-present and future perspectives. Nature Reviews 
Endocrinology, 8 (4), 228–236. 
Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G. F., Thian, F. S., 
Kobilka, T. S., Choi, H. J., Kuhn, P., Weis, W. I., Kobilka, B. K., and Stevens, R. 
C., 2007. High-resolution crystal structure of an engineered human β2-adrenergic 
G protein-coupled receptor. Science, 318 (5854), 1258–1265. 
Chidiac, P., Hebert, T. E., Valiquette, M., Dennis, M., and Bouvier, M., 1994. Inverse 
agonist activity of β-adrenergic antagonists. Molecular Pharmacology, 45, 490–
499. 
Chikumi, H., Vázquez-Prado, J., Servitja, J. M., Miyazaki, H., and Silvio Gutkind, J., 
2002. Potent activation of RhoA by Gαq and Gq-coupled receptors. The Journal of 
Biological Chemistry, 277 (30), 27130–27134. 
Chapter 6: Bibliography 
 
  
222 
Chruscinski, A. J., Rohrer, D. K., Schauble, E., Desai, K. H., Bernstein, D., and 
Kobilka, B. K., 1999. Targeted disruption of the β2 adrenergic receptor gene. The 
Journal of Biological Chemistry, 274 (24), 16694–16700. 
Chung, S., Funakoshi, T., and Civelli, O., 2008. Orphan GPCR research. British 
Journal of Pharmacology, 153, S339–S346. 
Codoñer-Franch, P. and Alonso-Iglesias, E., 2015. Resistin: Insulin resistance to 
malignancy. Clinica Chimica Acta, 438, 46–54. 
Colca, J. R., McDonald, W. G., Cavey, G. S., Cole, S. L., Holewa, D. D., Brightwell-
Conrad, A. S., Wolfe, C. L., Wheeler, J. S., Coulter, K. R., Kilkuskie, P. M., 
Gracheva, E., Korshunova, Y., Trusgnich, M., Karr, R., Wiley, S. E., Divakaruni, 
A. S., Murphy, A. N., Vigueira, P. A., Finck, B. N., and Kletzien, R. F., 2013. 
Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers 
(mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier 
Proteins. PLoS ONE, 8 (5), e61551. 
Colca, J. R., McDonald, W. G., and Kletzien, R. F., 2014. Mitochondrial target of 
thiazolidinediones. Diabetes, Obesity and Metabolism, 16 (11), 1048–1054. 
Contreras-Alcantara, S., Baba, K., and Tosini, G., 2010. Removal of melatonin receptor 
type 1 induces insulin resistance in the mouse. Obesity, 18 (9), 1861–1863. 
Cordonier, E., Jarecke, S., Hollinger, F., and Zempleni, J., 2015. Inhibition of acetyl-
CoA carboxylase activity prevents adipocyte differentiation in 3T3-L1 cells. The 
FASEB Journal, 29, 750-753. 
Corton, J. M., Gillespie, J. G., and Hardie, D. G., 1994. Role of the AMP-activated 
protein kinase in the cellular stress response. Current Biology, 4 (4), 315–324. 
Chapter 6: Bibliography 
 
  
223 
Corton, J. M., Gillespie, J. G., Hawley, S. A., and Hardie, D. G., 1995. 5-
aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating 
AMP-activated protein kinase in intact cells? European Journal of Biochemistry, 
229 (2), 558–565. 
Coughlan, K. A., Valentine, R. J., Ruderman, N. B., and Saha, A. K., 2014. AMPK 
activation: a therapeutic target for type 2 diabetes? Diabetes, Metabolic Syndrome 
and Obesity : Targets and Therapy, 7, 241–53. 
Daaka, Y., Pitcher, J. A., Richardson, M., Stoffel, R. H., Robishaw, J. D., and 
Lefkowitz, R. J., 1997. Receptor and G βγ isoform-specific interactions with G 
protein-coupled receptor kinases. Proceedings of the National Academy of 
Sciences of the United States of America, 94 (6), 2180–2185. 
Davies, S. P., Helps, N. R., Cohen, P. T. W., and Hardie, D. G., 1995. 5’-AMP inhibits 
dephosphorylation, as well as promoting phosphorylation, of the AMP-activated 
protein kinase. Studies using bacterially expressed human protein phosphatase-2C-
α and native bovine protein phosphatase-2Ac. FEBS Letters, 377 (3), 421–425. 
Defronzo, R. A., 2011. Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the 
Treatment of Type 2 Diabetes. Diabetes, 34, 789–794. 
Degli Esposti, M., 1998. Inhibitors of NADH-ubiquinone reductase: An overview. 
Biochimica et Biophysica Acta, 1364 (2), 222–235. 
Deveaux, V., Cadoudal, T., Ichigotani, Y., Teixeira-Clerc, F., Louvet, A., Manin, S., 
Nhieu, J. T. Van, Belot, M. P., Zimmer, A., Even, P., Cani, P. D., Knauf, C., 
Burcelin, R., Bertola, A., Le Marchand-Brustel, Y., Gual, P., Mallat, A., and 
Lotersztajn, S., 2009. Cannabinoid CB2 receptor potentiates obesity-associated 
inflammation, insulin resistance and hepatic steatosis. PLoS ONE, 4 (6). 
Chapter 6: Bibliography 
 
  
224 
Díaz-Delfín, J., Morales, M., and Caelles, C., 2007. Hypoglycemic Action of 
Thiazolidinediones/Peroxisome Proliferator–Activated Receptor γ by Inhibition of 
the c-Jun NH2-Terminal Kinase Pathway. Diabetes, 56, 1865–1871. 
Doménech, E., Maestre, C., Esteban-martínez, L., Partida, D., Pascual, R., Fernández-
miranda, G., Seco, E., Campos-Olivas, R., Pérez, M., Megias, D., Allen, K., 
López, M., Saha, A. K., Velasco, G., Rial, E., and Méndez, R., 2015. AMPK and 
PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic 
arrest. Nature Cell Biology, 17 (10), 1304. 
Donath, M. Y., 2014. Targeting inflammation in the treatment of type 2 diabetes: time 
to start. Nature Reviews Drug Discovery, 13 (6), 465–476. 
Dong, X., Zhao, Y., Huang, X., Lin, K., Chen, J., Wei, E., Liu, T., and Hu, Y., 2013. 
Structure-based drug design using GPCR homology modeling: toward the 
discovery of novel selective CysLT2 antagonists. European Journal of Medicinal 
Chemistry, 62, 754–763. 
Donnan, P. T., MacDonald, T. M., and Morris,  A. D., 2002. Adherence to prescribed 
oral hypoglycaemic medication in a population of patients with Type 2 diabetes: A 
retrospective cohort study. Diabetic Medicine, 19 (4), 279–284. 
Downes, G. B. and Gautam, N., 1999. The G protein subunit gene families. Genomics, 
62 (3), 544–552. 
Efremov, R. G., Baradaran, R., and Sazanov, L. A., 2010. The architecture of 
respiratory complex I. Nature, 465 (7297), 441–445. 
Ehlting, C., Lai, W. S., Schaper, F., Brenndorfer, E. D., Matthes, R. J., Heinrich, P. C., 
Ludwig, S., Blackshear, P. J., Gaestel, M., Haussinger, D., and Bode, J. G., 2007. 
Regulation of suppressor of cytokine signaling 3 (SOCS3) mRNA stability by 
Chapter 6: Bibliography 
 
  
225 
TNF-alpha involves activation of the MKK6/p38MAPK/MK2 cascade. Journal of 
Immunology, 178 (5), 2813–2826. 
Ejaz, A., Wu, D., Kwan, P., and Meydani, M., 2009. Curcumin inhibits adipogenesis in 
3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. The Journal of 
Nutrition, 139 (5), 919–925. 
Emanuela, F., Grazia, M., Marco, D. R., Maria Paola, L., Giorgio, F., and Marco, B., 
2012. Inflammation as a Link between Obesity and Metabolic Syndrome. Journal 
of Nutrition and Metabolism, 2012, 476380. 
Evers, A. and Klabunde, T., 2005. Structure-based drug discovery using GPCR 
homology modeling: Successful virtual screening for antagonists of the α1A 
adrenergic receptor. Journal of Medicinal Chemistry, 48 (4), 1088–1097. 
Fanelli, F. and De Benedetti, P. G., 2011. Update 1 of: computational modeling 
approaches to structure-function analysis of G protein-coupled receptors. Chemical 
Reviews, 111 (12), PR438–535. 
Fernández-Vizarra, E., Tiranti, V., and Zeviani, M., 2009. Assembly of the oxidative 
phosphorylation system in humans: What we have learned by studying its defects. 
Biochimica et Biophysica Acta, 1793 (1), 200–211. 
Fiser, A. and Sali, A., 2003a. Modeller: generation and refinement of homology-based 
protein structure models. Methods in Enzymology, 374, 461–491. 
Fiser, A. and Sali, A., 2003b. ModLoop: automated modeling of loops in protein 
structures. Bioinformatics, 19 (18), 2500–2501. 
Flohr, S., Kurz, M., Kostenis, E., Brkovich, A., Fournier, A., and Klabunde, T., 2002. 
Identification of nonpeptidic urotensin II receptor antagonists by virtual screening 
Chapter 6: Bibliography 
 
  
226 
based on a pharmacophore model derived from structure-activity relationships and 
nuclear magnetic resonance studies on urotensin II. Journal of Medicinal 
Chemistry, 45 (9), 1799–1805. 
Fogh, B. S., Multhaupt, H. A. B., and Couchman, J. R., 2014. Protein Kinase C, Focal 
Adhesions and the Regulation of Cell Migration. Journal of Histochemistry and 
Cytochemistry, 62 (3), 172–184. 
FRED. 2.2.4 ed., www.eyesopen.com, OpenEye Scientific Software, Santa Fe, NM, 
USA. 
Fredriksson, R., Lagerström, M. C., Lundin, L. G., and Schiöth, H. B., 2003. The G-
protein-coupled receptors in the human genome form five main families. 
Phylogenetic analysis, paralogon groups, and fingerprints. Molecular 
Pharmacology, 63 (6), 1256–1272. 
Fredriksson, R. and Schio, H. B., 2005. The Repertoire of G-Protein–Coupled 
Receptors in Fully Sequenced Genomes. Molecular Pharmacology, 67 (5), 1414–
1425. 
Fröjdö, S., Vidal, H., and Pirola, L., 2009. Alterations of insulin signaling in type 2 
diabetes: A review of the current evidence from humans. Biochimica et Biophysica 
Acta, 1792 (2), 83–92. 
Gage, D., 2012. Weight loss/maintenance as an effective tool for controlling type 2 
diabetes: novel methodology to sustain weight reduction. Diabetes/Metabolism 
Research and Reviews, 28, 214–218. 
Gao, Z., Hwang, D., Bataille, F., Lefevre, M., York, D., Quon, M. J., and Ye, J., 2002. 
Serine Phosphorylation of Insulin Receptor Substrate 1 by Inhibitor B Kinase 
Complex. The Journal of Biological Chemistry, 277 (50), 48115–48121. 
Chapter 6: Bibliography 
 
  
227 
Garber,  A. J., 2011. Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A 
review of their efficacy and tolerability. Diabetes Care, 34, S279–S284. 
García-Pérez, L. E., Alvarez, M., Dilla, T., Gil-Guillén, V., and Orozco-Beltrán, D., 
2013. Adherence to therapies in patients with type 2 diabetes. Diabetes Therapy, 4 
(2), 175–94. 
Gardner, J., Wu, S., Ling, L., Danao, J., Li, Y., Yeh, W. C., Tian, H., and Baribault, H., 
2012. G-protein-coupled receptor GPR21 knockout mice display improved glucose 
tolerance and increased insulin response. Biochemical and Biophysical Research 
Communications, 418 (1), 1–5. 
Ge, H., Li, X., Weiszmann, J., Wang, P., Baribault, H., Chen, J. L., Tian, H., and Li, Y., 
2008. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition 
of lipolysis and suppression of plasma free fatty acids. Endocrinology, 149 (9), 
4519–4526. 
Genova, M. L. and Lenaz, G., 2014. Functional role of mitochondrial respiratory 
supercomplexes. Biochimica et Biophysica Acta, 1837 (4), 427–443. 
Geraghty, K. M., Chen, S., Harthill, J. E., Ibrahim, A. F., Toth, R., Morrice, N. A., 
Vandermoere, F., Moorhead, G. B., Hardie, D. G., and MacKintosh, C., 2007. 
Regulation of multisite phosphorylation and 14-3-3 binding of AS160 in response 
to IGF-1, EGF, PMA and AICAR. The Biochemical Journal, 407 (2), 231–41. 
Gerich, J. E., 1993. Control of glycaemia. Bailliere’s Clinical Endocrinology and 
Metabolism, 7 (3), 551–586. 
Giri, S., Rattan, R., Haq, E., Khan, M., Yasmin, R., Won, J., Key, L., Singh, A. K., and 
Singh, I., 2006. AICAR inhibits adipocyte differentiation in 3T3L1 and restores 
metabolic alterations in diet-induced obesity mice model. Nutrition and 
Chapter 6: Bibliography 
 
  
228 
Metabolism, 3, 31. 
Goldsmith, Z. G., and Dhanasekaran, D. N., 2007. G Protein regulation of MAPK                            
.       networks. Oncogene, 26 (22), 3122–3142. 
Gonzalez, C. D., Lee, M. S., Marchetti, P., Pietropaolo, M., Towns, R., Vaccaro, M. I., 
Watada, H., and Wiley, J. W., 2011. The emerging role of autophagy in the 
pathophysiology of diabetes mellitus. Autophagy, 7 (1), 2–11. 
Goodman D.S., 1984, Overview of current knowledge of metabolism of vitamin A and 
carotenoids, The Journal of the National Cancer Institute, 73 (6), 1375-1379.  
Goodman Jr, O. B., Krupnick, J. G., Santini, F., Gurevich, V. V, Penn, R., Gagnon, A. 
W., Keen, J. H., and Benovic, J. L., 1996. β-arrestin acts as a clathrin adaptor in 
endocytosis of the β2-adrenergic receptor. Nature, 383, 447–450. 
Graham, T. E., Yang, Q., Blurt, M., Hammarstedt, A., Ciaraldi, T. P., Henry, R. R., 
Wason, C. J., Oberbach, A., Jansson, P. A., Smith, U., and Kahn, B. B., 2006. 
Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic 
Subjects. The New England Journal of Medicine, 354, 2552–2563. 
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, 
D. S., Turk, B. E., and Shaw, R. J., 2008. AMPK Phosphorylation of Raptor 
Mediates a Metabolic Checkpoint. Molecular Cell, 30 (2), 214–226. 
Hall, A., 1998. Rho GTPases and the actin cytoskeleton. Science, 279 (5350), 509–514. 
Hamm, H. E., 1998. The Many Faces of G Protein Signaling. The Journal of Biological 
Chemistry, 273 (21), 669–672. 
Han, M. S., Jung, D. Y., Morel, C., Lakhani, S. A., Kim, J. K., Flavell, R. A., and 
Davis, R. J., 2013. JNK Expression by Macrophages Promotes Obesity-induced 
Chapter 6: Bibliography 
 
  
229 
Insulin Resistance and Inflammation. Science, 339 (7405), 109–113. 
Hanefeld, M., Schell, E., Gouni-Berthold, Ioanna Melichar, M., Vesela, I., Johnson, D., 
Miao, S., Sullivan, T. J., Jaen, J. C., Schall, T. J., and Pirow, B., 2012. Orally-
Administered Chemokine Receptor CCR2 Antagonist CCX140-B in Type 2 
Diabetes: A Pilot Double-Blind, Randomized Clinical Trial. Diabetes and 
Metabolism, 3 (225), doi: 10.4172/2155–6156.1000225. 
Hansen, M., Sonne, D. P., and Knop, F. K., 2014. Bile Acid Sequestrants: Glucose-
Lowering Mechanisms and Efficacy in Type 2 Diabetes. Current Diabetes 
Reports, 14 (5), 482. 
Hardie, D. G., Carling, D., and Sim, A. T. R., 1989. The AMP-activated protein kinase: 
a multisubstrate regulator of lipid metabolism. Trends in Biochemical Sciences, 14 
(1), 20–23. 
Hardie, D. G., Carling, D., and Carlson, M., 1998. The AMP-activated/SNF1 protein 
kinase subfamily: metabolic sensors of the eukaryotic cell? Annual Review of 
Biochemistry, 67, 821–55. 
Hardie, D. G., 2011. AMP-activated protein kinase — an energy sensor that regulates 
all aspects of cell function. Genes and Development, 25, 1895–1908. 
Hardie, D. G., Ross, F. A., and Hawley, S. A., 2012. AMPK: a nutrient and energy 
sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology, 
13 (4), 251–262. 
Hart, M. J., Jiang, X., Kozasa, T., Roscoe, W., Singer, W. D., Gilman, A. G., Sternweis, 
P. C., and Bollag, G., 1998. Direct stimulation of the guanine nucleotide exchange 
activity of p115 RhoGEF by Gα13. Science, 280 (5372), 2112–2114. 
Chapter 6: Bibliography 
 
  
230 
Hawkins, P. C. D., Skillman,  A. G., Warren, G. L., Ellingson, B. A., and Stahl, M. T., 
2010. Conformer generation with OMEGA: Algorithm and validation using high 
quality structures from the protein databank and cambridge structural database. 
Journal of Chemical Information and Modeling, 50 (4), 572–584. 
Hawley, S. A., Davison, M., Woods, A., Davies, S. P., Beri, R. K., Carling, D., and 
Hardie, D. G., 1996. Characterization of the AMP-activated Protein Kinase Kinase 
from Rat Liver and Identification of Threonine 172 as the Major Site at Which It 
Phosphorylates AMP-activated Protein Kinase. The Journal of Biological 
Chemistry, 271 (44), 27879–27887. 
Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, 
D. R., and Hardie, D. G., 2003. Complexes between the LKB1 tumor suppressor, 
STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-
activated protein kinase cascade. Journal of Biology, 2 (4), 28. 
Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., 
Frenguelli, B. G., and Hardie, D. G., 2005. Calmodulin-dependent protein kinase 
kinase-β is an alternative upstream kinase for AMP-activated protein kinase. Cell 
Metabolism, 2 (1), 9–19. 
Hawley, S. A., Fullerton, M. D., Ross, F. A., Schertzer, J. D., Chevtzoff, C., Walker, K. 
J., Peggie, M. W., Zibrova, D., Green, K. A., Mustard, K. J., Kemp, B. E., 
Sakamoto, K., Steinberg, G. R., and Hardie, D. G., 2012. The Ancient Drug 
Salicylate Directly Activates AMP-Activated Protein Kinase. Science, 336, 918–
922. 
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., and Roth, J. D., 2015. Amylin: 
Pharmacology, Physiology, and Clinical Potential. Pharmacological Reviews, 67 
Chapter 6: Bibliography 
 
  
231 
(3), 564–600. 
Heinrich, P. C., Behrmann, I., Müller-Newen, G., Schaper, F., and Graeve, L., 1998. 
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. The 
Biochemical Journal, 334 (2), 297–314. 
Heller, J., 1975. Interactions of plasma retinol-binding protein with its receptor. Specific 
binding of bovine and human retinol-binding protein to pigment epithelium cells 
from bovine eyes. The Journal of Biological Chemistry, 250 (10), 3613-3619. 
 
Hemi, R., Yochananov, Y., Barhod, E., Kasher-Meron, M., Karasik,  A., Tirosh,  A., 
and Kanety, H., 2011. p38 Mitogen-Activated Protein Kinase-Dependent 
Transactivation of ErbB Receptor Family: A Novel Common Mechanism for 
Stress-Induced IRS-1 Serine Phosphorylation and Insulin Resistance. Diabetes, 60 
(4), 1134–1145. 
Henriksen, E. J., 2002. Exercise Effects of Muscle Insulin Signaling and Action Invited 
Review: Effects of acute exercise and exercise training on insulin resistance. 
Journal of Applied Physiology, 93, 788–796. 
Higashijima, T., Ferguson, K. M., Sternweis, P. C., Smigel, M. D., and Gilman,  A. G., 
1987. Effects of Mg2+ and the βγ-subunit complex on the interactions of guanine 
nucleotides with G proteins. The Journal of Biological Chemistry, 262 (2), 762–
766. 
Hinke, S. A., Martens, G. A., Cai, Y., Finsi, J., Heimberg, H., Pipeleers, D., and Van de 
Casteele, M., 2007. Methyl succinate antagonises biguanide-induced AMPK-
activation and death of pancreatic β-cells through restoration of mitochondrial 
electron transfer. British Journal of Pharmacology, 150 (8), 1031–1043. 
Chapter 6: Bibliography 
 
  
232 
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, 
M., and Hotamisligil, G. S., 2002. A central role for JNK in obesity and insulin 
resistance. Nature, 420 (6913), 333–336. 
Holst, B., Egerod, K. L., Jin, C., Petersen, P. S., Østergaard, M. V., Hald, J., Sprinkel,  
A. M. E., Størling, J., Mandrup-Poulsen, T., Holst, J. J., Thams, P., Ørskov, C., 
Wierup, N., Sundler, F., Madsen, O. D., and Schwartz, T. W., 2009. G protein-
coupled receptor 39 deficiency is associated with pancreatic islet dysfunction. 
Endocrinology, 150 (6), 2577–2585. 
Hood, D. A., 2009. Mechanisms of exercise-induced mitochondrial biogenesis in 
skeletal muscle. Applied Physiology, Nutrition, and Metabolism, 34 (3), 465–472. 
Hoppe, S., Bierhoff, H., Cado, I., Weber, A., Tiebe, M., Grummt, I., and Voit, R., 2009. 
AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply. 
Proceedings of the National Academy of Sciences of the United States of America, 
106 (42), 17781–17786. 
Horman, S., Vertommen, D., Heath, R., Neumann, D., Mouton, V., Woods, A., 
Schlattner, U., Wallimann, T., Carling, D., Hue, L., and Rider, M. H., 2006. Insulin 
antagonizes ischemia-induced Thr 172 phosphorylation of AMP-activated protein 
kinase α-subunits in heart via hierarchical phosphorylation of Ser 485/491. The 
Journal of Biological Chemistry, 281 (9), 5335–5340. 
Hotamisligil, G. S. and Spiegelman, B. M., 1994. Tumor necrosis factor α: a key 
component of the obesity-diabetes link. Diabetes, 43 (11), 1271–1278. 
Huang, C., Jacobson, M., and Schaller, M. D., 2004. MAP Kinases and cell migration. 
Journal of Cell Science, 117 (20), 4619-4628. 
Hubbard, S. R., 2013. The insulin receptor: Both a prototypical and atypical receptor 
Chapter 6: Bibliography 
 
  
233 
tyrosine kinase. Cold Spring Harbor Perspectives in Biology, 5 (3), a008946. 
Hurley, R. L., Barre, L. K., Wood, S. D., Anderson, K. A., Kemp, B. E., Means, A. R., 
and Witters, L. A., 2006. Regulation of AMP-activated protein kinase by multisite 
phosphorylation in response to agents that elevate cellular cAMP. The Journal of 
Biological Chemistry, 281 (48), 36662–36672. 
Huszar, D., Lynch, C. A., Fairchild-Huntress, V., Dunmore, J. H., Fang, Q., 
Berkemeier, L. R., Gu, W., Kesterson, R. A., Boston, B. A., Cone, R. D., Smith, F. 
J., Campfield, L. A., Burn, P., and Lee, F., 1997. Targeted disruption of the 
melanocortin-4 receptor results in obesity in mice. Cell, 88 (1), 131–141. 
Hutagalung, A. H. and Novick, P. J., 2011. Role of Rab GTPases in Membrane Traffic 
and Cell Physiology. Physiological Reviews, 91 (1), 119–149. 
Idris, I. and Donnelly, R., 2009. Sodium-glucose co-transporter-2 inhibitors: an 
emerging new class of oral antidiabetic drug. Diabetes, Obesity and Metabolism, 
11 (2), 79–88. 
Imamura, T., Vollenweider, P., Egawa, K., Clodi, M., Ishibashi, K., Nakashima, N., 
Ugi, S., Adams, J. W., Brown, J. H., and Olefsky, J. M., 1999. G alpha-q/11 
protein plays a key role in insulin-induced glucose transport in 3T3-L1 adipocytes. 
Molecular and Cellular Biology, 19 (10), 6765–6774. 
Inoki, K., Zhu, T., and Guan, K. L., 2003. TSC2 mediates cellular energy response to 
control cell growth and survival. Cell, 115 (5), 577–590. 
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., 
Peters,  A. L., Tsapas, A., Wender, R., and Matthews, D. R., 2015. Management of 
hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a 
Position statement of the American Diabetes Association (ADA) and the European 
Chapter 6: Bibliography 
 
  
234 
Association for the Study of Diabetes (EASD). Diabetes Care, 38 (6), 140–149. 
Ishii, M., Fei, H., and Friedman, J. M., 2003. Targeted disruption of GPR7, the 
endogenous receptor for neuropeptides B and W, leads to metabolic defects and 
adult-onset obesity. Proceedings of the National Academy of Sciences of the 
United States of America, 100 (18), 10540–10545. 
Isoda, K., Young, J. L., Zirlik, A., MacFarlane, L. A., Tsuboi, N., Gerdes, N., 
Schönbeck, U., and Libby, P., 2006. Metformin inhibits proinflammatory 
responses and nuclear factor-κB in human vascular wall cells. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 26 (3), 611–7. 
Jacobson, K. A., 2013. Structure-Based Approaches to Ligands for G Protein-Coupled 
Adenosine and P2Y Receptors, From Small Molecules to Nanoconjugates. Journal 
of Medicinal Chemistry, 56 (10), 3749–3767. 
Jager, J., Grémeaux, T., Cormont, M., Le Marchand-Brustel, Y., and Tanti, J. F., 2007. 
Interleukin-1β-Induced Insulin Resistance in Adipocytes through Down-
Regulation of Insulin Receptor Substrate-1 Expression. Endocrinology, 148 (1), 
241–251. 
Jäger, S., Handschin, C., St-Pierre, J., and Spiegelman, B. M., 2007. AMP-activated 
protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of 
PGC-1alpha. Proceedings of the National Academy of Sciences of the United 
States of America, 104 (29), 12017–22. 
Jeffrey, K. L., Camps, M., Rommel, C., and Mackay, C. R., 2007. Targeting dual-
specificity phosphatases: manipulating MAP kinase signalling and immune 
responses. Nature Reviews Drug Discovery, 6 (5), 391–403. 
Jenkins, Y., Sun, T. Q., Markovtsov, V., Foretz, M., Li, W., Nguyen, H., Li, Y., Pan, 
Chapter 6: Bibliography 
 
  
235 
A., Uy, G., Gross, L., Baltgalvis, K., Yung, S. L., Gururaja, T., Kinoshita, T., 
Owyang, A., Smith, I. J., McCaughey, K., White, K., Godinez, G., Alcantara, R., 
Choy, C., Ren, H., Basile, R., Sweeny, D. J., Xu, X., Issakani, S. D., Carroll, D. C., 
Goff, D. A., Shaw, S. J., Singh, R., Boros, L. G., Laplante, M. A., Marcotte, B., 
Kohen, R., Viollet, B., Marette, A., Payan, D. G., Kinsella, T. M., and Hitoshi, Y., 
2013. AMPK activation through mitochondrial regulation results in increased 
substrate oxidation and improved metabolic parameters in models of diabetes. 
PLoS ONE, 8 (12), 1–19. 
Jones, G. E., 2000. Cellular signaling in macrophage migration and chemotaxis. Journal 
of Leukocyte Biology, 68 (5), 593–602. 
Jorgensen, S. B., O’Neill, H. M., Sylow, L., Honeyman, J., Hewitt, K. A., Palanivel, R., 
Fullerton, M. D., Oberg, L., Balendran,  A., Galic, S., van der Poel, C., Trounce, I. 
A., Lynch, G. S., Schertzer, J. D., and Steinberg, G. R., 2013. Deletion of Skeletal 
Muscle SOCS3 Prevents Insulin Resistance in Obesity. Diabetes, 62 (1), 56–64. 
Kahn, B. B., Alquier, T., Carling, D., and Hardie, D. G., 2005. AMP-activated protein 
kinase: ancient energy gauge provides clues to modern understanding of 
metabolism. Cell Metabolism, 1 (1), 15–25. 
Kahn, S. E., Hull, R. L., and Utzschneider, K. M., 2006. Mechanisms linking obesity to 
insulin resistance and type 2 diabetes. Nature, 444 (7121), 840–6. 
Kamei, N., Tobe, K., Suzuki, R., Ohsugi, M., Watanabe, T., Kubota, N., Ohtsuka-
Kowatari, N., Kumagai, K., Sakamoto, K., Kobayashi, M., Yamauchi, T., Ueki, K., 
Oishi, Y., Nishimura, S., Manabe, I., Hashimoto, H., Ohnishi, Y., Ogata, H., 
Tokuyama, K., Tsunoda, M., Ide, T., Murakami, K., Nagai, R., and Kadowaki, T., 
2006. Overexpression of monocyte chemoattractant protein-1 in adipose tissues 
Chapter 6: Bibliography 
 
  
236 
causes macrophage recruitment and insulin resistance. The Journal of Biological 
Chemistry, 281 (36), 26602–26614. 
Kanai, M., Raz, A., and Goodman, D. S., 1968. Retinol-binding protein: the transport 
protein for vitamin A in human plasma. The Journal of Clinical Investigation, 47 
(9), 2025–2044. 
Kanazawa, I., Yamaguchi, T., Yano, S., Yamauchi, M., and Sugimoto, T., 2008. 
Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-
E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. 
Biochemical and Biophysical Research Communications, 375 (3), 414–419. 
Kanazawa, I., Yamaguchi, T., Yano, S., Yamauchi, M., and Sugimoto, T., 2009. 
Activation of AMP kinase and inhibition of Rho kinase induce the mineralization 
of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. 
The American Journal of Physiology Endocrinology and Metabolism, 296 (1), 
E139–E146. 
Kandadi, M. R., Rajanna, P. K., Unnikrishnan, M. K., Boddu, S. P., Hua, Y., Li, J., Du, 
M., Ren, J., and Sreejayan, N., 2010. 2-(3,4-Dihydro-2H-pyrrolium-1-yl)-
3oxoindan-1-olate (DHPO), a novel, synthetic small molecule that alleviates 
insulin resistance and lipid abnormalities. Biochemical Pharmacology, 79 (4), 
623–31. 
Kanneganti, T. D. and Dixit, V. D., 2012. Immunological complications of obesity. 
Nature Immunology, 13 (8), 707–712. 
Karik, K., Weissman, D., and Welsh, F. A., 2004. Inhibition of Toll-like Receptor and 
Cytokine Signaling-A Unifying Theme in Ischemic Tolerance. Journal of Cerebral 
Blood Flow and Metabolism, 1288–1304. 
Chapter 6: Bibliography 
 
  
237 
Karlsson, H. K. R., Hällsten, K., Björnholm, M., Tsuchida, H., Chibalin, A. V, 
Virtanen, K. A., Heinonen, O. J., Lönnqvist, F., Nuutila, P., and Zierath, J. R., 
2005. Effects of metformin and rosiglitazone treatment on insulin signaling and 
glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized 
controlled study. Diabetes, 54 (5), 1459–67. 
Kawaguchi, R., Yu, J., Honda, J., Hu, J., Whitelegge, J., Ping, P., Wiita, P., Bok, D., 
and Sun, H., 2007. A Membrane Receptor for Retinol Binding Protein Mediates 
Cellular Uptake of Vitamin A. Science, 820, 820–826. 
Kebede, M., Alquier, T., Latour, M. G., Semache, M., Tremblay, C., and Poitout, V., 
2008. The Fatty Acid Receptor GPR40 Plays a Role in Insulin Secretion In Vivo 
After High-Fat Feeding. Diabetes, 57 (9), 2432–2437. 
Kelly, M., Keller, C., Avilucea, P. R., Keller, P., Luo, Z., Xiang, X., Giralt, M., 
Hidalgo, J., Saha, A. K., Pedersen, B. K., and Ruderman, N. B., 2004. AMPK 
activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. 
Biochemical and Biophysical Research Communications, 320 (2), 449–454. 
Kemp, B. E., 2004. Bateman domains and adenosine derivatives form a binding 
contract. Journal of Clinical Investigation, 113 (2), 182–184. 
Kenakin, T., 2003. Ligand-selective receptor conformations revisited: the promise and 
the problem. Trends in Pharmacological Sciences, 24 (7), 346–354. 
Kern, P. A., Ranganathan, S., Li, C., Wood, L., and Ranganathan, G., 2001. Adipose 
tissue tumor necrosis factor and interleukin-6 expression in human obesity and 
insulin resistance. The American Journal of Physiology Endocrinology and 
Metabolism, 280 (5), 745–751. 
Khan, S. M., Sleno, R., Gora, S., Zylbergold, P., Laverdure, J., Labbé, J., and Miller, G. 
Chapter 6: Bibliography 
 
  
238 
J., 2013. The Expanding Roles of G βγ Subunits in G Protein – Coupled Receptor 
Signaling and Drug Action. Pharmacological Reviews, 545–577. 
Kim, J. H., Park, J. M., Kim, E. K., Lee, J. O., Lee, S. K., Jung, J. H., You, G. Y., Park, 
S. H., Suh, P. G., and Kim, H. S., 2010. Curcumin stimulates glucose uptake 
through AMPK-p38 MAPK pathways in L6 myotube cells. Journal of Cellular 
Physiology, 223 (3), 771–8. 
Kim, M. S., Hur, H. J., Kwon, D. Y., and Hwang, J.T., 2012. Tangeretin stimulates 
glucose uptake via regulation of AMPK signaling pathways in C2C12 myotubes 
and improves glucose tolerance in high-fat diet-induced obese mice. Molecular 
and Cellular Endocrinology, 358 (1), 127–34. 
Kimple, M. E., Neuman, J. C., Linnemann, A. K., and Casey, P. J., 2014. Inhibitory G 
proteins and their receptors: emerging therapeutic targets for obesity and diabetes. 
Experimental and Molecular Medicine, 46 (6), e102. 
Kishimoto, A., Takai, Y., Mori, T., Kikkawa, U., and Nishizuka, Y., 1980. Activation 
of Calcium and Phospholipid-dependent Protein Kinase By Diacylglycerol, Its 
Possiblr Relation to Phosphatidylinositol Turnover. The Journal of Biological 
Chemistry, 255 (11), 2273–2276. 
Klok, M. D., Jakobsdottir, S., and Drent, M. L., 2007. The role of leptin and ghrelin in 
the regulation of food intake and body weight in humans: A Review. Obesity 
Reviews, 8 (1), 21–34. 
Knall, C. and Johnson, G. L., 1998. G-protein regulatory pathways: rocketing into the 
twenty-first century. Journal of Cellular Biochemistry Supplements, 30-31, 137–
146. 
Kobilka, B. K., 2002. Agonist-induced conformational changes in the β2 adrenergic 
Chapter 6: Bibliography 
 
  
239 
receptor. The Journal of Peptide Research, 60 (6), 317–321. 
Kobilka, B. K., 2007. G protein coupled receptor structure and activation. Biochimica et 
Biophysica Acta, 1768 (4), 794–807. 
Koo, S. H., Flechner, L., Qi, L., Zhang, X., Screaton, R. A., Jeffries, S., Hedrick, S., Xu, 
W., Boussouar, F., Brindle, P., Takemori, H., and Montminy, M., 2005. The CREB 
coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature, 437 
(7062), 1109–1111. 
Kopin, A. S., Mathes, W. F., McBride, E. W., Nguyen, M., Al-Haider, W., Schmitz, F., 
Bonner-Weir, S., Kanarek, R., and Beinborn, M., 1999. The cholecystokinin-A 
receptor mediates inhibition of food intake yet is not essential for the maintenance 
of body weight. The Journal of Clinical Investigation, 103 (3), 383–391. 
Kopp, H. P., Krzyzanowska, K., Möhlig, M., Spranger, J., Pfeiffer,  A. F. H., and 
Schernthaner, G., 2005. Effects of marked weight loss on plasma levels of 
adiponectin, markers of chronic subclinical inflammation and insulin resistance in 
morbidly obese women. International Journal of Obesity, 29 (7), 766–771. 
Krakauer, J. C., McKenna, M. J., Buderer, N. F., Rao, D. S., Whitehouse, F. W., and 
Parfitt, A. M., 1995. Bone loss and bone turnover in diabetes. Diabetes, 44 (7), 
775–782. 
Krebs, E. G., 1989. The Albert Lasker Medical Awards. Role of the cyclic AMP-
dependent protein kinase in signal transduction. JAMA, 262 (13), 1815–1818. 
Kufareve, I., Rueda, M., Katritch, V., Stevens, R., and Abagyan, R., 2011. Status of 
GPCR modelling and docking as reflected by community-wide GPCR Dock 2010 
assessment. Structure, 19 (8), 1108–1126. 
Chapter 6: Bibliography 
 
  
240 
Kumar, A., Rajendran, V., Sethumadhavan, R., and Purohit, R., 2013. AKT kinase 
pathway: A leading target in cancer research. The Scientific World Journal, 2013. 
Kumar, N. and Dey, C. S., 2002. Metformin enhances insulin signalling in insulin-
dependent and-independent pathways in insulin resistant muscle cells. British 
Journal of Pharmacology, 137 (3), 329–336. 
Kuri-Harcuch, W., and Green, H., 1978. Adipose conversion of 3T3 cells depends on a 
serum factor. Proceedings of the National Academy of Sciences of the United 
States of America, 75 (12), 6107–6109. 
Kurth-Kraczek, E. J., Hirshman, M. F., Goodyear, L. J., and Winder, W. W., 1999. 5’ 
AMP-activated protein kinase activation causes GLUT4 translocation in skeletal 
muscle. Diabetes, 48 (8), 1667–1671. 
Ladenheim, E. E., Hampton, L. L., Whitney,  A. C., White, W. O., Battey, J. F., and 
Moran, T. H., 2002. Disruptions in feeding and body weight control in gastrin-
releasing peptide receptor deficient mice. The Journal of Endocrinology, 174 (2), 
273–281. 
Laemmli, U. K., 1970. Cleavage of structural proteins during the assembly of the head 
of bacteriophage  T4. Nature, 227 (5259), 680–685. 
Lalau, J. D., Arnouts, P., Sharif, A., and De Broe, M. E., 2015. Metformin and other 
antidiabetic agents in renal failure patients. Kidney International, 87 (2), 308–322. 
Lan, F., Cacicedo, J. M., Ruderman, N., and Ido, Y., 2008. SIRT1 Modulation of the 
Acetylation Status, Cytosolic Localization, and Activity of LKB1: Possible Role in 
AMP-Activated Protein Kinase Activation. The Journal of Biological Chemistry, 
283 (41), 27628–27635. 
Chapter 6: Bibliography 
 
  
241 
Lan, H., Vassileva, G., Corona, A., Liu, L., Baker, H., Golovko, A., Abbondanzo, S. J., 
Hu, W., Yang, S., Ning, Y., Del Vecchio, R. A., Poulet, F., Laverty, M., 
Gustafson, E. L., Hedrick, J. A., and Kowalski, T. J., 2009. GPR119 is required for 
physiological regulation of glucagon-like peptide-1 secretion but not for metabolic 
homeostasis. Journal of Endocrinology, 201 (2), 219–230. 
Lantier, L., Fentz, J., Mounier, R., Leclerc, J., Treebak, J. T., Pehmoller, C., Sanz, N., 
Sakakibara, I., Saint-Amand, E., Rimbaud, S., Maire, P., Marette,  A., Ventura-
Clapier, R., Ferry,  A., Wojtaszewski, J. F. P., Foretz, M., and Viollet, B., 2014. 
AMPK controls exercise endurance, mitochondrial oxidative capacity, and skeletal 
muscle integrity. The FASEB Journal, 28 (7), 3211–3224. 
Lappano, R. and Maggiolini, M., 2011. G protein-coupled receptors: novel targets for 
drug discovery in cancer. Nature Reviews Drug Discovery, 10 (1), 47–60. 
Larance, M., Ramm, G., Stöckli, J., Van Dam, E. M., Winata, S., Wasinger, V., 
Simpson, F., Graham, M., Junutula, J. R., Guilhaus, M., and James, D. E., 2005. 
Characterization of the role of the Rab GTPase-activating protein AS160 in 
insulin-regulated GLUT4 trafficking. The Journal of Biological Chemistry, 280 
(45), 37803–37813. 
Larance, M., Ramm, G., and James, D. E., 2008. The GLUT4 code. Molecular 
Endocrinology, 22 (2), 226–233. 
Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., 
McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., Lopez, R., Thompson, J. 
D., Gibson, T. J., and Higgins, D. G., 2007. Clustal W and Clustal X version 2.0. 
Bioinformatics, 23 (21), 2947–2948. 
Larsson, C., 2006. Protein kinase C and the regulation of the actin cytoskeleton. 
Chapter 6: Bibliography 
 
  
242 
Cellular Signalling, 18 (3), 276–284. 
Laskowski, R., Rullmann, J. A., MacArthur, M., Kaptein, R., and Thornton, J., 1996. 
AQUA and PROCHECK-NMR: Programs for checking the quality of protein 
structures solved by NMR. Journal of Biomolecular NMR, 8 (4), 477–486. 
Latek, D., Pasznik, P., Carlomagno, T., and Filipek, S., 2013. Towards Improved 
Quality of GPCR Models by Usage of Multiple Templates and Profile-Profile 
Comparison. PLoS ONE, 8 (2), 1–10. 
LeBrasseur, N. K., Kelly, M., Tsao, T. S., Farmer, S. R., Saha, A. K., Ruderman, N. B., 
and Tomas, E., 2006. Thiazolidinediones can rapidly activate AMP-activated 
protein kinase in mammalian tissues. The American Journal of Physiology 
Endocrinology and Metabolism, 291 (1), E175–E181. 
Lee, B. and Shao, J., 2012. Adiponectin and lipid metabolism in skeletal muscle. Acta 
Pharmaceutica Sinica B, 2 (4), 335–340. 
Lee, J. O., Lee, S. K., Kim, J. H., Kim, N., You, G. Y., Moon, J. W., Kim, S. J., Park, S. 
H., and Kim, H. S., 2012. Metformin regulates glucose transporter 4 (GLUT4) 
translocation through AMP-activated protein kinase (AMPK)-mediated Cbl/CAP 
signaling in 3T3-L1 preadipocyte cells. The Journal of Biological Chemistry, 287 
(53), 44121–9. 
Lee, M. S., 2014. Role of islet β cell autophagy in the pathogenesis of diabetes. Trends 
in Endocrinology and Metabolism, 25 (12), 620–627. 
Lee, Y. S., Kok-Seng Poh, L., and Loke, K. Y., 2002. A Novel Melanocortin 3 Receptor 
Gene (MC3R) Mutation Associated with Severe Obesity. The Journal of 
Endochrinology and Metabolism, 87, 1423–1426. 
Chapter 6: Bibliography 
 
  
243 
Leff, P., 1995. The two-state model of receptor activation. Trends in Pharmacological 
Sciences, 16 (3), 89–97. 
Leff, P., Scaramellini, C., Law, C., and McKechnie, K., 1997. A three-state receptor 
model of agonist action. Trends in Pharmacological Sciences, 18 (10), 355–362. 
Levert, K. L., Waldrop, G. L., and Stephens, J. M., 2002. A biotin analog inhibits 
acetyl-CoA carboxylase activity and adipogenesis. The Journal of Biological 
Chemistry, 277 (19), 16347–16350. 
Li, J., Spletter, M. L., Johnson, D. A., Wright, L. S., Svendsen, C. N., and Johnson, J. 
A., 2005. Rotenone-induced caspase 9/3-independent and -dependent cell death in 
undifferentiated and differentiated human neural stem cells. Journal of 
Neurochemistry, 92 (3), 462–476. 
Li, P., Oh, D. Y., Bandyopadhyay, G., Lagakos, W. S., Osborn, O., Johnson, A., Chung, 
H., Maris, M., Ofrecio, M., Taguchi, S., Lu, M., and Olefsky, J. M., 2015. LTB4 
causes macrophage-mediated inflammation and directly induces insulin resistance 
in obesity. Nature Medicine, 21 (3), 239–247. 
Li, Y., Xu, S., Mihaylova, M. M., Zheng, B., Hou, X., Jiang, B., Park, O., Luo, Z., 
Lefai, E., Shyy, J. Y. J., Gao, B., Wierzbicki, M., Verbeuren, T. J., Shaw, R. J., 
Cohen, R. A., and Zang, M., 2011. AMPK Phosphorylates and Inhibits SREBP 
Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced 
Insulin-Resistant Mice. Cell Metabolism, 13 (4), 376–388. 
Lin, K., Lin, J., Wu, W. I., Ballard, J., Lee, B. B., Gloor, S. L., Vigers, G. P. A., 
Morales, T. H., Friedman, L. S., Skelton, N., and Brandhuber, B. J., 2012. An 
ATP-site on-off switch that restricts phosphatase accessibility of Akt. Science 
Signaling, 5 (223), ra37. 
Chapter 6: Bibliography 
 
  
244 
Liu, Z. G., Hsu, H., Goeddel, D. V., and Karin, M., 1996. Dissection of TNF receptor 1 
effector functions: JNK activation is not linked to apoptosis while NF-κB 
activation prevents cell death. Cell, 87 (3), 565–576. 
Lohse, M. J., Benovic, J. L., Codina, J., Caron, M. G., and Lefkowitz, R. J., 1990. β-
arrestin: a protein that regulates β-adrenergic receptor function. Science, 248, 
1547–1550. 
Lopez-Castejon, G. and Brough, D., 2011. Understanding the mechanism of IL-1β 
secretion. Cytokine and Growth Factor Reviews, 22 (1), 189–195. 
Lumeng, C. N., Bodzin, J. L., and Saltiel, A. R., 2007. Obesity induces a phenotypic 
switch in adipose tissue macrophage polarization. The Journal of Clinical 
Investigation, 117 (1), 175–184. 
Luo, H. R., Huang, Y. E., Chen, J. C., Saiardi, A., Iijima, M., Ye, K., Huang, Y., 
Nagata, E., Devreotes, P., and Snyder, S. H., 2003. Inositol Pyrophosphates 
Mediate Chemotaxis in Dictyostelium via Pleckstrin Homology Domain-
PtdIns(3,4,5)P3 Interactions. Cell, 114, 559–572. 
Ma, P. and Zemmel, R., 2002. Value of novelty? Nature Reviews Drug Discovery, 1 (8), 
571–572. 
Mackenzie, R. W. and Elliott, B. T., 2014. Akt/PKB activation and insulin signaling: a 
novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes, 
Metabolic Syndrome and Obesity : Targets and Therapy, 7, 55–64. 
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X. M., Braddock, D. T., Albright, R. 
A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., Jurczak, M. J., 
Camporez, J. P., Lee, H. Y., Cline, G. W., Samuel, V. T., Kibbey, R. G., and 
Shulman, G. I., 2014. Metformin suppresses gluconeogenesis by inhibiting 
Chapter 6: Bibliography 
 
  
245 
mitochondrial glycerophosphate dehydrogenase. Nature, 510 (7506), 542–546. 
Marsin,  A. S., Bertrand, L., Rider, M. H., Deprez, J., Beauloye, C., Vincent, M. F., Van 
den Berghe, G., Carling, D., and Hue, L., 2000. Phosphorylation and activation of 
heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. 
Current Biology, 10 (20), 1247–1255. 
Marsin, A. S., Bouzin, C., Bertrand, L., and Hue, L., 2002. The stimulation of 
glycolysis by hypoxia in activated monocytes is mediated by AMP-activated 
protein kinase and inducible 6-phosphofructo-2-kinase. The Journal of Biological 
Chemistry, 277 (34), 30778–30783. 
Martin, D. S. D., Leonard, S., Devine, R., Redondo, C., Kinsella, G. K., Breen, C. J., 
McEneaney, V., Rooney, M., Porter, R. K., Sivaprasadarao, A., Stephens, J. C., 
and Findlay, J. B. C., 2016. Novel mitochondrial complex I inhibitors restore 
glucose-handling abilities of high-fat fed mice. Journal of Molecular 
Endocrinology, DOI: 10.1530/JME-15-0225 
Martinon, F., Burns, K., and Tschopp, J., 2002. The inflammasome: a molecular 
platform triggering activation of inflammatory caspases and processing of proIL-β. 
Molecular Cell, 10 (2), 417–426. 
Matsuda, I. and Aiba, A., 2004. Receptor knock-out and knock-in strategies. Methods in 
Molecular Biology, 259, 379–390. 
Matsuzaki, S. and Humphries, K. M., 2015. Selective Inhibition of Deactivated 
Mitochondrial Complex I by Biguanides. Biochemistry, 54 (11), 2011–2021. 
McArdle, M. A., Finucane, O. M., Connaughton, R. M., McMorrow, A. M., and Roche, 
H. M., 2013. Mechanisms of Obesity-Induced Inflammation and Insulin 
Resistance: Insights into the Emerging Role of Nutritional Strategies. Frontiers in 
Chapter 6: Bibliography 
 
  
246 
Endocrinology, 4 (May), 1–23. 
McGann, M., 2011. FRED pose prediction and virtual screening accuracy. Journal of 
Chemical Information and Modeling, 51 (3), 578–596. 
McGaughey, G. B., Sheridan, R. P., Bayly, C. I., Culberson, J. C., Kreatsoulas, C., 
Lindsley, S., Maiorov, V., Truchon, J. F., and Cornell, W. D., 2007. Comparison of 
topological, shape, and docking methods in virtual screening. Journal of Chemical 
Information and Modeling, 47 (4), 1504–1519. 
Meister, J., Le Duc, D., Ricken, A., Burkhardt, R., Thiery, J., Pfannkuche, H., Polte, T., 
Grosse, J., Schoneberg, T., and Schulz, A., 2014. The G Protein-coupled Receptor 
P2Y14 Influences Insulin Release and Smooth Muscle Function in Mice. The 
Journal of Biological Chemistry, 289, 23353–23366. 
Merrill, G. F., Kurth, E. J., Hardie, D. G., and Winder, W. W., 1997. AICA riboside 
increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in 
rat muscle. The American Journal of Physiology, 273, 1107–1112. 
Michalsky, E., Goede, A., and Preissner, R., 2003. Loops In Proteins (LIP)-a 
comprehensive loop database for homology modelling. Protein Engineering, 16 
(12), 979–985. 
Middelbeek, R. J. W., Chambers, M. A., Tantiwong, P., Treebak, J. T., An, D., 
Hirshman, M. F., Musi, N., and Goodyear, L. J., 2013. Insulin stimulation 
regulates AS160 and TBC1D1 phosphorylation sites in human skeletal muscle. 
Nutrition and Diabetes, 3, e74. 
Mihaylova, M. M., Vasquez, D. S., Ravnskjaer, K., Denechaud, P. D., Yu, R. T., 
Alvarez, J. G., Downes, M., Evans, R. M., Montminy, M., and Shaw, R. J., 2011. 
Class IIa Histone Deacetylases are Hormone-activated regulators of FOXO and 
Chapter 6: Bibliography 
 
  
247 
Mammalian Glucose Homeostasis. Cell, 145 (4), 607–621. 
Miller, R. A., Chu, Q., Xie, J., Foretz, M., Viollet, B., and Birnbaum, M. J., 2013. 
Biguanides suppress hepatic glucagon signalling by decreasing production of 
cyclic AMP. Nature, 494 (7436), 256–260. 
Minokoshi, Y., Kim, Y. B., Peroni, O. D., Fryer, L. G. D., Muller, C., Carling, D., and 
Kahn, B. B., 2002. Leptin stimulates fatty-acid oxidation by activating AMP-
activated protein kinase. Nature, 415 (6869), 339–343. 
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., 
Oku, A., Tsuda, K., Toyokuni, S., Hiai, H., Mizunoya, W., Fushiki, T., Holst, J. J., 
Makino, M., Tashita, A., Kobara, Y., Tsubamoto, Y., Jinnouchi, T., Jomori, T., and 
Seino, Y., 2002. Inhibition of gastric inhibitory polypeptide signaling prevents 
obesity. Nature Medicine, 8 (7), 738–742. 
Molinuevo, M. S., Schurman, L., McCarthy, A. D., Cortizo, A. M., Tolosa, M. J., 
Gangoiti, M. V., Arnol, V., and Sedlinsky, C., 2010. Effect of metformin on bone 
marrow progenitor cell differentiation: in vivo and in vitro studies. Journal of Bone 
and Mineral Research, 25 (2), 211–221. 
Momcilovic, M., Hong, S. P., and Carlson, M., 2006. Mammalian TAK1 Activates Snf1 
Protein Kinase in Yeast and Phosphorylates AMP-activated Protein Kinase in 
Vitro. The Journal of Biological Chemistry, 281 (35), 25336–25343. 
Mráček, T., Drahota, Z., and Houštěk, J., 2013. The function and the role of the 
mitochondrial glycerol-3-phosphate dehydrogenase in mammalian tissues. 
Biochimica et Biophysica Acta, 1827 (3), 401–410. 
Mu, J., Brozinick, J. T., Valladares, O., Bucan, M., and Birnbaum, M. J., 2001. A role 
for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose 
Chapter 6: Bibliography 
 
  
248 
transport in skeletal muscle. Molecular Cell, 7 (5), 1085–1094. 
Muenzner, M., Tuvia, N., Deutschmann, C., Witte, N., Tolkachov, A., Valai, A., Henze, 
A., Sander, L. E., Raila, J., and Schupp, M., 2013. Retinol-binding protein 4 and its 
membrane receptor STRA6 control adipogenesis by regulating cellular retinoid 
homeostasis and retinoic acid receptor α activity. Molecular and cellular biology, 
33 (20), 4068–82. 
Munday, M. R., Campbell, D. G., Carling, D., and Hardie, D. G., 1988. Identification 
by amino acid sequencing of three major regulatory phosphorylation sites on rat 
acetyl-CoA carboxylase. European Journal of Biochemistry, 175 (2), 331–338. 
Nagata, A., Ito, M., Iwata, N., Kuno, J., Takano, H., Minowa, O., Chihara, K., Matsui, 
T., and Noda, T., 1996. G protein-coupled cholecystokinin-B/gastrin receptors are 
responsible for physiological cell growth of the stomach mucosa in vivo. 
Proceedings of the National Academy of Sciences of the United States of America, 
93 (21), 11825–11830. 
Naor, Z., Benard, O., and Seger, R., 2000. Activation of MAPK cascades by G-protein-
coupled receptors: The case of gonadotropin-releasing hormone receptor. Trends in 
Endocrinology and Metabolism, 11 (3), 91–99. 
Nauck, M. A. and Friedrich, N., 2013. Do GLP-1-Based Therapies Increase Cancer 
Risk? Diabetes Care, 36, S245–S252. 
Neer, E. J., 1995. Heterotrimeric G proteins: organizers of transmembrane signals. Cell, 
80 (2), 249–257. 
Nguyen, M. T. A., Favelyukis, S., Nguyen, A. K., Reichart, D., Scott, P. A., Jenn, A., 
Liu-Bryan, R., Glass, C. K., Neels, J. G., and Olefsky, J. M., 2007. A 
Subpopulation of Macrophages Infiltrates Hypertrophic Adipose Tissue and Is 
Chapter 6: Bibliography 
 
  
249 
Activated by Free Fatty Acids via Toll-like Receptors 2 and 4 and JNK-dependent 
Pathways. The Journal of Biological Chemistry, 282 (48), 35279–35292. 
Nie, T., Hui, X., Gao, X., Li, K., Lin, W., Xiang, X., Ding, M., Kuang, Y., Xu, A., Fei, 
J., Wang, Z., and Wu, D., 2012. Adipose tissue deletion of Gpr116 impairs insulin 
sensitivity through modulation of adipose function. FEBS Letters, 586 (20), 3618–
3625. 
Norseen, J., Hosooka, T., Hammarstedt, A., Yore, M. M., Kant, S., Aryal, P., Kiernan, 
U. A., Phillips, D. A., Maruyama, H., Kraus, B. J., Usheva, A., Davis, R. J., Smith, 
U., and Kahn, B. B., 2012. Retinol-Binding Protein 4 Inhibits Insulin Signaling in 
Adipocytes by Inducing Proinflammatory Cytokines in Macrophages through a c-
Jun N-Terminal Kinase- and Toll-Like Receptor 4-Dependent and Retinol-
Independent Mechanism. Molecular and Cellular Biology, 32 (10), 2010–2019. 
OMEGA, www.eyesopen.com, OpenEye Scientific Software, Santa Fe, NM, USA. 
O’Neill, H. M., Holloway, G. P., and Steinberg, G. R., 2013. AMPK regulation of fatty 
acid metabolism and mitochondrial biogenesis: Implications for obesity. Molecular 
and Cellular Endocrinology, 366 (2), 135–151. 
O’Neill, H. M., Maarbjerg, S. J., Crane, J. D., Jeppesen, J., Jørgensen, S. B., Schertzer, 
J. D., Shyroka, O., Kiens, B., van Denderen, B. J., Tarnopolsky, M. A., Kemp, B. 
E., Richter, E. A., and Steinberg, G. R., 2011. AMP-activated protein kinase 
(AMPK) β1β2 muscle null mice reveal an essential role for AMPK in maintaining 
mitochondrial content and glucose uptake during exercise. Proceedings of the 
National Academy of Sciences of the United States of America, 108 (38), 16092–7. 
O’Rourke, R. and Metcalf, M., 2009. Depot-specific differences in inflammatory 
mediators and a role for NK cells and IFN-γ in inflammation in human adipose 
Chapter 6: Bibliography 
 
  
250 
tissue. International Journal of Obesity, 33 (9), 978–990. 
O’Sullivan, L. A., Liongue, C., Lewis, R. S., Stephenson, S. E. M., and Ward, A. C., 
2007. Cytokine receptor signaling through the Jak–Stat–Socs pathway in disease. 
Molecular Immunology, 44 (10), 2497–2506. 
Offermanns, S., 2003. G-proteins as transducers in transmembrane signalling. Progress 
in Biophysics and Molecular Biology, 83 (2), 101–130. 
Offermanns, S., Heiler, E., Spicher, K., and Schultz, G., 1994. Gq and G11 are 
concurrently activated by bombesin and vasopressin in Swiss 3T3 cells. FEBS 
Letters, 349 (2), 201–204. 
Oh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. 
J., Watkins, S. M., and Olefsky, J. M., 2010. GPR120 Is an Omega-3 Fatty Acid 
Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects. 
Cell, 142 (5), 687–698. 
Ohki-Hamazaki, H., Watase, K., Yamamoto, K., Ogura, H., Yamano, M., Yamada, K., 
Maeno, H., Imaki, J., Kikuyama, S., Wada, E., and Wada, K., 1997. Mice lacking 
bombesin receptor subtype-3 develop metabolic defects and obesity. Nature, 390 
(6656), 165–169. 
Oldham, W. M. and Hamm, H. E., 2006. Structural basis of function in heterotrimeric G 
proteins. Quarterly Reviews of Biophysics, 39 (2), 117–166. 
Oldham, W. M. and Hamm, H. E., 2008. Heterotrimeric G protein activation by G-
protein-coupled receptors. Nature Reviews Molecular Cell Biology, 9 (1), 60–71. 
Osborn, O., Oh, D. Y., Mcnelis, J., Sanchez-alavez, M., Talukdar, S., Lu, M., Li, P., 
Thiede, L., Morinaga, H., Kim, J. J., Heinrichsdorff, J., Nalbandian, S., Ofrecio, J. 
Chapter 6: Bibliography 
 
  
251 
M., Scadeng, M., Schenk, S., Hadcock, J., Bartfai, T., and Olefsky, J. M., 2012. G 
protein – coupled receptor 21 deletion improves insulin sensitivity in diet-induced 
obese mice. The Journal of Clinical Investigation, 122 (7), 2444–2453. 
Osborn, O. and Olefsky, J. M., 2012. The cellular and signaling networks linking the 
immune system and metabolism in disease. Nature Medicine, 18 (3), 363–374. 
van der Ouweland, A. M. W., Dressen, J. C. F. M., Verdijk, M., Knoers, N. V. A. M., 
Monnens, L. A. H., Rocchi, M., and van Oost, B. A., 1992. Mutations in the 
vasopressin type 2 rebeptor gene (AVPR2) associated with nephrogenic diabetes 
insipidus. Nature, 2, 99–102. 
Owen, M. R., Doran, E., and Halestrap, A. P., 2000. Evidence that metformin exerts its 
anti-diabetic effects through inhibition of complex 1 of the mitochondrial 
respiratory chain. Biochemical Society, 614, 607–614. 
Pang, T., Zhang, Z. S., Gu, M., Qiu, B. Y., Yu, L. F., Cao, P. R., Shao, W., Su, M. B., 
Li, J. Y., Nan, F. J., and Li, J., 2008. Small Molecule Antagonizes Autoinhibition 
and Activates AMP-activated Protein Kinase in Cells. The Journal of Biological 
Chemistry, 283 (23), 16051–16060. 
Pappalardo, M., Shachaf, N., Basile, L., Milardi, D., Zeidan, M., Raiyn, J., Guccione, 
S., and Rayan, A., 2014. Sequential Application of Ligand and Structure Based 
Modeling Approaches to Index Chemicals for Their hH4R Antagonism. PLoS 
ONE, 9 (10), e109340. 
Park, S. H., Gammon, S. R., Knippers, J. D., Paulsen, S. R., Rubink, D. S., and Winder, 
W. W., 2002. Phosphorylation-activity relationships of AMPK and acetyl-CoA 
carboxylase in muscle. Journal of Applied Physiology, 92 (6), 2475-2482. 
Park, S. H., Ryu, S. Y., Yu, W. J., Han, Y. E., Ji, Y. S., Oh, K., Sohn, J. W., Lim, A., 
Chapter 6: Bibliography 
 
  
252 
Jeon, J. P., Lee, H., Lee, K. H., Lee, S. H., Berggren, P. O., Jeon, J. H., and Ho, W. 
K., 2013. Leptin promotes KATP channel trafficking by AMPK signaling in 
pancreatic-cells. Proceedings of the National Academy of Sciences of the United 
States of America, 110 (31), 12673–12678. 
Patsouris, D., Li, P. P., Thapar, D., Chapman, J., Olefsky, J. M., and Neels, J. G., 2008. 
Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin 
resistant animals. Cell Metabolism, 8 (4), 301–309. 
Paula, G. S. M., Souza, L. L., Cabanelas, A., Bloise, F. F., Mello-Coelho, V., Wada, E., 
Ortiga-Carvalho, T. M., Oliveira, K. J., and Pazos-Moura, C. C., 2010. Female 
mice target deleted for the neuromedin B receptor have partial resistance to diet-
induced obesity. The Journal of Physiology, 588 (Pt 9), 1635–1645. 
Pedroso, J. A. B., Buonfiglio, D. C., Cardinali, L. I., Furigo, I. C., Ramos-Lobo, A. M., 
Tirapegui, J., Elias, C. F., and Donato, J., 2014. Inactivation of SOCS3 in leptin 
receptor-expressing cells protects mice from diet-induced insulin resistance but 
does not prevent obesity. Molecular Metabolism, 3 (6), 608–618. 
Pernicova, I. and Korbonits, M., 2014. Metformin-mode of action and clinical 
implications for diabetes and cancer. Nature Reviews Endocrinology, 10 (3), 143–
156. 
Perola, E. and Charifson, P. S., 2004. Conformational analysis of drug-like molecules 
bound to proteins: an extensive study of ligand reorganization upon binding. 
Journal of Medicinal Chemistry, 47 (10), 2499–2510. 
Pessin, J. E., Thurmond, D. C., Elmendorf, J. S., Coker, K. J., and Okada, S., 1999. 
Molecular Basis of Insulin- stimulated GLUT4 Vesicle Trafficking. The Journal of 
Biological Chemistry, 274 (5), 2593–2596. 
Chapter 6: Bibliography 
 
  
253 
Pierce, K. L. and Lefkowitz, R. J., 2001. Classical and new roles of β-arrestins in the 
regulation of G-protein-coupled receptors. Nature Reviews Neuroscience, 2 (10), 
727–733. 
Pierce, K. L., Premont, R. T., and Lefkowitz, R. J., 2002. Seven-transmembrane 
receptors. Nature Reviews Molecular Cell Biology, 3 (9), 639–650. 
Pirola, L., Johnston,  A. M., and Van Obberghen, E., 2004. Modulation of insulin 
action. Diabetologia, 47 (2), 170–184. 
Pospisilik, J. A., Knauf, C., Joza, N., Benit, P., Orthofer, M., Cani, P. D., Ebersberger, 
I., Nakashima, T., Sarao, R., Neely, G., Esterbauer, H., Kozlov, A., Kahn, C. R., 
Kroemer, G., Rustin, P., Burcelin, R., and Penninger, J. M., 2007. Targeted 
Deletion of AIF Decreases Mitochondrial Oxidative Phosphorylation and Protects 
from Obesity and Diabetes. Cell, 131 (3), 476–491. 
Prasad, A., Jia, Y., Chakraborty, A., Li, Y., Jain, S. K., Zhong, J., Roy, S. G., Loison, 
F., Mondal, S., Sakai, J., Blanchard, C., Snyder, S. H., and Luo, H. R., 2011. 
Inositol hexakisphosphate kinase 1 regulates neutrophil function in innate 
immunity by inhibiting phosphatidylinositol-(3,4,5)-trisphosphate signaling. 
Nature immunology, 12 (8), 752–760. 
Premont, R. T., Inglese, J., and Lefkowitz, R. J., 1995. Protein kinases that 
phosphorylate activated G protein-coupled receptors. The FASEB Journal, 9 (2), 
175–182. 
Priest, B. T., Bell, I. M., and Garcia, M. L., 2008. Role of hERG potassium channel 
assays in drug development. Channels, 2 (2), 87–93. 
Qatanani, M. and Lazar, M. A., 2007. Mechanisms of obesity-associated insulin 
resistance: Many choices on the menu. Genes and Development, 21 (12), 1443–
Chapter 6: Bibliography 
 
  
254 
1455. 
Quan, W., Lim, Y. M., and Lee, M. S., 2012. Role of autophagy in diabetes and 
endoplasmic reticulum stress of pancreatic β-cells. Experimental and Molecular 
Medicine, 44 (2), 81–88. 
Quintens, R., Singh, S., Lemaire, K., De Bock, K., Granvik, M., Schraenen, A., 
Vroegrijk, I. O. C. M., Costa, V., Van Noten, P., Lambrechts, D., Lehnert, S., Van 
Lommel, L., Thorrez, L., De Faudeur, G., Romijn, J. A., Shelton, J. M., Scorrano, 
L., Lijnen, H. R., Voshol, P. J., Carmeliet, P., Mammen, P. P. A., and Schuit, F., 
2013. Mice Deficient in the Respiratory Chain Gene Cox6a2 Are Protected against 
High-Fat Diet-Induced Obesity and Insulin Resistance. PLoS ONE, 8 (2), e56719. 
Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M., and Soubrié, P., 2004. CB1 
cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced 
obesity and enhanced leptin sensitivity. International Journal of Obesity, 28 (4), 
640–648. 
Rayasam, G. V., Tulasi, V. K., Sodhi, R., Davis, J. A., and Ray, A., 2009. Glycogen 
synthase kinase 3: more than a namesake. British Journal of Pharmacology, 156 
(6), 885–898. 
Rehm, A., 1997. Assembly and Intracellular Targeting of the βγ Subunits of 
Heterotrimeric G Proteins. The Journal of Cell Biology, 137 (2), 305–317. 
Reinehr, T., 2013. Type 2 diabetes mellitus in children and adolescents. World Journal 
of Diabetes, 4 (6), 270. 
Rena, G., Pearson, E. R., and Sakamoto, K., 2013. Molecular mechanism of action of 
metformin: Old or new insights? Diabetologia, 56 (9), 1898–1906. 
Chapter 6: Bibliography 
 
  
255 
Rhee, S. G., 2001. Regulation of Phosphoinositide-specific Phospholipase C. Annual 
Review of Biochemistry, 70, 281–312. 
Richter, E. A. and Ruderman, N. B., 2009. AMPK and the Biochemistry of Exercise: 
Implications for Human Health and Disease. The Biochemical Journal, 2 (418), 
261–275. 
Robertson, R. P., Halter, J. B., and Porte, D., 1976. A role for α-adrenergic receptors in 
abnormal insulin secretion in diabetes mellitus. The Journal of Clinical 
Investigation, 57 (3), 791–795. 
Rochester, C. D. and Akiyode, O., 2014. Novel and emerging diabetes mellitus drug 
therapies for the type 2 diabetes patient. World Journal of Diabetes, 5 (3), 305–15. 
Rodgers, R. J., Ishii, Y., Halford, J. C. G., and Blundell, J. E., 2002. Orexins and 
appetite regulation. Neuropeptides, 36 (5), 303–325. 
Romero-Zerbo, S. Y., Rafacho, A., Díaz-Arteaga, A., Suárez, J., Quesada, I., Imbernon, 
M., Ross, R. A., Dieguez, C., de Fonseca, F. R., Nogueiras, R., Nadal, A., and 
Bermúdez-Silva, F. J., 2011. Role for the putative cannabinoid receptor GPR55 in 
the islets of Langerhans. Journal of Endocrinology, 211 (2), 177–185. 
Rosenbaum, D. M., Rasmussen, S. G. F., and Kobilka, B. K., 2009. The structure and 
function of G-protein-coupled receptors. Nature, 459, 356–363. 
Rosengren, A. H., Jokubka, R., Tojjar, D., Granhall, C., Hansson, O., Li, D. Q., 
Nagaraj, V., Reinbothe, T. M., Tuncel, J., Eliasson, L., Groop, L., Rorsman, P., 
Salehi, A., Lyssenko, V., Luthman, H., and Renström, E., 2010. Overexpression of 
α2A-adrenergic receptors contributes to type 2 diabetes. Science, 327 (5962), 217–
220. 
Chapter 6: Bibliography 
 
  
256 
Rubinsztein, D. C., Codogno, P., and Levine, B., 2012. Autophagy modulation as a 
potential therapeutic target for diverse diseases. Nature Reviews Drug Discovery, 
11 (9), 709–730. 
Ruderman, N. B., Saha,  A. K., Vavvas, D., and Witters, L. A., 1999. Malonyl-CoA, 
fuel sensing, and insulin resistance. The American Journal of Physiology 
Endocrinology and Metabolism, 276 (1), E1–E18. 
Rzonca, S. O., Suva, L. J., Gaddy, D., Montague, D. C., and Lecka-Czernik, B., 2004. 
Bone Is a Target for the Antidiabetic Compound Rosiglitazone. Endocrinology, 
145 (1), 401–406. 
Sabio, G. and Davis, R. J., 2014. TNF and MAP kinase signaling pathways. Seminars in 
Immunology, 26 (3), 237–245. 
Sachithanandan, N., Fam, B. C., Fynch, S., Dzamko, N., Watt, M. J., Wormald, S., 
Honeyman, J., Galic, S., Proietto, J., Andrikopoulos, S., Hevener, A. L., Kay, T. 
W. H., and Steinberg, G. R., 2010. Liver-specific suppressor of cytokine signaling-
3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in 
fatty liver and obesity. Hepatology, 52 (5), 1632–1642. 
Saiardi, A., Sciambi, C., McCaffery, J. M., Wendland, B., and Snyder, S. H., 2002. 
Inositol pyrophosphates regulate endocytic trafficking. Proceedings of the 
National Academy of Sciences of the United States of America, 99 (22), 14206–
14211. 
Samuel, B. S., Shaito, A., Motoike, T., Rey, F. E., Backhed, F., Manchester, J. K., 
Hammer, R. E., Williams, S. C., Crowley, J., Yanagisawa, M., and Gordon, J. I., 
2008. Effects of the gut microbiota on host adiposity are modulated by the short-
chain fatty-acid binding G protein-coupled receptor, Gpr41. Proceedings of the 
Chapter 6: Bibliography 
 
  
257 
National Academy of Sciences of the United States of America, 105 (43), 16767–
16772. 
Sanders, M. J., Grondin, P. O., Hegarty, B. D., Snowden, M. A., and Carling, D., 2007. 
Investigating the mechanism for AMP activation of the AMP-activated protein 
kinase cascade. The Biochemical Journal, 403 (1), 139–148. 
Sano, H., 2003. Insulin-stimulated Phosphorylation of a Rab GTPase-activating Protein 
Regulates GLUT4 Translocation. The Journal of Biological Chemistry, 278 (17), 
14599–14602. 
Sassmann, A., Gier, B., Gröne, H. J., Drews, G., Offermanns, S., and Wettschureck, N., 
2010. The Gq/G11-mediated signaling pathway is critical for autocrine 
potentiation of insulin secretion in mice. The Journal of Clinical Investigation, 120 
(6), 2184–2193. 
Schweitzer, G. G., Arias, E. B., and Cartee, G. D., 2012. Sustained postexercise 
increases in AS160 Thr642 and Ser588 phosphorylation in skeletal muscle without 
sustained increases in kinase phosphorylation. Journal of Applied Physiology, 113 
(12), 1852–61. 
Scott, J. W., van Denderen, B. J. W., Jorgensen, S. B., Honeyman, J. E., Steinberg, G. 
R., Oakhill, J. S., Iseli, T. J., Koay, A., Gooley, P. R., Stapleton, D., and Kemp, B. 
E., 2008. Thienopyridone Drugs Are Selective Activators of AMP-Activated 
Protein Kinase β1-Containing Complexes. Chemistry and Biology, 15 (11), 1220–
1230. 
Seasholtz, T. M., Majumdar, M., and Brown, J. H., 1999. Rho as a mediator of G 
protein-coupled receptor signaling. Molecular Pharmacology, 55 (6), 949–956. 
Senn, J. J., Klover, P. J., Nowak, I. A., and Mooney, R. A., 2002. Interleukin-6 induces 
Chapter 6: Bibliography 
 
  
258 
cellular insulin resistance in hepatocytes. Diabetes, 51 (12), 3391–3399. 
Shackelford, D. B. and Shaw, R. J., 2009. The LKB1-AMPK pathway: metabolism and 
growthcontrol in tumor suppression. Nature Reviews Cancer, 9 (8), 563–575. 
Shah, M., Kola, B., Bataveljic,  A., Arnett, T. R., Viollet, B., Saxon, L., Korbonits, M., 
and Chenu, C., 2010. AMP-activated protein kinase (AMPK) activation regulates 
in vitro bone formation and bone mass. Bone, 47 (2), 309–319. 
Shapiro, H., Shachar, S., Sekler, I., Hershfinkel, M., and Walker, M. D., 2005. Role of 
GPR40 in fatty acid action on the β cell line INS-1E. Biochemical and Biophysical 
Research Communications, 335 (1), 97–104. 
Sharma, G. and Prossnitz, E. R., 2011. Mechanisms of estradiol-induced insulin 
secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic 
β-cells. Endocrinology, 152 (8), 3030–3039. 
Shenoy, S. K., Drake, M. T., Nelson, C. D., Houtz, D. A., Xiao, K., Madabushi, S., 
Reiter, E., Premont, R. T., Lichtarge, O., and Lefkowitz, R. J., 2006. β-arrestin-
dependent, G protein-independent ERK1/2 activation by the β2 adrenergic 
receptor. The Journal of Biological Chemistry, 281 (2), 1261–1273. 
Shepherd, P. R., Withers, D. J., and Siddle, K., 1998. Phosphoinositide 3-kinase: the 
key switch mechanism in insulin signalling. The Biochemical Journal, 333 (3), 
471–490. 
Shi, G., Partida-Sánchez, S., Misra, R. S., Tighe, M., Borchers, M. T., Lee, J. J., Simon, 
M. I., and Lund, F. E., 2007. Identification of an alternative Gαq-dependent 
chemokine receptor signal transduction pathway in dendritic cells and 
granulocytes. The Journal of Experimental Medicine, 204 (11), 2705–2718. 
Chapter 6: Bibliography 
 
  
259 
Siderovski, D. P. and Willard, F. S., 2005. The GAPs, GEFs, and GDIs of 
heterotrimeric G-protein α-subunits. International Journal of Biological Sciences, 
1 (2), 51–66. 
Siehler, S., 2009. Regulation of RhoGEF proteins by G12/13-coupled receptors. British 
Journal of Pharmacology, 158 (1), 41–49. 
Silha, J. V., Krsek, M., Skrha, J. V., Sucharda, P., Nyomba, B. L. G., and Murphy, L. J., 
2003. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: 
Correlations with insulin resistence. European Journal of Endocrinology, 149 (4), 
331–335. 
Simon-Szabó, L., Kokas, M., Mandl, J., Kéri, G., and Csala, M., 2014. Metformin 
attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation 
of IRS-1 and apoptosis in rat insulinoma cells. PLoS ONE, 9 (6), E978–7. 
Singh, A. S., Mulder, C., Twisk, J. W. R., van Mechelen, W., and Chinapaw, M. J. M., 
2008. Tracking of childhood overweight into adulthood: a systematic review of the 
literature. Obesity Reviews, 9 (5), 474–488. 
Sivaprasadarao, A., and Findlay, J. B., 1988a. The interaction of retinol-binding protein 
with its plasma-membrane receptor, The Biochemical Journal, 255 (2), 561-569. 
 
Sivaprasadarao, A., and Findlay, J. B, 1988b. The mechanism of uptake of retinol by 
plasma-membrane vesicles, The Biochemical Journal, 255 (2), 571-9. 
 
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, 
M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C., 1985. 
Measurement of protein using bicinchoninic acid. Analytical Biochemistry, 150 
(1), 76–85. 
Chapter 6: Bibliography 
 
  
260 
Smith, R. J., Sam, L. M., Justen, J. M., Bundy, G. L., Bala, G. A., and Bleasdale, J. E., 
1990. Receptor-coupled signal transduction in human polymorphonuclear 
neutrophils: effects of a novel inhibitor of phospholipase C-dependent processes on 
cell responsiveness. The Journal of Pharmacology and Experimental Therapeutics, 
253 (2), 688–697. 
Smrcka, A. V., 2008. G protein βγ subunits: Central mediators of G protein-coupled 
receptor signalling. Cellular and Molecular Life Sciences, 65 (14), 2191–2214. 
Solinas, G. and Karin, M., 2010. JNK1 and IKKβ : molecular links between obesity and 
metabolic dysfunction. The FASEB Journal, 24 (8), 2596–2611. 
Sommer, U., Schmid, C., Sobota, R. M., Lehmann, U., Stevenson, N. J., Johnston, J. A., 
Schaper, F., Heinrich, P. C., and Haan, S., 2005. Mechanisms of SOCS3 
Phosphorylation upon Interleukin-6 Stimulation: Contributions if Src- and 
Receptor-Tyrosine Kinases. The Journal of Biological Chemistry, 280 (36), 
31478–31488. 
Sørensen, H., Winzell, M. S., Brand, C. L., Fosgerau, K., Gelling, R. W., Nishimura, E., 
and Ahren, B., 2006. Glucagon receptor knockout mice display increased insulin 
sensitivity and impaired beta-cell function. Diabetes, 55 (12), 3463–3469. 
Spinazzi, M., Casarin, A., Pertegato, V., Salviati, L., and Angelini, C., 2012. 
Assessment of mitochondrial respiratory chain enzymatic activities on tissues and 
cultured cells. Nature Protocols, 7 (6), 1235–1246. 
Stebbins, J. L., De, S. K., Machleidt, T., Becattini, B., Vazquez, J., Kuntzen, C., Chen, 
L. H., Cellitti, J. F., Riel-Mehan, M., Emdadi, A., Solinas, G., Karin, M., and 
Pellecchia, M., 2008. Identification of a new JNK inhibitor targeting the JNK-JIP 
interaction site. Proceedings of the National Academy of Sciences of the United 
Chapter 6: Bibliography 
 
  
261 
States of America, 105 (43), 16809–16813. 
Stein, S. A., Lamos, E. M., and Davis, S. N., 2013. A review of the efficacy and safety 
of oral antidiabetic drugs. Expert Opinion on Drug Safety, 12 (2), 153–175. 
Stein, S. C., Woods, A., Jones, N. A., Davison, M. D., and Carling, D., 2000. The 
regulation of AMP-activated protein kinase by phosphorylation. The Biochemical 
Journal, 345 (3), 437–443. 
Steinberg, G. R. and Kemp, B. E., 2009. AMPK in Health and Disease. Physiological 
Reviews, 89 (3), 1025–1078. 
Steneberg, P., Rubins, N., Bartoov-Shifman, R., Walker, M. D., and Edlund, H., 2005. 
The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired 
glucose homeostasis in mouse. Cell Metabolism, 1 (4), 245–258. 
Stephens, L., Radenberg, T., Thiel, U., Vogel, G., Khoo, K. H., Dell, A., Jackson, T. R., 
Hawkins, P. T., and Mayr, G. W., 1993. The detection, purification, structural 
characterization, and metabolism of diphosphoinositol pentakisphosphate(s) and 
bisdiphosphoinositol tetrakisphosphate(s). The Journal of Biological Chemistry, 
268 (6), 4009–4015. 
Stevens, R. C., Cherezov, V., Katritch, V., Abagyan, R., Kuhn, P., Rosen, H., and 
Wüthrich, K., 2013. The GPCR Network: a large-scale collaboration to determine 
human GPCR structure and function. Nature Reviews Drug Discovery, 12 (1), 25–
34. 
Stockert, J. A. and Devi, L. A., 2015. Advancements in therapeutically targeting orphan 
GPCRs. Frontiers in Pharmacology, 6, 1–8. 
Strathmann, M. P. and Simon, M. I., 1991. Gα 12 and Gα 13 subunits define a fourth 
Chapter 6: Bibliography 
 
  
262 
class of G protein alpha subunits. Proceedings of the National Academy of 
Sciences of the United States of America, 88 (13), 5582–5586. 
Strowski, M. Z., Kohler, M., Chen, H. Y., Trumbauer, M. E., Li, Z., Szalkowski, D., 
Gopal-Truter, S., Fisher, J. K., Schaeffer, J. M., Blake, A. D., Zhang, B. B., and 
Wilkinson, H. A., 2003. Somatostatin receptor subtype 5 regulates insulin 
secretion and glucose homeostasis. Molecular Endocrinology, 17 (1), 93–106. 
Sullivan, J. E., Brocklehurst, K. J., Marley,  A. E., Carey, F., Carling, D., and Beri, R. 
K., 1994. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with 
AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS 
Letters, 353 (1), 33–36. 
Sumara, G., Formentini, I., Collins, S., Sumara, I., Windak, R., Bodenmiller, B., 
Ramracheya, R., Caille, D., Jiang, H., Platt, K. A., Meda, P., Aebersold, R., 
Rorsman, P., and Ricci, R., 2009. Regulation of PKD by the MAPK p38δ in 
Insulin Secretion and Glucose Homeostasis. Cell, 136 (2), 235–248. 
Sun, D., Li, S., Wu, H., Zhang, M., Zhang, X., Wei, L., Qin, X., and Gao, E., 2015. 
Oncostatin M (OSM) protects against cardiac ischaemia/reperfusion injury in 
diabetic mice by regulating apoptosis, mitochondrial biogenesis and insulin 
sensitivity. Journal of Cellular and Molecular Medicine, 19 (6), 1296–1307. 
Sun, L. and Ye, R. D., 2012. Role of G protein-coupled receptors in inflammation. Acta 
Pharmacologica Sinica, 33 (3), 342–350. 
Sun, Y., Butte, N. F., Garcia, J. M., and Smith, R. G., 2008. Characterization of adult 
ghrelin and ghrelin receptor knockout mice under positive and negative energy 
balance. Endocrinology, 149 (2), 843–850. 
Sundaram, M., Sivaprasadarao, A., DeSousa, M. M., and Findlay, J. B., 1998. The 
Chapter 6: Bibliography 
 
  
263 
transfer of retinol from serum retinol-binding protein to cellular retinol-binding 
protein is mediated by a membrane receptor. The Journal of Biological Chemistry, 
273 (6), 3336–42. 
Taggart, A. K. P., Kero, J., Gan, X., Cai, T. Q., Cheng, K., Ippolito, M., Ren, N., 
Kaplan, R., Wu, K., Wu, T. J., Jin, L., Liaw, C., Chen, R., Richman, J., Connolly, 
D., Offermanns, S., Wright, S. D., and Waters, M. G., 2005. (D)-β-
Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor 
PUMA-G. The Journal of Biological Chemistry, 280 (29), 26649–26652. 
Tan, Y., Ichikawa, T., Li, J., Si, Q., Yang, H., Chen, X., Goldblatt, C. S., Meyer, C. J., 
Li, X., Cai, L., and Cui, T., 2011. Diabetic Downregulation of Nrf2 Activity via 
ERK Contributes to Oxidative Stress-Induced Insulin Resistance in Cardiac Cells 
In Vitro and In Vivo. Diabetes, 60 (2), 625–633. 
Tang, X., Wang, Y., Li, D., Luo, J., and Liu, M., 2012. Orphan G protein-coupled 
receptors (GPCRs): biological functions and potential drug targets. Acta 
Pharmacologica Sinica, 33 (3), 363–371. 
Tao, Y. X., 2008. Constitutive activation of G protein-coupled receptors and diseases: 
Insights into mechanisms of activation and therapeutics. Pharmacology and 
Therapeutics. 120 (2), 129-148. 
Tautermann, C. S., 2014. GPCR structures in drug design, emerging opportunities with 
new structures. Bioorganic and Medicinal Chemistry Letters, 24 (17), 4073–4079. 
Tavakol, S., Kashani, I. R., Azami, M., Khoshzaban, A., Tavakol, B., Kharrazi, S., 
Ebrahimi, S., and Sorkhabadi, S. M. R., 2012. In vitro and in vivo investigations on 
bone regeneration potential of laminated hydroxyapatite/gelatin nanocomposite 
scaffold along with DBM. Journal of Nanoparticle Research, 14 (1265), doi: 
Chapter 6: Bibliography 
 
  
264 
10.1007/s11051-012-1265-y 
Tecott, L. H., Sun, L. M., Akana, S. F., Strack, A. M., Lowenstein, D. H., Dallman, M. 
F., and Julius, D., 1995. Eating disorder and epilepsy in mice lacking 5-HT2c 
serotonin receptors. Nature, 374 (6522), 542–546. 
Thiebaud, D., Jacot, E., DeFronzo, R. A., Maeder, E., Jequier, E., and Felber, J. P., 
1982. The effect of graded doses of insulin on total glucose uptake, glucose 
oxidation, and glucose storage in man. Diabetes, 31 (11), 957–963. 
Thompson, P. E. and Findlay, J. B., 1984. Phosphorylation of ovine rhodopsin. 
Identification of the phosphorylated sites. The Biochemical Journal, 220 (3), 773–
80. 
Thulé, P. M. and Umpierrez, G., 2014. Sulfonylureas: A New Look at Old Therapy. 
Current Diabetes Reports, 14 (4), 473. 
Tobin, A. B., 2008. G-protein-coupled receptor phosphorylation: where, when and by 
whom. British Journal of Pharmacology, 153, S167–S176. 
Toker, A. and Marmiroli, S., 2014. Signaling specificity in the Akt pathway in biology 
and disease. Advances in Biological Regulation, 55, 28–38. 
Tolson, K. P., Garcia, C., Yen, S., Simonds, S., Stefanidis, A., Lawrence, A., Smith, J. 
T., and Kauffman, A. S., 2014. Impaired kisspeptin signaling decreases 
metabolism and promotes glucose intolerance and obesity. The Journal of Clinical 
Investigation, 124 (7), 3075–3079. 
Tomkin, G. H., 2014. Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 
inhibitors. World Journal of Diabetes, 5 (5), 636–650. 
Tornqvist, H. E., Pierce, M. W., Frackelton,  A. R., Nemenoff, R. A., and Avruch, J., 
Chapter 6: Bibliography 
 
  
265 
1987. Identification of insulin receptor tyrosine residues autophosphorylated in 
vitro. The Journal of Biological Chemistry, 262 (21), 10212–9. 
Tournier, C., Dong, C., Turner, T. K., Jones, S. N., Flavell, R. A., and Davis, R. J., 
2001. MKK7 is an essential component of the JNK signal transduction pathway 
activated by proinflammatory cytokines. Genes and Development, 15 (11), 1419–
1426. 
Treebak, J. T., Glund, S., Deshmukh, A., Klein, D. K., Long, Y. C., Jensen, T. E., 
Jørgensen, S. B., Viollet, B., Andersson, L., Neumann, D., Wallimann, T., Richter, 
E. A., Chibalin, A. V, Zierath, J. R., and Wojtaszewski, J. F. P., 2006. AMPK-
mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK 
catalytic and regulatory subunits. Diabetes, 55 (7), 2051–8. 
Tremblay, F., Perreault, M., Klaman, L. D., Tobin, J. F., Smith, E., and Gimeno, R. E., 
2007. Normal food intake and body weight in mice lacking the G protein-coupled 
receptor GPR39. Endocrinology, 148 (2), 501–506. 
Trinquet, E., Fink, M., Bazin, H., Grillet, F., Maurin, F., Bourrier, E., Ansanay, H., 
Leroy, C., Michaud, A., Durroux, T., Maurel, D., Malhaire, F., Goudet, C., Pin, J. 
P., Naval, M., Hernout, O., Chrétien, F., Chapleur, Y., and Mathis, G., 2006. D-
myo-Inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to 
monitor G protein-coupled receptor activation. Analytical Biochemistry, 358 (1), 
126–135. 
Tsutsumi, C., Okuno, M., Tannous, L., Piantedosi, R., Allan, M., Goodman, D. S., and 
Blaner, W. S., 1992. Retinoids and retinoid-binding protein expression in rat 
adipocytes. The Journal of Biological Chemistry, 267, 1805–1810. 
Tuncman, G., Hirosumi, J., Solinas, G., Chang, L., Karin, M., and Hotamisligil, G. S., 
Chapter 6: Bibliography 
 
  
266 
2006. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity 
and insulin resistance. Proceedings of the National Academy of Sciences of the 
United States of America, 103 (28), 10741–6. 
Turban, S., Stretton, C., Drouin, O., Green, C. J., Watson, M. L., Gray, A., Ross, F., 
Lantier, L., Viollet, B., Hardie, D. G., Marette, A., and Hundal, H. S., 2012. 
Defining the contribution of AMP-activated protein kinase (AMPK) and protein 
kinase C (PKC) in regulation of glucose uptake by metformin in skeletal muscle 
cells. The Journal of Biological Chemistry, 287 (24), 20088–99. 
Turner, N., Li, J., Gosby, A., To, S. W. C., Cheng, Z., Miyoshi, H., Taketo, M. M., 
Cooney, G. J., Kraegen, E. W., James, D. E., Hu, L., and Li, J., 2008. Berberine 
and Its More Biologically Available Derivative Dihyroberberine, Inhibit 
Mitochondrial Respiration. Diabetes, 57 (May), 1414–1418. 
Ueda, H., Morishita, R., Narumiya, S., Kato, K., and Asano, T., 2004. Gαq/11 signaling 
induces apoptosis through two pathways involving reduction of Akt 
phosphorylation and activation of RhoA in HeLa cells. Experimental Cell 
Research, 298 (1), 207–217. 
Ueki, K., Kondo, T., and Kahn, C. R., 2004. Suppressor of cytokine signaling 1 (SOCS-
1) and SOCS-3 cause insulin resistance through inhibition of tyrosine 
phosphorylation of insulin receptor substrate proteins by discrete mechanisms. 
Molecular and Cellular Biology, 24 (12), 5434–46. 
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., and Hotamisligil, G. S., 1997. 
Protection from obesity-induced insulin resistance in mice lacking TNF-α function. 
Nature, 389 (6651), 610–614. 
Vadlakonda, L., Dash, A., Pasupuleti, M., Anil Kumar, K., and Reddanna, P., 2013. The 
Chapter 6: Bibliography 
 
  
267 
Paradox of Akt-mTOR Interactions. Frontiers in Oncology, 3 (June), 165. 
Vandanmagsar, B., Youm, Y., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., 
Ravussin, E., and Stephens, J. M., 2011. The NALP3/NLRP3 Inflammasome 
Instigates Obesity-Induced Autoinflammation and Insulin Resistance. Nature 
Medicine, 17 (2), 179–188. 
Venkataraman, C. and Kuo, F., 2005. The G-protein coupled receptor, GPR84 regulates 
IL-4 production by T lymphocytes in response to CD3 crosslinking. Immunology 
Letters, 101 (2), 144–153. 
Vernochet, C., Mourier, A., Bezy, O., Macotela, Y., Boucher, J., Rardin, M. J., An, D., 
Lee, K. Y., Ilkayeva, O. R., Zingaretti, C. M., Emanuelli, B., Smyth, G., Cinti, S., 
Newgard, C. B., Gibson, B. W., Larsson, N. G., and Kahn, C. R., 2012. Adipose-
Specific Deletion of TFAM Increases Mitochondrial Oxidation and Protects Mice 
against Obesity and Insulin Resistance. Cell Metabolism, 16 (6), 765–776. 
Vingtdeux, V., Chandakkar, P., Zhao, H., Davies, P., and Marambaud, P., 2011. Small-
Molecule Activators of AMP-Activated Protein Kinase (AMPK), RSVA314 and 
RSVA405, Inhibit Adipogenesis. Molecular Medicine, 17 (9-10), 1022–1030. 
Viollet, B., Horman, S., Leclerc, J., Lantier, L., Foretz, M., Billaud, M., Giri, S., and 
Andreelli, F., 2010. AMPK inhibition in health and disease. Critical Reviews in 
Biochemistry and Molecular Biology, 45 (4), 276–295. 
Vogt, S., Grosse, R., Schultz, G., and Offermanns, S., 2003. Receptor-dependent RhoA 
activation in G12/G13-deficient cells. Genetic evidence for an involvement of 
Gq/G11. The Journal of Biological Chemistry, 278 (31), 28743–28749. 
Voigt, J. P., Schade, R., Fink, H., and Hörtnagl, H., 2002. Role of 5-HT1A receptors in 
the control of food intake in obese Zucker rats of different ages. Pharmacology, 
Chapter 6: Bibliography 
 
  
268 
Biochemistry, and Behavior, 72 (2), 403–409. 
Wallenius, V., Wallenius, K., Ahren, B., Rudling, M., Carlsten, H., Dickson, S. L., 
Ohlsson, C., and Jansson, J. O., 2002. Interleukin-6-deficient mice develop mature-
onset obesity. Nature Medicine, 8 (1), 75–79. 
Wess, J., 1997. G-protein-coupled receptors: molecular mechanisms involved in 
receptor activation and selectivity of G-protein recognition. The FASEB Journal, 
11 (5), 346–54. 
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., and 
Tataranni, P. A., 2001. Hypoadiponectinemia in Obesity and Type 2 Diabetes : 
Close Association with Insulin Resistance and Hyperinsulinemia. The Journal of 
Endochrinology and Metabolism, 86 (5), 1930–1935. 
Wheaton, W. W., Weinberg, S. E., Hamanaka, R. B., Soberanes, S., Sullivan, L. B., 
Anso, E., Glasauer, A., Dufour, E., Mutlu, G. M., Scott Budigner, G. R., and 
Chandel, N. S., 2014. Metformin inhibits mitochondrial complex I of cancer cells 
to reduce tumorigenesis. eLife, (3), 1–18. 
White, M. F., 1997. The insulin signalling system and the IRS proteins. Diabetologia, 
40 (2), 2–17. 
Wiederstein, M. and Sippl, M. J., 2007. ProSA-web: interactive web service for the 
recognition of errors in three-dimensional structures of proteins. Nucleic Acids 
Research, 35 (Web Server issue), W407–10. 
Wikström, M., 1984. Two protons are pumped from the mitochondrial matrix per 
electron transferred between NADH and ubiquinone. FEBS Letters, 169 (2), 300–
304. 
Chapter 6: Bibliography 
 
  
269 
Wilcox, G., 2005. Insulin and insulin resistance. The Clinical Biochemist Reviews, 26 
(2), 19–39. 
Winder, W. W. and Hardie, D. G., 1996. Inactivation of acetyl-CoA carboxylase and 
activation of AMP-activated protein kinase in muscle during exercise. The 
American Journal of Physiology, 270 (2), 299–304. 
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Dorfman, R., Wang, Y., 
Zielenski, J., Mastronardi, F., Maezawa, Y., Drucker, D., Engleman, E., and 
Winer, D., 2009. Normalization of Obesity-Associated Insulin Resistance through 
Immunotherapy: CD4+ T Cells Control Glucose Homeostasis. Nature Medicine, 
15 (8), 921–929. 
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, 
D., Schlattner, U., Wallimann, T., Carlson, M., and Carling, D., 2003. LKB1 Is the 
Upstream Kinase in the AMP-Activated Protein Kinase Cascade. Current Biology, 
13 (22), 2004–2008. 
World Health Organization, 2014. Global status report on noncommunicable diseases 
2014. Geneva, World Health Organization. 
Wundenberg T., and Mayr, G. W., 2012. Synthesis and biological actions of 
diphosphoinositol phosphates (inositol pyrophosphates), regulators  of cell 
homeostasis. Biological Chemistry, 393 (9), 979–998. 
Xiang, Z., 2006. Advances in homology protein structure modeling. Current Protein 
and Peptide Science, 7 (3), 217–227. 
Xiao, B., Sanders, M. J., Underwood, E., Heath, R., Mayer, F. V, Carmena, D., Jing, C., 
Walker, P. A., Eccleston, J. F., Haire, L. F., Saiu, P., Howell, S. A., Aasland, R., 
Martin, S. R., Carling, D., and Gamblin, S. J., 2011. Structure of mammalian 
Chapter 6: Bibliography 
 
  
270 
AMPK and its regulation by ADP. Nature, 472 (7342), 230–233. 
Xiao, B., Sanders, M. J., Carmena, D., Bright, N. J., Haire, L. F., Underwood, E., Patel, 
B. R., Heath, R. B., Walker, P. A., Hallen, S., Giordanetto, F., Martin, S. R., 
Carling, D., and Gamblin, S. J., 2013. Structural basis of AMPK regulation by 
small molecule activators. Nature Communications, 4, 1–10. 
Xiao, S. H., Reagan, J. D., Lee, P. H., Fu, A., Schwandner, R., Zhao, X., Knop, J., 
Beckmann, H., and Young, S. W., 2008. High throughput screening for orphan and 
liganded GPCRs. Combinatorial Chemistry and High Throughput Screening, 11 
(3), 195–215. 
Xu, J., Morinaga, H., Oh, D., Li, P., Chen,  A., Talukdar, S., Lazarowski, E., Olefsky, J. 
M., and Kim, J. J., 2012. GPR105 Ablation Prevents Inflammation and Improves 
Insulin Sensitivity in Mice with Diet-Induced Obesity. The Journal of 
Immunology, 189 (4), 1992–1999. 
Yamada, M., Miyakawa, T., Duttaroy, A., Yamanaka, A., Moriguchi, T., Makita, R., 
Ogawa, M., Chou, C. J., Xia, B., Crawley, J. N., Felder, C. C., Deng, C. X., and 
Wess, J., 2001. Mice lacking the M3 muscarinic acetylcholine receptor are 
hypophagic and lean. Nature, 410 (6825), 207–212. 
Yamaguchii, A., Suda, T., and Komori, T., 2000. Regulation of Osteoblast 
Differentiation Mediated by. Endocrine Reviews, 21, 393–411. 
Yang, L., Li, P., Fu, S., Calay, E. S., and Hotamisligil, G. S., 2010. Defective Hepatic 
Autophagy in Obesity Promotes ER Stress and Causes Insulin Resistance. Cell 
Metabolism, 11 (6), 467–478. 
Yang, Q., Graham, T. E., Mody, N., Preitner, F., Peroni, O. D., Zabolotny, J. M., 
Kotani, K., Quadro, L., and Kahn, B. B., 2005. Serum retinol binding protein 4 
Chapter 6: Bibliography 
 
  
271 
contributes to insulin resistance in obesity and type 2 diabetes. Nature, 436 (7049), 
356–362. 
Yang, Z., Hulver, M., McMillan, R. P., Cai, L., Kershaw, E. E., Yu, L., Xue, B., and 
Shi, H., 2012. Regulation of Insulin and Leptin Signaling by Muscle Suppressor of 
Cytokine Signaling 3 (SOCS3). PLoS ONE, 7 (10), e47493. 
Young, P. A., Leonard, S., Martin, D. S. D., and Findlay, J. B. C., 2015. The effect of 
Retinol Binding Protein on the Proteome of C2C12 muscle cells. 
Diabetes/Metabolism Research and Reviews, DOI: 10.1002/dmrr.2764. 
Young, P. A., Leonard, S., Martin, D. S. D., and Findlay, J. B. C., 2016. Analysis of the 
effect of a novel therapeutic for Type II Diabetes on the proteome of a muscle cell 
line. Proteomics. 16 (1), 70–79. 
Yu, X., McCorkle, S., Wang, M., Lee, Y., Li, J., Saha,  A. K., Unger, R. H., and 
Ruderman, N. B., 2004. Leptinomimetic effects of the AMP kinase activator 
AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. 
Diabetologia, 47 (11), 2012–2021. 
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z. W., Karin, M., and Shoelson, 
S. E., 2001. Reversal of obesity- and diet-induced insulin resistance with 
salicylates or targeted disruption of Ikkβ. Science, 293 (5535), 1673–1677. 
Yue, J. T. Y., Burdett, E., Coy, D. H., Giacca, A., Efendic, S., and Vranic, M., 2012. 
Somatostatin receptor type 2 antagonism improves glucagon and corticosterone 
counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic 
rats. Diabetes, 61 (1), 197–207. 
Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, 
Chapter 6: Bibliography 
 
  
272 
K., Willson, J. K., Markowitz, S., Zhou, S., Diaz Jr, L. A., Velculescu, V. E., 
Lengauer, C., Kinzler, K. W., Vogelstein, B., and Papadopoulos, N., 2009.  
Glucose deprivation contributes to the development of   KRAS pathway mutations 
in tumor cells. Science, 325 (5947), 1555–1559. 
Zeleznikar, R. J., Heyman, R. A., Graeff, R. M., Walseth, T. F., Dawis, S. M., Butz, E. 
A., and Goldberg, N. D., 1990. Evidence for compartmentalized adenylate kinase 
catalysis serving a high energy phosphoryl transfer function in rat skeletal muscle. 
The Journal of Biological Chemistry, 265 (1), 300–311. 
Zeqiraj, E., Filippi, B. M., Deak, M., Alessi, D. R., and van Aalten, D. M. F., 2009. 
Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of 
kinase activation. Science, 326 (5960), 1707–1711. 
Zhang, W., Patil, S., Chauhan, B., Guo, S., Powell, D. R., Le, J., Klotsas, A., Matika, 
R., Xiao, X., Franks, R., Heidenreich, K. A., Sajan, M. P., Farese, R. V., Stolz, D. 
B., Tso, P., Koo, S. H., Montminy, M., and Unterman, T. G., 2006. FoxO1 
Regulates Multiple Metabolic Pathways in the Liver: Effects on Gluconeogenic, 
Glycolytic and Lipogenic Gene Expression. The Journal of Biological Chemistry, 
281 (15), 10105–10117. 
Zhang, W., Thompson, B. J., Hietakangas, V., and Cohen, S. M., 2011. MAPK/ERK 
Signaling Regulates Insulin Sensitivity to Control Glucose Metabolism in 
Drosophila. PLoS Genetics, 7 (12), e1002429. 
Zheng, J. and Ramirez, V. D., 2000. Inhibition of mitochondrial proton F0F1-
ATPase/ATP synthase by polyphenolic phytochemicals. British Journal of 
Pharmacology, 130 (5), 1115–1123. 
Zhou, Y., Wang, D., Zhu, Q., Gao, X., Yang, S., Xu, A., and Wu, D., 2009. Inhibitory 
Chapter 6: Bibliography 
 
  
273 
effects of A-769662, a novel activator of AMP-activated protein kinase, on 3T3-L1 
adipogenesis. Biological and Pharmaceutical Bulletin, 32 (6), 993–998. 
Zinzalla, V., Stracka, D., Oppliger, W., and Hall, M. N., 2011. Activation of mTORC2 
by Association with the Ribosome. Cell, 144 (5), 757–768. 
Zou, Y., Weis, W. I., and Kobilka, B. K., 2012. N-terminal T4 lysozyme fusion 
facilitates crystallization of a G protein coupled receptor. PLoS ONE, 7 (10), 
e46039. 
 
 
